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Complement and microglia mediate sensory-motor synaptic loss in normal 




Movement is an essential behavior that is controlled by motor circuits. Within spinal motor 
circuits, motor neurons bridge the central and peripheral nervous systems by conveying central 
commands to the skeletal muscles. The precise assembly and refinement of spinal motor circuits is 
required for normal motor behavior. It is known for several brain regions that during development a 
larger than needed number of synapses are produced and subsequently eliminated. However, the 
mechanisms responsible for spinal motor circuit refinement and synapse maintenance are poorly 
understood. Similarly, the molecular mechanisms by which gene mutations cause dysfunction and 
elimination of synapses in neurodegenerative diseases that occur during the development are 
unknown.  
Complement proteins have emerged as critical mediators of synaptic refinement and circuit 
plasticity. Therefore, this study aimed to address whether complement proteins are involved in the 
synaptic refinement of spinal sensory-motor circuitry. Additionally, to address whether similar 
mechanisms are responsible for elimination of synapses in neurodegeneration, spinal muscular 
atrophy (SMA) was utilized as a model disease. SMA is a neurodegenerative disease that occurs 
during early development. It is caused by reduced levels of the ubiquitously expressed SMN 
protein. The hallmarks of SMA are loss of motor neurons, muscle atrophy and abnormal postural 
reflexes. It has been previously shown that decreased number of select synapses and sensory-motor 
circuit dysfunction precede motor neuron loss. The mechanisms leading to this selective synapse 
loss on SMN deficient motor neurons remained unknown. This study investigated whether 
complement-dependent mechanisms are involved in synapse elimination in SMA.  
Results of this study demonstrated that the complement protein C1q – initiating protein of 
classical pathway, is required for the refinement of spinal sensory-motor circuits during the normal 
development. Synaptic density analysis revealed significantly higher number of proprioceptive 
synapses in C1q-/- mice. Functional assays showed a larger response in spinal reflexes in C1q-/- 
mice compared to WT mice, demonstrating that these synapses are functional. Strikingly, results of 
this study demonstrate that specific muscle-identified motor pools in C1q-/- mice receive 
inappropriate proprioceptive synapses at the end of the first postnatal week – the period during 
which behavioral studies revealed impaired righting times. Collectively, findings of this study 
 
 
demonstrate an important and novel role for complement proteins in early postnatal development of 
spinal sensory-motor circuits.  
Importantly, results of this study also demonstrate in a mouse model of spinal muscular 
atrophy that synaptic dysfunction and elimination is mediated by complement proteins and 
microglia-dependent mechanisms. C1q was found to tag vulnerable SMA synapses, leading to 
activation of the classical complement pathway, deposition of C3 protein and microglia-mediated 
elimination. Beside the phagocytic role in synapse elimination, microglia were found to be the main 
source of C1q in developing spinal cord. In vivo neutralization of C1q rescued synapses destined to 
be eliminated alleviating the severe SMA mouse phenotype. In addition, functional assays 
employing the ex vivo spinal cord preparation demonstrated that synapses rescued from elimination 
are functional, providing further evidence that SMA is a disease of motor circuits. Similarly, 
pharmacological depletion of microglia rescued the number of synapses, conferring behavioral 
benefit in SMA mice. These findings suggest that aberrant activation of classical complement 
pathway and microglial phagocytic activity mediate synaptic loss in a mouse model of SMA and 
identify blockade of C1q as a novel therapeutic target.  
Collectively, results of this study identify a critical role for the classical complement 
pathway in the refinement of developing spinal sensory-motor circuits, while its aberrant activation 
contributes to the pathology of neurodegenerative motor neuron disease spinal muscular atrophy.  
Key words: C1q, complement, motor neuron, proprioceptive synapse, sensory-motor circuit, spinal 
muscular atrophy, microglia, SMN 
Scientific field: Biology 









Комплемент и микроглија као посредници губитка сензорно-





Кретање је есенцијално понашање које је контролисано од стране моторних 
неуронских мрежа. У оквиру кичмених моторних мрежа, моторни нурони служе као мост 
између централног и периферног нервног система преносећи централне команде скелетним 
мишићима. Прецизно успостављање и преуређивање кичмених моторних мрежа је 
неопходно за нормално моторичко понашање. Познато је да се током развића појединих 
деловима мозга формира више него што је потребно синапси које касније бивају 
елиминисане. Међутим, механизми који су одговорни за преуређивање кичмених моторних 
мрежа и за одржавање синапси недовољно су испитани. Слично, молекуларни механизми 
одговорни за генским мутацијама изазвану дисфункцију и елиминацију синапси у 
неуродегенеративним болестима које се јављају током развића тренутно су непознати.  
Протеини система комплемента су се показали као критични медијатори финог 
синаптичког подешавања и пластичности неуронских мрежа. Стога је ова студија имала за 
циљ да испита да ли су протеини комплемент система умешани у синаптичкo преуређивање 
кичмене сензорно-моторне неуронске мреже. Додатно, не би ли се испитало да ли су слични 
механизми одговорни за елиминацију синапси током неуродегенерације, спинална мишићна 
атрофија (СМА) је коришћена као модел неуродегенартивнe болести. СМА је 
неуродегенеративна болест која се јавља рано током развића. Изазивана је смањењем нивоа 
убиквитно експримираног SMN (енг. survival motor neuron) протеина. Карактеристике СМА 
су губитак моторних неурона, атрофија мишића и абнормални постурални рефлекси. 
Претходно је показано да снижени бројеви одређених синапси и дисфункција сензорно-
моторне неуронске мреже предходе губитку моторних неурона. Механизми који доводе до 
овог селективног губитка синапси на моторним неуронима којима недостаје SMN тренутно 
су непознати. У овој студији је испитано да ли су комплемент-зависни мезанизми умешани у 
елиминацију синапси у СМА.  
Резултати ове студије показују да је комплемент протеин  C1q – иницијални протеин 
класичног пута, неопходан за преуређивање кичмених сензорно-моторних мрежа током 
 
 
нормалног развића. Анализе синаптичке густине откриле су знатно већи број 
проприоцептивних синапси код C1q-/- мишева. Функционални тестови су показали већи 
одговор кичмених рефлекса код C1q-/- мишева у поређењу са WT (енг. Wild Type) 
мишевима, доказујући да су ове синапсе функционалне. Изненађујуће, резултати ове студије 
показују да специфичнни мишићем-идентификовани моторни неурони C1q-/- мишева 
примају неадекватне проприоцептивне синапсе на крају прве постнаталне недеље – период 
током ког су студије понашања откриле поремећај у времену потребном да се мишеви 
усправе. Свеукупно, резултати ове студије показали су важну и нову улогу протеина система 
комплемента у раном постнаталном развићу кичмених сензорно-моторних мрежа.  
Оно што је битно, резултати ове студије додатно су још показали, у мишјем моделу 
спиналне мишићне атрофије, да је дисфункција и елиминација синапси посредована 
протеинима система комплемента и микроглија-зависним механизмима. Откривено је да C1q 
означава рањиве СМА синасе, што води активацији класичног пута комплемента, таложењу 
C3 протеина и микроглија-посредованој елиминацији. Поред фагоцитне улоге у елиминацији 
синапси, откривено је још да је микроглија и главни извор C1q протеина током развића 
кичмене мождине. In vivo неутрализација C1q протеина спасила је синапсе предвиђене за 
елиминацију ублажавајући тешки фенотип СМА код мишева. Поред тога, функционални 
тестови користећи ex vivo препарате кичмене мождине показали су да су синапсе спашене од 
елиминације функционалне, пружајући додатне доказе да је СМА болест моторних мрежа. 
Слично томе, фармаколошко уклањање микроглије утицало је на очување броја синапси, 
доприносећи побољшању понашања СМА мишева. Ова открића сугеришу да неадекватна 
активација класичног пута комплемента и фагоцитна активност микроглије посредују у 
губитку синапси у мишјем моделу СМА и идентификују блокаду C1q као нову терапијску 
мету.  
Свеукупно, резултати ове студије идентификују критичну улогу класичног пута 
система комплемента у преуређивању кичмених сензорно-моторних неуронских мрежа у 
развоју, док његова неадекватна активација доприноси патологији неуродегенеративне 
болести моторних неурона, спиналној мишићној атрофији.  
Кључне речи: C1q, комплемент, моторни неурон, проприоцептивна синапса, сензорно-
моторна мрежа, спинална мишићна атрофија, микроглија, SMN 
Научна област: Биологија 
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1.1. The spinal sensory–motor reflex circuit 
 
The development of coordinated locomotor behavior in vertebrates depends on the precise 
establishment of selective contacts between the discrete neuronal populations in the spinal cord and 
the peripheral nervous system. The precise assembly of the circuits needed for movement  requires 
generation of many different cell types to facilitate the complex connections between the motor 
neurons (MN), sensory neurons (SN), interneurons (IN), and the muscle (Dasen, 2009; Grillner and 
Jessell, 2009). The specification of distinct neuronal subtypes in the spinal cord is largely mediated 
through inductive signals and transcription factors networks which are operating within the 
progenitor and postmitotic cells (Dasen, 2009; Jessell, 2000). The mechanisms that specify the 
identity of neural cells transcription factor expression patterns appear to specify the precise cellular 
programs that control axonal guidance as well as synaptic specificities of neurons (Dasen, 2009; 
Goulding and Pfaff, 2005). Spinal circuits have to be adequately fined tuned in order to recruit in a 
specific order the different muscle groups and smoothly execute motor commands. The critical step 
in the spinal circuits formation is the precise navigation of motor axons toward their specific muscle 
targets. All subsequent connections to motor neurons including descending inputs originating from 
higher brain centers, sensory neurons and local interneurons, are confined by the motor neuron 
axons’ peripheral connections (Dasen, 2009). All these synaptic inputs have to be properly formed 
and maintained in order to have precise fine output from spinal motor circuits resulting in 
recruitment of specific muscles and generation of movement.  
Pioneering studies which characterized the spinal sensory–motor reflex circuit were 
performed by Eccles and colleagues back in the 1950s (Eccles et al., 1957) . They demonstrated that 
stretch of a peripheral muscle is carried through proprioceptive sensory neuron afferents onto 
specific spinal motor neurons. This information is then relayed back to the muscle – via the spinal 
cord - from which it originated, thus driving reflex contraction (Figure 1) (Eccles et al., 1957; 
Mears and Frank, 1997; Plant et al., 2018; Windhorst, 2007). The stretch reflex can be thought as 
the primary building unit of controlled movements in vertebrates, including humans. The circuitry 
of stretch reflex includes three distinct cell types: muscle fibers in the periphery, alpha motor 
neurons in the spinal cord whose axons project to the muscle, and proprioceptive sensory neurons in 
dorsal root ganglion, whose afferents project into the spinal cord through dorsal roots and originate 
in skeletal muscle (Figure 1). Muscle spindles are specialized sensory endings which are embedded 
in the muscle. Upon muscle stretch they increase their length which leads to the increase in firing 
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frequency of primary proprioceptive sensory afferents. Proprioceptive neurons synapse directly 
onto alpha motor neurons and on other spinal interneurons. They release glutamate which activates 
ionotropic glutamate receptors present on soma and dendrites of motor neurons. This evokes 
excitatory postsynaptic potentials (EPSPs) and depolarizes motor neurons membrane to reach the 
voltage threshold needed to generate an action potential. Action potentials are propagated along 
axons of motor neurons in order to reach their peripheral targets which results in the muscle fibers 
activation, causing the contraction of muscle fibers they innervate.  Hence, muscle contraction is 
counteracting the initial muscle stretch (Fletcher and Mentis, 2017).  
The sensory–motor circuit is devoted to proprioceptive control - stabilization and the sense 
of the limb in space. From the behavioral point of view, sensory-motor circuit has been well 
characterized. Experimental disruptions of the circuit result in characteristic functional and 
behavioral abnormalities. Perturbations to proprioceptive sensory afferents projecting onto motor 
neurons causes serious disorganization of locomotor function (Arber et al., 2000; Plant et al., 2018). 
Coordinated stepping movements, which are needed for  locomotor behaviors, are significantly 
impaired if missing proprioceptive feedback (Akay et al., 2014; Plant et al., 2018; Takeoka et al., 
2014). 
 
Figure 1. The stretch reflex in mammals. (A) A schematic illustration of the spinal sensory-motor 
circuit. Motor neurons (shown in blue) are located within the ventral spinal cord. They project their 
axons to the skeletal muscle and synapse at the NMJ. Muscle spindles (shown in purple) are 
specialized sensory organs which are embedded within the muscle and get activated by muscle 
stretch. While the cell bodies of proprioceptive sensory neurons (shown in green) are located within 
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the dorsal root ganglia (DRG), their axons originate from the muscle spindle. The proximal part of 
proprioceptive axons makes entry to the spinal cord via the dorsal root. In the spinal cord they make 
direct – monosynaptic excitatory contacts with motor neurons. Adapted from (Fletcher and Mentis, 
2017). 
 
1.1.1. Motor neurons 
 
Motor neurons are the sole mediators through which brain triggers contractions of skeletal 
muscles in order to control all body movements, from walking to those critical for survival  such as 
breathing and swallowing (Kanning et al., 2010). Spinal motor neurons are unique as they are one 
of a few neuronal cell types whose axons span outside of CNS. Also unique to spinal motor neurons 
is the output of their activity – contraction of a muscle. Consequently, it does not surprise that they 
are probably the best molecularly and functionally characterized neuronal cell type in vertebrates 
(Price and Briscoe, 2004). The specification of motor neuron identity can be seen as a three-stage 
process (Jessell, 2000). The generic motor neuron specification of identity happens first, leading to 
generation of appropriately positioned motor neurons in the spinal cord. During the second stage, 
the somata of functionally associated motor neuron groups, which are destined to have common 
projection targets, will settle in columns longitudinally oriented in spinal cord with axons projecting 
toward the target regions. Finally, during the third stage, cell bodies of motor neurons innervating 
same muscle form clusters known as motor pools, and in which are specialized synaptic contacts 
formed between premotor neurons and motor neurons. All these steps require extracellular signals 
which regulate cell-autonomous intrinsic determinants of motor neuron identity, and together shape 
and define the development of motor neurons (Jessell, 2000; Price and Briscoe, 2004). 
Spinal motor neurons are divided into columns which are topographically segregated and  
innervate distinct peripheral domains (Figure 2) (Dasen and Jessell, 2009). The hypaxial motor 
column (HMC)  and the medial motor column (MMC) are evolutionarily the oldest motor 
subclasses, innervating body wall and axial musculature, respectively (Fetcho, 1987; Gutman et al., 
1993). Preganglionic motor column (PGC) and the lateral motor column (LMC) are evolutionary 
younger. They appeared with the development of paired appendages (Jung and Dasen, 2015). The 
LMC motor neurons which innervate limb muscles, are formed  at limb levels of spinal cord 
(Romanes, 1951). Rostral and thoracic lumbar levels of spinal cord are home to PGC motor neurons 
which innervate sympathetic ganglia (Prasad and Hollyday, 1991). Formation of the phrenic motor 
column (PMC) is reserved to cervical levels of the spinal cord. PMC motor neurons innervate the 
diaphragm, and are found only in mammals (Allan and Greer, 1997; Jung and Dasen, 2015). Lastly, 
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located in the most caudal aspects of the spinal cord are sacral motor neurons which  innervate 
pelvic floor muscles (Figure 2) (Dasen and Jessell, 2009; Hancock and Peveto, 1979; Mendelsohn, 
2016). 
        
Figure 2. Motor neuron divisional, columnar and pool organization. (A) Motor pools and motor 
columns are specifically positioned along the rostro-caudal axis. The somata of motor neurons that 
send axons to limbs are located within the lateral motor column (LMC) at lumbar and brachial 
spinal cord levels. Preganglionic column (PGC) motor neurons and hypaxial motor column (HMC) 
motor neurons are located at thoracic levels. Medial motor column (MMC) motor neurons are 
located at all rostro-caudal spinal cord levels. Within the LMC motor pools are generated at specific 
rostro-caudal positions. (B) Projection patterns of columnar motor neuron subtypes. LMC motor 
neurons send their axons to the limb. PGC motor neurons project to the sympathetic chain ganglia 
(scg), HMC motor neurons send their axons to intercostal muscles and body wall muscles (m), 
MMC neurons project to the axial muscle. Adapted from (Dasen and Jessell, 2009). 
 
Within a column, the collection of motor neurons innervating a single skeletal muscle 
represent a motor pool. The  overall organization of motor pools within the spinal cord is 
topological: more rostral pools innervate more proximally positioned muscles in a limb, whereas 
medial and lateral motor neurons innervate  ventral and dorsal limb muscles, respectively (Figure 3) 




Figure 3. Example of topological organization of motor pools. Within the limb innervating pools 
(2: biceps – shown in red and 3: brachioradialis – shown in green), those that innervate more 
proximal muscles are located more rostrally in spinal cord. Thoracic motor neurons (4) innervate 
intercostal muscles (4) whereas phrenic motor neurons (1) located in the cervical spinal cord 
innervate the diaphragm (1), which is due to the more rostral position of the diaphragm precursors 
during development. Adapted from (Kanning et al., 2010). 
 
Motor neurons of an adult are classified based on functionally distinct characteristics into 
diverse classes and subtypes. According to the muscle fiber type that each class innervates motor 
neurons can be divided into alpha (α), beta (β), and gamma (γ) motor neurons. Alpha motor neurons 
(α-MNs) drive muscle contraction and innervate extrafusal skeletal muscle fibers. Gamma motor 
neurons also known as fusimotor neurons (γ-MNs) selectively innervate intrafusal muscle fibers of 
the muscle spindle (Kanning et al., 2010). Phylogenetically, they are the most developed neurons in 
mammals, whereas lower vertebrates regulate sensitivity of their muscle spindles through β-skeleto-
fusimotor system alone (Shneider et al., 2009). Gamma and alpha motor neurons differ in their 
central and peripheral patterns of connectivity as well as in their morphology (Friese et al., 2009). 
While α-MNs predominate within motor pools γ-MNs compose approximately a third of all motor 
neurons in a given pool. Alpha motor neurons are responsible for generation of force to move the 
skeleton by contracting extrafusal muscle fibers. Gamma motor neurons, on the other hand, 
innervate intrafusal fibers that modulate muscle spindles sensitivity to stretch (Friese et al., 2009; 
Kanning et al., 2010; Kuffler et al., 1951).  Alpha and gamma motor neurons are also profoundly 
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different with respect to their connectivity profile and morphology, reflecting upon their different 
functions and targets. (Friese et al., 2009; Kanning et al., 2010). Gamma motor neurons are 
significantly smaller than α-MNs with the average diameter of their cell body being half the length 
of the smallest alpha motor neurons. Gamma motor neurons also have smaller axon caliber which 
results in slower conduction velocities (Burke et al., 1977; Kanning et al., 2010; Shneider et al., 
2009). The dendritic trees of alpha and gamma motor neurons are similar in length, but those of 
gamma motor neurons have overall simpler dendritic arborization  with significantly less branching 
(Kanning et al., 2010; Westbury, 1982). Alpha and gamma motor neurons also differ in their 
connectivity patterns within the spinal cord. While most of α-MNs receive direct Ia input from 
proprioceptive sensory neurons, all γ-MNs lack monosynaptic connections from Ia proprioceptive 
sensory afferents (Eccles et al., 1960; Eccles et al., 1957; Friese et al., 2009; Kanning et al., 2010). 
Hence, alpha and gamma motor neurons have generally distinct presynaptic inputs and postsynaptic 
targets. The third class of motor neurons called β-motor neurons represents less well-defined 
population of spinal motor neurons and innervate both extra- and intrafusal fibers (Kanning et al., 
2010). 
 
1.1.2.  Sensory neurons 
 
A precise control of motor behaviors is achieved by integration of motor and sensory 
systems in the central nervous system (CNS) (Imai and Yoshida, 2018). Motor output coordination 
depends on sensory feedback which informs CNS about muscle status and external stimuli in real 
time. Sensory neurons (SNs) have their cell bodies within dorsal root ganglion (DRG) but their 
projections extend  to the peripheral targets and relay to CNS neurons (Catela et al., 2015). Similar 
to motor neurons, the specific functions and identities of sensory neurons are encoded within their 
unique molecular profiles (Catela et al., 2015; Zheng et al., 2019). Nonetheless, sensory neurons 
and motor neurons differ largely in their organization. While motor neurons are organized into 
discrete motor pool and columnar subtypes, sensory neurons are scattered throughout the DRG.  
Thus, an individual DRG accommodates sensory neurons with unique profiles and differing 
peripheral targets (Abraira and Ginty, 2013; Catela et al., 2015; Dasen, 2009). 
 
1.1.2.1. Proprioceptive sensory neurons 
 
Motor neuron activity, which delivers directions to muscles in all motor behaviors, is in part 
coordinated, by proprioceptive sensory neurons. They transmit information from the periphery 
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about muscle position as well as the contraction status to the motor neurons, acting as a feedback 
loop to generate correct motor responses. Proprioceptive sensory neurons are subdivided into large 
and medium diameter neurons. Large diameter proprioceptive neurons are groups Ia and Ib, 
whereas medium diameter proprioceptive neurons represent group II  (Brown, 1981; Imai and 
Yoshida, 2018). Both group Ia and group II proprioceptive neurons synapse in the periphery at 
muscle spindles - structures enclosed in skeletal muscles, transmitting the information about 
changes in muscle stretch or length (Figure 4) (Brown, 1981; Catela et al., 2015; Hoheisel U, 1989; 
SA., 1992). Group Ib proprioceptive neurons project their axons peripherally to Golgi tendon 
organs which are embedded within the muscle, and centrally to the intermediate spinal cord, in 
which they form indirect connections with motor neurons via spinal interneurons.  In the ventral 
spinal cord, group II proprioceptive neurons project sparsely (Brown and Fyffe, 1979; Catela et al., 
2015). 
 
Figure 4. Sensorimotor circuits. Simplified illustration of the monosynaptic reflex circuit in which 
proprioceptive sensory neurons (shown in red) send information to the spinal cord from a specific 
muscle. Proprioceptive neurons synapse directly onto motor neurons that innervate same muscle 
peripherally. Proprioceptive neurons also make secondary connections with motor neurons that 
innervate muscle synergists but not with the motor neurons that innervate antagonistic muscles. 
Adapted from (Catela et al., 2015). 
 
In mice, proprioceptive afferents reach muscles and the spinal cord around embryonic day 
10.5 (E10.5) (Imai and Yoshida, 2018; Ozaki and Snider, 1997). Axons enter the spinal cord 
through dorsal root around E12.5, forming monosynaptic contacts with motor neurons by E17 (Imai 
8 
 
and Yoshida, 2018; Mears and Frank, 1997; Ozaki and Snider, 1997; Seebach and Ziskind-
Conhaim, 1994). Group Ia projections synapse directly onto alpha motor neurons  innervating the 
same – or homonymous - muscle which their Ia afferents contact in the periphery (Brown, 1981; 
Burke et al., 1977; Catela et al., 2015; Eccles et al., 1957; Mears and Frank, 1997). This Ia 
proprioceptive sensory neurons – alpha motor neurons – muscle feedback loop represents the basis 
of  the monosynaptic spinal reflex arc as well as  the foundation of the homeostatic muscle activity 
maintenance (Catela et al., 2015; Windhorst, 2007). Group Ia proprioceptive neurons also synapse 
onto motor neurons innervating synergistic muscles – but importantly not antagonistic muscles. 
Beside the connections with motor neurons group Ia proprioceptive neurons also synapse onto 
inhibitory interneurons which are involved in control of the antagonistic muscle activity (Figure 4) 
(Brown, 1981; Catela et al., 2015; Mendelsohn et al., 2015).However, early during development 
motor neurons do receive proprioceptive inputs originating from antagonistic muscles (Seebach and 
Ziskind-Conhaim, 1994), that are eliminated at postnatal ages(Poliak et al., 2016) . The molecular 
mechanisms behind this refinement of sensory-motor circuitry are currently unknown. 
Due to the fact that Ia proprioceptive afferents form specific direct monosynaptic 
connections with precise motor neuron pools (Eccles et al., 1957) these circuits became elegant 
model systems for studying the molecular mechanisms responsible for the synaptic specificity(Imai 
and Yoshida, 2018). Monosynaptic connections are formed by E17 and it was believed that their 
establishment is independent of neuronal activity (Imai and Yoshida, 2018; Mears and Frank, 
1997).  Results from a recent study however, demonstrate that monosynaptic heteronymous 
sensory-motor connections for the related muscle pair, ankle flexor muscle - tibialis  anterior (TA), 
and toe extensor muscle – extensor digitorum longus (EDL),  are coordinated via sensory neuron 
activity-dependent process (Mendelsohn et al., 2015).In early postnatal mouse, TA proprioceptive 
sensory neurons make weak heteronymous monosynaptic connections with the EDL motor neurons 
but strong homonymous monosynaptic homonymous connections with the TA motor neurons. 
When proprioceptive sensory neuron activity is blocked, the density and the number of 
heteronymous connections is enhanced without any effect on homonymous connections 
(Mendelsohn et al., 2015). This study suggests that sensory inputs coordinate establishment of 
heteronymous, but not homonymous connections in an activity-dependent manner. 
The monosynaptic sensory-motor circuits simplicity makes them an ideal model system for 
studying molecular mechanisms involved in the neuronal circuits formation and maintenance and 
for studying mechanisms of synapse elimination and circuitry perturbations that occur in 
neurodegenerative diseases (Imai and Yoshida, 2018). Disintegration of neuronal networks through 
synaptic elimination lead  to compromised neuronal output and underlies neurodegenerative 
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diseases such as frontotemporal dementia (FTD), Alzheimer’s disease (AD) and spinal muscular 
atrophy (SMA)(Lui et al., 2016; Tisdale and Pellizzoni, 2015; Verret et al., 2012; Vukojicic et al., 
2019). However, unlike FTD and Alzheimer’s disease, SMA occurs during early development both 
in animal models and humans (Montes et al., 2009; Tisdale and Pellizzoni, 2015)suggesting that 
affected neuronal networks are immature and therefore could be more vulnerable to synaptic 
perturbations (Vukojicic et al., 2019). 
 
1.2. Spinal Muscular Atrophy 
 
Spinal muscular atrophy (SMA) is a group of inherited neuromuscular disorders, which are 
genetically heterogeneous and characterized by the spinal motor neurons defect, which leads to 
progressive weakness and atrophy of skeletal muscles, which is associated with the loss of spinal 
motor neurons (Oskoui et al., 2017; Sumner and Fischbeck, 2007). The first clinical description of 
SMA was published in 1891 and the wide clinical spectrum of the disease, with detailed descriptions 
across severities, was recognized over the next century. In 1990, mapping of the gene locus to 
chromosome 5q13.2 in both acute and chronic forms confirmed that indeed this clinical spectrum  
represents the same disease (Gilliam et al., 1990; Melki et al., 1990). Shortly after, in 1995 the 
survival motor neuron (SMN) gene was identified on chromosome 5q (Lefebvre et al., 1995). 
Homozygous mutations or deletions of the survival motor neuron 1 (SMN1) causing SMN protein 
deficiency, are associated with the most prevalent form of proximal SMA. Although SMA patients 
have mutations in ubiquitous SMN1 gene, they retain copies of almost identical hypomorphic gene 
named SMN2 (Lefebvre et al., 1995; Tisdale and Pellizzoni, 2015). While human have both SMN1 
and SMN2 gene, non-human primates and the rest of the animals lack SMN2, and have only one 
SMN gene (Rochette et al., 2001). From the time SMA was first described until today, there has been 
a progressive growth in understanding of the disease mechanisms.  Creation of SMA animal models 
in the early 2000s was critical in studying the mechanisms involved in the disease (Oskoui et al., 
2017).  
 
1.2.1. The SMN Gene 
 
The SMN gene region is located on chromosome 5q13 and has a 500 kb inverted duplication 
element. The duplicated region consists of at least four genes as well as the repetitive elements, 
making it prone to deletions and rearrangements.  The SMN1 gene is located within the telomeric 
copy and in SMA patients this gene interrupted or deleted. The SMN2 gene, which shares more than 
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99% of nucleotide identity with SMN1 and differs only in five nucleotides is located within the 
centromeric copy (Figure 5) (Oskoui et al., 2017; Sumner and Fischbeck, 2007). While SMN1 gene 
yields full-length transcripts, SMN2 gene mostly produces transcripts that lack exon 7. This happens 
due to the C-to-T transition in exon 7 of SMN2 gene which causes creation of an exon-splicing 
suppressor sequence (Kashima et al., 2007; Lorson and Androphy, 2000). This doesn’t change an 
amino acid sequence, but it does affect alternative splicing of the SMN2 gene, which results in exon 
7 exclusion from majority of SMN2 transcripts. The outcome is the production of truncated and 
unstable full length SMN protein.  Approximately  90–95% of SMN2 transcripts will produce 
truncated protein and only 5–10% functional full-length protein (Kashima et al., 2007; Lefebvre et 
al., 1995; Oskoui et al., 2017). All healthy individuals who happen to have one SMN1 copy and lack 
SMN2 copies, will have 50% of full-length functional SMN protein which will be sufficient for a 
normal life. However, the majority of SMA patients have 2-3 SMN2 copies in Type I, Type II, and 
in some Type III patients and no SMN1 gene. These patients are predicted to have 20–30% of full-
length SMN protein at a maximum rate of 10%  per SMN2 gene (Oskoui et al., 2017; Sumner and 
Fischbeck, 2007). SMA Type III patients carrying four copies of SMN2 gene have around 40% of 
SMN protein, which is still below the 50% that healthy carriers produce. Additionally, 
asymptomatic individuals have been described lacking SMN1gene and carrying five copies of 
SMN2 gene. They would be predicted to produce 50% of functional SMN protein (Mailman et al., 
2002; Oskoui et al., 2017). Within the general population carrying two copies of SMN1, there is a 
variability in the number of SMN2 copy numbers. Approximately 15% of these individuals have no 
SMN2 copies, 33% carries only one SMN2 copy, and 50% carries two SMN2 copies (Mailman et al., 
2002). Complete depletion of SMN - absence of SMN1 and SMN2 genes - is incompatible with life 
(Deguise et al., 2017; Schrank et al., 1997b). Thus, all SMA patients carry at least one SMN2 gene 
copy. Among SMA patients a rough correlation exists between SMN2 copy numbers and clinical 
severity (Lefebvre et al., 1997). The levels of SMN protein range from 22% to 23% in type I SMA 
fetal spinal cords  (Lefebvre et al., 1997). Reduction of SMN protein levels was found to be even 
greater in postmortem spinal cords from Type I SMA patients who carried two copies of SMN2 
(Coovert et al., 1997). In SMA patients who have affected both copies of SMN1, low level of SMN 
protein is present, depending on the quality and copy number of their SMN2 genes (Oskoui et al., 




Figure 5. Schematic illustration of human SMN1 and SMN2 genes. SMN1 and SMN2 
genes are located on chromosome 5. SMA patients have mutations or deletions in both copies of 
SMN1. A transition C-to-T at the 840 position of SMN2 gene results in exon 7 skipping during 
splicing. A result is production of truncated, nonfunctional SMN protein. Only small portion ~ 5–
10% of full-length mRNA is produced from SMN2 gene, and results in full-length functional SMN 
protein. Adapted from (Darras, 2015). 
 
The majority of SMA patients (95-98%) with the most common form – 5q SMA have a 
homozygous deletion that involves exon 7 of SMN1 gene. The remaining patients have a 
heterozygous point mutation and a deletion. De novo mutations do occur at about 2% which is a 
relatively high rate, and happens because SMN gene region is unstable, and contains beside the 
inverted repeat of SMN1 gene and SMN2, other repetitive elements - low copy number repeats, 
which make it more susceptible to rearrangements (Oskoui et al., 2017; Wirth et al., 1997).  
The most common subtype of SMA is Type I and occurs with the prevalence of 4.1 cases 
per 100 000 live births (Mostacciuolo et al., 1992). The SMA Type I is the most severe form of the 
disease and occurs with the highest incidence compared to other subtypes. Approximately80–96% 
of children with SMA Type I have one or two SMN2 gene copies and around 4–20% carry three 
copies. About 82% of children with SMA Type II carry three copies of SMN2 gene, and around 96–
100% of SMA Type III patients have three or four SMN2 copies (Figure 6) (Arkblad et al., 2009; 
Feldkotter et al., 2002; Oskoui et al., 2017). Although copy number of SMN2 gene is known as 
the main phenotype modifier it does not predict phenotype accurately. There is a growing 
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evidence of other factors that contribute to SMA severity. These potential modifiers of SMA 
include epigenetic modifiers, various proteins which interact with SMN or promote motor 
neuron survival and splicing or transcriptional factors influencing SMN2 expression 
(Maretina et al., 2018). 
                                              
 
Figure 6. Diagram of the frequency of SMA patients with type I, type II, and type III SMA in 
comparison to SMN2 copy number. In 80% of SMA Type I patients, one or two SMN2 copies are 
present. 82% of SMA Type II patients have three SMN2 copies, and 96% of SMA Type III patients 
carries three or four copies of SMN2. Adapted from (Feldkotter et al., 2002). 
 
1.2.2. The SMN protein 
 
The full-length SMN protein consist of 294 amino acids and weighs 38 kDa (also known as 
FL-SMN). SMN is ubiquitously expressed – found in all cells, and is located in cytoplasm and in 
the nucleus. In the nucleus, SMN localizes to structures called Gemini of coiled bodies, or simply 
“gems”(Liu and Dreyfuss, 1996). The SMA severity was found to correlate with the number of 
gems found in patient fibroblasts (Coovert et al., 1997).  The SMN protein and several Gemin 
proteins form a large macromolecular complex – SMN complex - that facilitates assembly of the 
spliceosomal small nuclear ribonucleoproteins (snRNPs). The snRNPs are crucial components of 
the spliceosome complex, with an essential role in pre-mRNA splicing (Pellizzoni et al., 2002). 
Additionally, SMN protein may have critical roles in axonal mRNAs transport in motor neurons 
and in assisting arginine methylation of certain splicing-related proteins. SMN protein may be also 
involved in different processes neuromuscular junction and in muscle. However, it is currently 
unclear whether SMN deficiency caused splicing defect or disruption of axonal SMN function, or 
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yet unknown SMN function, or simply combination of all is behind the SMA pathogenesis (Arnold 
and Burghes, 2013; Oskoui et al., 2017). It has been shown in mice and other organisms, that 
complete absence of SMN protein is embryonic lethal (Monani et al., 2000). However, why are 
motor neurons specifically vulnerable in case of partial SMN deficiency is currently unclear. 
Function of SMN protein and its role in pathogenesis of SMA remains to be better understood 
(Burghes and Beattie, 2009; Oskoui et al., 2017).  
 
1.2.3. Clinical characteristics of SMA in human 
 
SMA patients have proximal muscle weakness that is usually symmetric and affects lower 
limbs more than patient’s upper limbs. While disease involves intercostal muscle, diaphragm is 
relatively spared (Arnold and Burghes, 2013; Oskoui et al., 2017; Sumner and Fischbeck, 2007). 
 The muscle weakness and the atrophy in SMA is attributed to motor neuron loss and dysfunction.  
The neuromuscular junction function and development is impaired across SMA subtypes (Goulet et 
al., 2013; Wadman et al., 2012).The skeletal muscle pathology observed in children affected with 
SMA is a reflection of motor neuron disorder with a neurogenic type atrophy and a Type I fiber 
hypertrophy (Oskoui et al., 2017). The severity of SMA is variable with heterogeneous clinical 
features across subtypes. 
 
1.2.3.1. Type I Spinal Muscular Atrophy 
 
Type I SMA (Werdnig–Hoffmann disease), is the most severe and the most common form 
of the disease. Affected infants, experience in the first 6 months of life (Zerres and Rudnik-
Schoneborn, 1995) proximal weakness, which affects their legs more than arms., movement 
deficiencies and reduced muscle tone. These infants usually show generalized hypotonia 
demonstrated by “frog-leg posture” when lying horizontally and facing up, tongue fasciculations, 
areflexia and they slip through on a vertical suspension (Figure 7a and 7b). These babies have a 
weak cry, difficulty sucking and swallowing, and they do not reach developmental milestone of 
rolling over independently or being able to stay seated independently (“nonsitters”) or sit up 
unassisted. Their thorax is bell-shaped, with evidence of diaphragmatic breathing and intercostal 




Figure 7. SMA Type I clinical manifestations (A) Dangling lower limbs and lack of hip flexion is 
notable with vertical suspension. Upper limbs tend to slip through examiner’s hands. Head lag due 
to the lack of neck flexion. (B) When infant is supine, “frog-leg” positioning of the legs is notable 
with the absence of traction response. (C) Head lag with examiner’s attempts to pull infant into the 
sitting position. Adapted from (Oskoui et al., 2017). 
 
In the SMA Type I patients  often other organ dysfunction and involvement is recognized, 
which points to the fact that SMN protein is ubiquitously expressed (Heier et al., 2010). In infants 
affected by severe forms as well as in mouse models, hypovascularity or vascular depletion are 
dominant characteristic. A resulting consequence of these vascular defects is functional hypoxia of 
spinal motor neurons (Somers et al., 2016). SMA patients have normal cognition and even higher 
than average intelligence has been reported (von Gontard et al., 2002). Further classification of 
SMA Type I disease is made based on the onset of symptoms. Infants in which symptoms are noted 
prenatally or during the first week of life are classified as SMA Type IA. Most of them carry only 
one copy of SMN2 gene and they die in less than one month, usually soon after birth. Infants in 
which symptoms develop between first week of life and three months of age are classified as SMA 
Type IB, and those who develop symptoms sometime between three and six months of age usually 
have two SMN2 copies and are classified as SMA Type IC. Most infants affected with SMA Type I, 
without intervention do not survive beyond the age of two years. However, with management of 
pulmonary complications and appropriate respiration support, gastrointestinal and nutritional 
support, orthopedic care and rehabilitative interventions survival has been prolonged beyond the 
second year (Arnold and Burghes, 2013; Oskoui et al., 2007). Until recently there was not a single 
medication approved for treatment of SMA patients. The first ever approved medication for 
treatment of SMA was Nusinersen, (commercial name Spinraza) by Biogen (Garber, 2016). 
Nusinersen is an antisense oligonucleotide (ASO) designed to target intron 7 on the SMN2 hnRNA 
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(Castro and Iannaccone, 2014; Corey, 2017; Shahryari et al., 2019) and modulate alternative 
splicing by increasing exon 7 inclusion in the processed final RNA, resulting in increased levels of 
functional full length SMN protein in the central nervous system (Corey, 2017; Shahryari et al., 
2019; Zanetta et al., 2014).  Nusinersen was approved in December 2016 by US Food and Drug 
Administration (FDA) when it also became the first antisense drug acting to restore an exon 
inclusion during pre-mRNA splicing(Ottesen, 2017). It involves intrathecal administration 
(Chiriboga, 2017). Another gene therapy drug, developed by AveXis (Novartis) under brand name 
Zolgensma (Onasemnogene Abeparvovec, AVXS-10), was recently FDA approved (May 2019) for 
SMA patients younger than two years of age. Zolgensma is a single dose, AAV9-based (adeno-
associated virus) gene therapy administered intravenously.  Zolgensma is a recombinant non-
replicating AAV9 containing a copy of functional human SMN1 gene which is under the control of 
cytomegalovirus enhancer/chicken-β-actin-hybrid promoter in order to express SMN1 selectively in 
SMA patients motor neurons (Malone et al., 2019; Mendell et al., 2017; Shahryari et al., 2019; 
Waldrop and Kolb, 2019). Although there has been a great improvement in recent years with a 
development of these gene therapies for SMA, none of the treatments can cover all the aspects of 
the disease pathology and neither of them are considered a cure for the disease. Thus, a 
combinatorial therapeutic strategy might be the most effective for treating this devastating disease.  
 
1.2.3.2. Type II Spinal Muscular Atrophy 
 
Children affected with SMA Type II, which is known as Dubowitz disease or intermediate 
SMA usually present first symptoms between six and eighteen months of age.  Type II patients 
achieve the ability to sit without support and stay seated independently, although in some cases this 
ability may be lost over time. Children with SMA Type II are never able to stand or walk unaided 
(“sitters”) and majority has three SMN2 copies (Arnold and Burghes, 2013; Arnold et al., 2015; 
Oskoui et al., 2017). Affected children have predominantly proximal muscle weakness involving 
their lower limbs more than the upper limbs, areflexia and, hypotonia. Face and muscles of the eye 
are usually unaffected (Butchbach, 2016). Additionally, these children may develop respiratory 
difficulties and hypoventilation while asleep. Survival of SMA type II patients is into adulthood, 
though it can be shorter especially in children with respiratory difficulties. (Arnold and Burghes, 
2013; Oskoui et al., 2017). Previously reported survival rates of 98.5% at 5 years and 68.5% at 25 
years have increased past their 25th birthday with  respiratory and nutritional support (Zerres et al., 




1.2.3.3. Type III Spinal Muscular Atrophy 
 
Children affected with SMA Type III, also known as Kugelberg–Welander disease achieve 
independent mobility (“walkers”), though proximal weakness may cause falls and difficulty 
climbing stairs. Additionally, some patients may lose the ability to stand and walk over time and 
rely on wheelchair to move around. Symptoms appear after eighteen months of age. Type III SMA 
patients have proximal muscles affecting their lower limbs more than upper limbs. Clinical 
diagnosis can be more challenging as tendon reflexes are usually preserved at the time of 
examination. Most patients develop scoliosis, foot deformities and respiratory muscle weakness. 
Most patients carry three or four SMN2 copies (Arnold et al., 2015). Type III SMA accounts for 
approximately 30% of overall SMA cases. Life expectancy of SMA Type III patients does not  
significantly differ  from the normal population (Oskoui et al., 2017; Zerres and Davies, 1999; 
Zerres et al., 1997). 
 
1.2.3.4. Type IV Spinal Muscular Atrophy 
 
SMA Type IV is a late-onset SMA, with symptoms usually present after 21 years of age 
with the mean age of onset in the mid-thirties. This mildest form is the least prevalent subtype and 
accounts for less than 5% of all SMA cases (Arnold et al., 2015). Patients with SMA type IV have 
proximal limb girdle weakness but they achieve motor milestones and they maintain mobility 
throughout their life and carry  four or eight copies of SMN2 gene (Butchbach, 2016). Life 
expectancy for Type IV SMA patients is normal.  
 
1.2.4. Animal models 
 
In the past two decades, significant progress has been made in understanding the molecular 
basis of the SMA clinical spectrum which allowed creation of SMA animal models. Beside mouse 
models, which are perhaps the most widely used, SMA has been also studied in Caenorhabditis 
elegans, Drosophila, and Zebrafish models which due to the simplicity of model organisms allow 
for easy molecular and genetic manipulation (Edens et al., 2015). Mice, unlike humans, have only 
one SMN gene which is equivalent to human SMN1 (DiDonato et al., 1997; Viollet et al., 1997). As 
in all species, homozygous knockout of Smn1 is embryonically lethal (Schrank et al., 1997a). 
Introduction of one or two copies of human SMN2 rescues the embryo, resulting in mice with a 
severe SMA-like phenotype. These mice die around postnatal day 5 (Hsieh-Li et al., 2000; Monani 
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et al., 2000). In contrast, introduction of eight to sixteen copies of human SMN2 gene in the Smn  
knockout mouse rescues the phenotype with no difference in life span than wild-type mice(Le et al., 
2005; Monani et al., 2000). The ∆7 SMA mice have in addition to two copies of human SMN2, and 
an SMN transgene that lacks exon 7 (SMNΔ7). This addition of SMNΔ7 prolongs lifespan of mice 
to around 13.3 days after birth. The ∆7 SMA mouse model is among most widely used SMA 
models to date (Hsieh-Li et al., 2000; Le et al., 2005; Monani et al., 2000). This animal model was 
used for all the studies presented here. SMAΔ7 mice experience selective spinal motor neuron 
death, muscle atrophy, and closely recapitulate clinical characteristics seen in human Type I 

































































































Figure 8. Late stage SMAΔ7 mouse vs WT littermate.  Wild type (WT) mouse at postnatal day 
11 (P11) on the left side of the image. SMA littermate on the right side of the image with evident 
severe muscle atrophy and loss of posture. Photo courtesy of Dr Charlotte Sumner. 
 
Although hallmarks of SMA are death of motor neurons and muscle atrophy, one of the 
earliest manifestations of disease in SMAΔ7 mouse model is sensory-motor dysfunction (Mentis et 
al., 2011). Circuit dysfunction which is a consequence of SMN deficiency that causes disease could 
be an initiating and/or propagating drive of impaired motor behavior. Neurodegeneration is usually 
attributed to dysfunction of a specific neuronal cell type which is vulnerable to disease mechanisms 
(Rademakers et al., 2012). In SMA, although SMN is ubiquitously expressed, spinal motor neurons 
are somehow selectively susceptible to SMN deficiency. SMA was thought to be motor neuron -
autonomous disease, in which neurodegeneration is due to the motor neuron death and dysfunction 
per se. However, it is possible that dysfunction of neurons that are primary targets in the disease 
process may affect their synaptic partners and further aggravate the disease (Palop and Mucke, 
2010). Animal models have a key role in addressing these and similar questions in order to decipher 
the disease mechanisms and in testing the therapeutic effect of potential drugs. 
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1.2.5. Motor Neuron Death 
 
Majority of the autopsy studies on postnatal spinal cords from SMA patients have described 
motor neuron loss as severe (Korinthenberg et al., 1997; Simic et al., 2000). Although SMN level is 
reduced in all tissues, the hallmark of  the SMA  is selective loss of motor neurons in spinal cord in 
humans as well as in mouse models of the disease (Burghes and Beattie, 2009; Simon et al., 2017; 
Tisdale and Pellizzoni, 2015). Furthermore, even within individual motor neuron pools there is 
marked differential vulnerability (Simon et al., 2017). It has been demonstrated that, spinal alpha 
MNs (which innervate proximal muscles) are preferentially affected and also degenerate early 
compared to alpha MNs that innervate distal muscles which are relatively spared (Mentis et al., 
2011). Moreover, motor neurons in SMA show segment-specific, differential vulnerabilities noted 
along the rostro-caudal axis. Motor neurons from lumbar level L1, that innervate proximal  and 
axial muscles are affected more profoundly and earlier in the disease process than motor neurons in 
the L5 region, that innervate distal hindlimb muscles (Mentis et al., 2011; Tisdale and Pellizzoni, 
2015). Furthermore, medial motor column motor neurons which innervate axial muscles are 
affected more than the lateral motor column motor neurons that innervate distal muscles. This is 
consistent with observations in SMA patients (Mentis et al., 2011). Additionally, in a severe model 
of SMA gamma MNs were observed to be spared (Powis and Gillingwater, 2016). Interestingly, 
ubiquitous SMN deficiency induces selective death of specific vulnerable motor neuron pools while 
sparing resistant ones that share similar functional properties and developmental programs (Simon 
et al., 2017).In addition, other spinal neurons are also spared in SMA (Powis and Gillingwater, 
2016). In recent study a convergent pathway involving p53 has been proposed as a key mediator of 
SMN deficiency-induced motor neuron death. Phosphorylation of p53 serine 18 was identified as a 
death-specific marker which is selectively found in vulnerable SMA motor neurons but not in 
resistant ones or in spinal interneurons even though nuclear accumulation of p53 are present late in 
the disease process in SMA mice (Simon et al., 2017). 
 
1.2.6. Sensory-Motor circuitry impairment 
 
Apart from spinal motor neurons death, SMA is characterized by additional pathologies 
occurring centrally, at synapses contacting motor neurons soma and dendrites as well as distally - at 
the neuromuscular junction (Figure 9). The NMJ defects involve reduced vesicle content, 
presynaptic neurofilament accumulation, impaired synaptic transmission, and defects in  motor 
endplate development and in acetylcholine receptor clustering at postsynaptic membrane (Kariya et 
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al., 2008; Lee et al., 2011; Ling et al., 2010a; Murray et al., 2008; Tisdale and Pellizzoni, 2015). 
Functional and morphological impairments of the NMJ correlate with decreased myofiber size 
delayed NMJ development and with muscle denervation, which is all notably pronounced in 
vulnerable SMA muscles (Kariya et al., 2008; Kong et al., 2009; Ling et al., 2010a; Murray et al., 
2008; Tisdale and Pellizzoni, 2015). 
Beside appropriate connectivity needed between muscles on periphery and motor neurons in 
spinal cord, proper wiring between motor neurons and other neurons is crucial for normal motor 
behavior. Perturbations of neuronal circuits are being recognized as critical determinants of 
neurodegenerative disorders (Fletcher and Mentis, 2017; Tisdale and Pellizzoni, 2015). It has been 
shown that  motor neurons in SMA have reduced glutamatergic synaptic inputs from local spinal 
interneurons and from proprioceptive sensory neurons (Figure 9) (Ling et al., 2010a; Mentis et al., 
2011). Moreover, sensory-motor neurotransmission was showed to be severly impaired and 
associated with dysfunction of proprioceptive sensory synapses in SMA mice (Mentis et al., 2011). 
However, molecular mechanisms reponsible for  dysfunction of proprioceptive synapses and for 
their reduced numbers are not well understood. Addtionally, it has been demonstrated that SMA 
motor neurons have altered firing properties along with increased intrinsic excitability (Mentis et 
al., 2011). This functional changes  might be a homeostatic response to reduction in excitatory drive 
originating from premotor neurons (Mentis et al., 2011; Tisdale and Pellizzoni, 2015).  
 
       
Figure 9. Schematic illustration of the key functional and morphological abnormalities of the 
motor system in SMA mouse models. Spinal motor neurons are shown in dark blue,  
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proprioceptive neurons in green and local interneurons in light blue. The specific deficits of the 
circuitry centrally and at the periphery are indicated. Adapted from (Tisdale and Pellizzoni, 2015). 
 
Taken together, these findings suggest that SMN deficiency induced synaptic abnormalities 
in the sensory-motor system are at least partially responsible for the severe motor dysfunction seen 
in SMA. In support of this, is the observation that functional and structural sensory-motor circuitry 
impairment precede motor neuron death. To better understand disease process and design treaments 
it was important to identify the importance of cell-autonomous and non-cell autonomous 
mechanisms contributions to the disease pathology (Fletcher and Mentis, 2017; Tisdale and 
Pellizzoni, 2015). Previous studies have demonstrated in SMA mice that pan-neuronal SMN 
expression rescues disease phenotype. However, SMN specific restoration in  muscles did not 
improve the severe phenotype (Gavrilina et al., 2008). Furthermore when SMN is selectively 
depleted from motor neuron progenitors, motor neurons will die and as a consequence will be a 
mild SMA phenotype (Park et al., 2010). Additionally, motor-neuron-specific resotration of SMN 
has been demonstrated to improve motor neuron loss. However, it has little effect on SMA mice 
survival (Gogliotti et al., 2012; Martinez et al., 2012; Tisdale and Pellizzoni, 2015). Taken together, 
results of these studies indicated that neuronal dysfunction plays a critical role in SMA pathology 
and that SMA is a disease defined by dysfunction of different motor system components and not 
solely motor neurons (Tisdale and Pellizzoni, 2015). In order to decipher mecanisms involved in 
SMA pathogenesis it is important to unravel the role(s) of different motor system components in the 
disease process. Although motor neuron death is a cell autonomous event, a recent study has 
demonstrated that SMN deficiency induces defects in other neuronal types that also contribute to  
pathology of motor system  in SMA (Fletcher et al., 2017) suggesting that SMA is a disease defined 
by dysfunction of different motor system components and not solely motor neurons (Fletcher et al., 
2017; Tisdale and Pellizzoni, 2015).  
 
1.2.7. Sensory-motor circuitry pathology in SMA is due to proprioceptive – autonomous 
mechanisms 
 
            To determine the cellular origin of sensory-motor circuit dysfunction in SMA, Fletcher and 
colleagues used genetic manipulations to selectively restore SMN in the following neurons: i) solely 
in motor neurons, ii) solely in proprioceptive neurons, or iii) both neuronal classes in SMA mice 
(Fletcher et al., 2017). Parvalbumin::Cre (PvCre) mice were crossed with the conditional inversion 
SMA mice to restore SMN protein in proprioceptive neurons (SMA+PvCre). During the first ten 
postnatal days parvalbumin is expressed in proprioceptive neurons exclusively (Mendelsohn et al., 
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2015) and has the similar level of expression in WT and SMA mice (Fletcher et al., 2017). 
Although parvalbumin expression is observed at P5 in the cerebellum (Fletcher et al., 2017), the 
righting behaviors are not dependent on cerebellar activity,  until the second postnatal week 
(Altman, 1997; Fletcher et al., 2017). In the study by Fletcher et al (2017), the authors restored 
SMN in motor neurons by crossing the conditional inversion SMA mice with mice that express Cre 
under the ChAT (Choline Acetyltransferase) promoter (SMA+ChATCre) (Fletcher et al., 2017). 
         To define the effect of SMN loss on motor neuron dysfunction, the authors performed 
intracellular recordings from vulnerable spinal motor neurons using whole cell patch clamp 
following dorsal root stimulation (Fletcher et al., 2017).  The EPSP amplitude was measured in L2 
motor neurons in WT, SMA, SMA+PvCre and SMA+ChATCre following the proprioceptive fiber 
stimulation. No significant change was observed in the motor neuron resting membrane potential 
for any of the experimental groups. Importantly, the reduction of EPSP amplitude observed in SMA 
motor neurons was restored in SMA+PvCre but not in SMA+ChATCre motor neurons (Fletcher et al., 
2017) (Figure 10, A-B) suggesting that motor neuron dysfunction is a non-cell autonomous 




Figure 10. Selective restoration of SMN in proprioceptive neurons in SMA mice restores 
EPSP amplitude. (A) Intracellular responses of monosynaptic EPSPs following supramaximal 
stimulation of L2 dorsal root in homonymous motor neurons for WT, SMA, SMA +PvCre and 
SMA+ChATCre L2 mice at postnatal day 4 (P4). The peak of EPSP amplitude measured at 3 ms 
after the onset of response is indicated by arrows. Arrowheads indicate the stimulus artifact. (B) 
Graph shows the average peak of EPSP amplitude in motor neurons for the experimental groups 
shown in (A). * P<0.05, ** P<0.01, one-way ANOVA, Tukey’s post hoc analysis. Adapted from 




1.2.8. Dysfunction and death of motor neurons are distinct and independent events in SMA 
 
The hallmark of SMA is motor neuron death (Tisdale and Pellizzoni, 2015). 
Hyperexcitability of motor neurons has been implicated in neuronal death in amyotrophic lateral 
sclerosis (ALS) (Umemiya et al., 1993) and upon axotomy of facial (Umemiya et al., 1993) and 
spinal motor neurons (Mentis et al., 2007). These results raised the possibility that synaptic 
dysfunction might be causally related to motor neuron death in SMA. To address this possibility, 
Fletcher et al counted the number of vulnerable (L2) motor neurons in mice in which SMN was 
selectively restored in either motor neurons (SMA+ChATCre) or in proprioceptive neurons 
(SMA+PvCre) as previously described (Mentis et al., 2011). No significant motor neuron loss was 
observed at postnatal day 2 (P2), whereas 34% of motor neurons were lost at P4 and 42% at P11 
(Fletcher et al., 2017) (Figure 11, A-B). 
 
 
Figure 11. Motor neuron loss in SMA is mediated by cell autonomous mechanisms. (A) 
Confocal images of L2 motor neurons visualized by ChAT immunoreactivity (and shown in white) 
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in WT (n=3), SMA (n=4), SMA+PvCre (n=3), SMA+ChATCre (n=4) and SMA+(Pv+ChAT)Cre (n=4) 
mice at P4. (B) Time course (P2–P11) of the total L2 motor neurons number for the experimental 
groups shown in (A). All data are represented as mean ± s.e.m. # P<0.05, one-way ANOVA (WT v 
SMA); * P<0.05, one-way ANOVA, Tukey’s post hoc analysis. Adapted from (Fletcher et al., 
2017). 
 
 Selective restoration of SMN in proprioceptive neurons (SMA+PvCre) did not prevent motor 
neuron death, whereas SMN restoration in motor neurons (SMA+ChATCre) rescued motor neurons 
both at early (P4) and late (P11) stages of disease. There was no additional motor neuron rescue 
observed in SMA+(Pv+ChAT)Cre mice (Fletcher et al., 2017) (Figure 11, A-B). Collectively, these 
results demonstrated that motor neuron death is not induced by SMN-deficiency in sensory neurons, 
indicating that motor neuron death in SMA is a motor-neuron cell autonomous event due to SMN 
deficiency in motor neurons per se. Furthermore, these results separated death and dysfunction of 
motor neurons as two independent and distinct events, suggesting that they are driven by different 
mechanisms. 
 
1.3. Complement and microglia in CNS development and neurodegeneration 
 
1.3.1. Complement proteins in the periphery  
 
The complement system consist of ~60  distinct circulating and membrane-bond plasma 
proteins. They interact with each other to opsonize pathogens, activating array of inflammatory 
responses which further aid in fighting infection (Medzhitov and Janeway, 2000). In the periphery, 
complement is a leading mediator of inflammation. Complement proteins serve as a first line of 
defense, playing a crucial role in the defense against infection, by a quick elimination of  invading 
pathogens. Complement system have also an important role in regulating adaptive immune 
response. Furthermore, complement system plays an immune surveillance role through removal of 
cellular debris and apoptotic cells , thus protecting against autoimmunity (Carroll and Isenman, 
2012; Medzhitov and Janeway, 2002; Presumey et al., 2017; Ricklin et al., 2010). Complement 
proteins interact one with another through a sequential enzymatic cascade which results in 
elimination of pathogens. Surrounding host cells are normally protected from complement through 
membrane-bound inhibitors expressed on their cell surface. Soluble complement proteins are 
inactive zymogens until they encounter the pathogen’s cell membrane or a foreign material. Upon 
binding to a target, complement proteins overgo structural changes, followed by proteolytic 
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cleavage, and finally assembly into convertases - active enzyme complexes - which will 
subsequently activate downstream proteins leading to pathogen lysis or phagocytosis (Coulthard et 
al., 2018; Dunkelberger and Song, 2010; Janeway, 2001; Stephan et al., 2012). Because circulating 
complement proteins are inactive zymogens, they can be widely distributed until needed locally 
(Janeway, 2001; Noris and Remuzzi, 2013). Endothelial cells and leukocytes recognize products of 
complement proteolytic cleavage and aid migration of immune cells to sites of inflammation and 
complement-opsonized agents (Coulthard et al., 2018; Medzhitov and Janeway, 2000). The 
complement system can be activated by three separate pathways (Figure 12). They all converge on 
cleavage of complement component C3 – a central molecule in the complement system, that 
produces effector complement fragments which drive complement functions, including the 
elimination of pathogens, debris, and cellular structures. However, all three pathways differ in the 
way they get activated (Coulthard et al., 2018; Janeway, 2001; Noris and Remuzzi, 2013).  
 
 
Figure 12. The complement pathway activation: classical, lectin and alternative pathway. 
The complement components are activated in a cascade-like manner by one of three major 
pathways: The classical pathway is initiated when C1q interacts with one of its binding partners 
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(e.g. antibodies, DNA, RNA, serum pentraxns, apoptotic cells). C1r and C1s proteases bind C1q tail 
region and form the C1 complex. Binding of C1q complex to target induces conformational change 
in the C1q leading to enzymatic activity in C1r cleavage of C1s and generation of active serine 
protease. Activated C1s cleaves C4 and C2 and generates C3 convertase (C3b2b), which cleaves C3 
activating downstream components. The lectin pathway is initiated by the binding of mannose 
binding lectin (MBL) to the residues of mannose on the cell surface. The alternative pathway is 
spontaneously activated through spontaneous C3 hydrolysis and serves to amplify he pathway 
initiated by classical or lectin cascade. All three pathways converge on the complement component, 
C3. C3 cleavage generates opsonin C3b  and anaphylactic peptide C3a. C3b/iC3b  opsonization 
leads to elimination of the target by phagocytes expressing C3 receptors. C3b joins C4b2a (the C3 
convertase) forming the C5 convertase (C4b2a3b complex) which generates anaphylatoxin C5a, 
that binds to C5a receptors (C5aR) on phagocytes. Potent complement activation can lead to the 
terminal complement cascade activation and the target cell lysis through the insertion of membrane 
attack complex (MAC) - the pore-forming C5b-C9 complex. Adapted from (Stephan et al., 2012). 
 
The classical pathway is activated when C1q - the initiating protein of the pathway, binds to 
one of its various ligands, including serum pentraxins, antigen-antibody complexes, C reactive 
protein (CRP), viral membranes, polyanions (RNA, DNA, , and lipopolysaccharides), and apoptotic 
cells (Gaboriaud et al., 2011; Kang et al., 2006; Kishore and Reid, 2000; Stephan et al., 2012), 
When C3 is cleaved, activated C3 fragments - C3b and iC3b opsonize targets leading to its 
elimination by phagocytic cells through C3 receptors (i.e., CR3/Cd11b, Figure 12). Furthermore, 
potent C3 activation can provoke the terminal activation of classical pathway resulting in cell lysis 
by formation of the lytic membrane attack complex (MAC) (Figure 12)(Janeway, 2001). The lectin 
pathway, which is an antibody-independent pathway, is initiated when the mannose binding lectin 
(MBL) or a group of related proteins binds to terminal sugar moieties that are expressed on 
glycoproteins or polysaccharides on cell membranes (Degn et al., 2007; Fujita, 2002; Janeway, 
2001; Stephan et al., 2012). The alternative pathway is  spontaneously activated and can serve as an 
amplification loop of classical and lectin pathway (Janeway, 2001) acting as an amplifier. 
Considering that complement pathways results in such powerful destructive and 
inflammatory effects they must be tightly regulated. Importantly, when activated, critical 
complement components are promptly inactivated if they do not bind to the surface (i.e.pathogen) 
on which their activation was originally initiated. Additionally, there are several check points in 
pathways at which comlement regulatory proteins act to protect host cells from unintended damage 
or elimination. Balance between activation and inhibition of the complement activation is critical 
for a correct complement function as well as for the tissue homeostasis (Janeway, 2001; Kim and 
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Song, 2006; Zipfel and Skerka, 2009). While, a battery of well described regulatory proteins tightly 
controls complement cascade in the periphery, little is known about complement regulators in the 
CNS.  
 
1.3.2. Complement in developmental synaptic pruning 
 
            Traditionally, the brain has been viewed as an immune privileged organ. Studies from early 
and mid 20th century involving transplantation of tumor, fetal tissue and skin grafts into the brain 
gave rise to this concept. In support of it, are anatomical characteristics of the brain and spinal cord 
as they are protected by meninges and the cerebrospinal fluid. Additionally, presence of the blood-
brain barrier (BBB), protects from the entry of pathogens, harmful factors and circulating immune 
cells. However, in recent years, this thought of immune privilege has shifted significantly with the 
growing knowledge that the immune and nervous system interact in various ways. These complex 
neuroimmune interactions exist under homeostatic as well as under pathological conditions 
(Louveau et al., 2015; Stephan et al., 2012). Additionally, recent demonstration of Meningeal 
Lymphatic System existance (Louveau et al., 2018), further modifies the immune privileged view of 
CNS. Both, central nervous and immune system have a wide array of molecules and signaling 
pathways with different and comparable functions in each system. Among these immune-nervous 
system “cross road” molecules are the classical complement pathway components.While the role of 
the classical complement cascade in the periphery is well known, its function in the central nervous 
system is under wide-ranging investigation.  
At birth, the vertebrate brain contains excess synapses, between neurons. For the 
establishment of the precise, mature neural circuits, these excess connections must be removed. 
This process is called synaptic pruning (Hua and Smith, 2004; Katz and Shatz, 1996). Elimination 
of synapses during circuitry refinement is a developmental process in which certain subsets of 
synapses are removed while the remaining ones are strengthened and maintained (Paolicelli et al., 
2011; Schafer et al., 2012; Stephan et al., 2012; Tenner et al., 2018). Synaptic pruning occurs 
during postnatal development -a period of remarkable plasticity, but depending on the CNS region 
and neuronal circuit, during different critical periods.  
Rodent visual system has served as a model system to study synaptic pruning in the brain. 
Recent research revealed an unexpected and remarkable role for the classical complement pathway 
in the refinement of visual inputs to the lateral geniculate nucleus (LGN) during the early postnatal 
eye-specific segregation (Stevens et al. 2007). Synaptic pruning is a critical process necessary for 
correct establishment of neuronal circuits and is thought to be driven by neuronal activity, in such 
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way that less active or “weak” synapses are removed, which allows for maturation and 
strengthening of more active ones. Complement proteins are widely expressed in the postnatal brain 
but during the active circuitry remodeling periods they localize specifically to the subsets of 
developing synapses. Classical complement pathway components tag synapses for removal by 
microglia that express complement receptors (Presumey et al., 2017; Schafer et al., 2012; Stevens et 
al., 2007). There is a growing evidence that related, complement-based mechanisms are involved in 
synaptic pruning and circuitry refinement in  other areas of developing brain (Chu et al., 2010; 
Coulthard et al., 2018; Stevens et al., 2007). Thus, it is critical to understand when and where are 
complement components normally expressed in the CNS, as that will help unravel complement 
functions during normal development as well as in disease. Additionally, it would be important to 
understand whether complement-dependent synaptic pruning could be a mechanism for 
developmental synapse elimination in other regions of CNS, as much of the current knowledge is 
coming from the visual system.  
When the synaptic refinement goes wrongly, neuronal circuitries are not properly formed 
resulting in either too few, too many, or inappropriate synapses. These circuitry perturbations are 
thought to underlie numerous neurological disorders. Recent studies have indicated involvement of 
complement proteins in neurodevelopmental disorders, such as schizophrenia and autism (Fagan et 
al., 2017; Presumey et al., 2017; Sekar et al., 2016). Furthermore, these developmental synaptic 
pruning mechanisms appear to be reactivated in neurodegeneration and by aging (Presumey et al., 
2017). 
 
1.3.3. C1q structure and function 
 
            C1q is the first subcomponent of the C1 complex serving as a recognition molecule in the 
classical complement cascade. However, C1q can act both dependent or independent of classical 
complement pathway (Janeway, 2001). The human C1q protein weighing 460 kDa is composed of 
18 polypeptides and up to 226 amino acid residues each. C1q consists of 6 heterotrimers each of 
which contains C1qA, C1qB, and C1qC chains. Thus, C1q heterotrimers have collagen-like triple 
helices structure and associate in their N-terminal portion forming a “stalk”, that later separates into 
individual “stems”. Each stem terminates with a C-terminal globular domain (gC1q), each 
containing a C1qA, C1qB, and C1qC chain (Figure 13) (Gaboriaud et al., 2003; Kishore and Reid, 




Figure 13. Structural organization of the C1q molecule. (A) C1q molecule is made of 6A, 6B 
and 6C chains. (B) The chains form six individual strands. Each strand is made up of A-B dimer, 
noncovalently associated with a C-chain. (C) Two strands are disulphide-bonded through adjacent 
C-chains and form a doublet. Finally, three doublets are noncovalently linked and form the intact 
hexameric C1q. Adapted from (Ghebrehiwet, 2018). 
 
While the C-terminal parts form gC1q that allows ligand recognition the N-terminal regions 
stabilize C1q through interchain disulfide bridges forming (CLR or cC1q). Approximately 35 
residues of the N-terminal part of all six C1q heterotrimers have cylinder-shaped organization after 
which they separate into individual stems following a kink which is in each heterotrimer caused by 
an imperfect GXY triplet pattern occurring in C1qA and C1qC chains (Kilchherr et al., 1985; 
Mortensen et al., 2017).The final structure of C1q molecule bears resemblance to a bouquet of 
tulips (Figure 13). Globular C1q domain, gC1q, at the C-terminus and a short N-terminal collagen-
like region represent two unique functional and structural domains (Figure 13) (Brodsky-Doyle et 
al., 1976; Cho, 2019; Knobel et al., 1975).  
 They are independent one of another and interact with diverse biological structures which 
includes cell-associated  and pathogen-associated molecules (Cho, 2019). Globular head domains of 
C1q are responsible for ligand recognition. Each of the three gC1q subunits has particular surface 
patterns in regards to their hydrophobic and charged residues, thus may be expected to present 
individual specific recognition properties. In addition, compact trimeric C1q head structure  allows 
recognition of the ligand by residues contributed from two or sometimes even three subunits, which 
therefor broadens the recognition spectrum of the C1q (Gaboriaud et al., 2003). This may partially 
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explain the observation that many C1q ligands show significant interaction with several residues of 
all three globular domain subunits (Kishore et al., 2003). 
 
1.3.4. The classical complement pathway in neurodegeneration 
 
Synapse elimination is mostly considered a developmental process. However, synapse loss 
and dysfunction have been highly recognized as an early hallmark of numerous neurodegenerative 
diseases including Alzheimer's disease,  Huntington’s, Prion diseases, Frontotemporal dementia  
and Spinal Muscular Atrophy (Lipton et al., 2001; Mallucci, 2009; Mentis et al., 2011; Selkoe, 
2002; Smith et al., 2005; Verret et al., 2012). Besides the role of complement proteins in normal 
brain development recent studies have implicated involvement of the C1q and classical complement 
pathway in aging process and in neurodegenerative diseases. 
Expression and activation of complement has been reported in Alzheimer's patient tissue as 
well as in mouse models. Furthermore, C1q was found to localize to synapses in mouse models of 
Alzheimer's disease which implicates complement-mediated synapse loss in Alzheimer's disease A 
significant upregulation of C1q was found in the retina of a mouse model of glaucoma. Moreover, 
C1q-deficient mice were found to be protected from the synapse loss and the resulting dendrite 
atrophy (Presumey et al., 2017; Stevens et al., 2007; Williams et al., 2016). C1q was also found to 
be upregulated in a mouse model of progranulin-deficient Frontotemporal dementia, where is also  
involved in the disease progression (Lui et al., 2016). All mentioned neurodegenerative diseases 
have different ages of onset, affect different CNS regions and have different etiologies, yet 
complement is upregulated in all and has similar involvement in disease progression. Thus, 
complement-mediated synaptic loss may be an early characteristic of neurodegenerative diseases in 
general (Presumey et al., 2017). There is a mounting evidence that implicates complement proteins 
involvement in other neurodegenerative diseases such as Huntington’s disease (HD) , Parkinson’s 
disease (PD), and amyotrophic lateral sclerosis (ALS) (Kjaeldgaard et al., 2018; Loeffler et al., 
2006; Tenner et al., 2018; Woodruff et al., 2006; Yamada et al., 1992). Beside indications for 
complement involvement, other common characteristic of these diseases is an increase in  
microglial and astrocytic activation which further supports that complement factors may be 
potentially contributing to their pathogenesis (Brennan et al., 2016; Tenner et al., 2018). 
Although there seems to be a connection between complement activation and 
neurodegeneration in Alzheimer’s, Glaucoma and Frontotemporal dementia, there are many open 
questions remained to be answered. Could similar complement-dependent mechanisms be active in 
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other disease affected CNS regions, where synaptic loss is characteristic of neurodegeneration? 
Additionally, whether these synapse elimination mechanisms in neurodegeneration represent a 
reactivation of the developmental program specific for an affected circuitry remains unclear. 
Importantly, studying the involvement of classical complement cascade will help in uncovering 
mechanisms involved in synaptic loss and may provide new potential therapeutic targets in order to 
slow or ameliorate the disease phenotype. 
 
1.3.5. The Role of Microglia in Synapse Elimination 
 
Microglia are immune cells unique to the CNS. They represent resident macrophages in the 
brain and play critical roles in normal brain development. Microglia are unique among the 
mononuclear phagocytes as they are the only cells that do not originate from the bone marrow but 
from the yolk sac’s hematopoietic stem cells. From yolk sac microglia migrate early in the 
development to the brain (Ginhoux et al., 2010; Kierdorf et al., 2013; Presumey et al., 2017). When 
they populate and get settled in the brain, they are not under normal conditions replenished by 
peripheral cells from the circulation. It has been demonstrated that microglia are long-lived cells, 
with approximately half of them surviving the entire life span of a mouse (Füger et al., 2017; Yona 
et al., 2013).Microglia are highly motile CNS cells which allows them to promptly respond to 
infections and injuries. Although their functions in the normal brain are not fully elucidated, it is 
known that microglia in the normal brain development, through the interactions with neurons 
participate in neuronal migration, neurogenesis, developmental neuronal apoptosis and synaptic 
development as well as synapse function. Microglia have an important role in brain wiring because 
they promote synapse development. In  support of this are numerous reports of microglia in close 
relation with spines,  small dendritic protrusions enclosing postsynaptic compartment of typically 
one excitatory synapse (Nayak et al., 2014; Presumey et al., 2017; Tremblay et al., 2011).  
Recent research implicates microglia in synaptic pruning in developing brain via 
complement-dependent and independent mechanisms (Hong et al., 2016; Neniskyte and Gross, 
2017; Tenner et al., 2018; Werneburg et al., 2016). Microglia are found to be more phagocytic 
during the early postnatal period and specifically in regions of active circuitry refinement (Schafer 
et al., 2012; Tenner et al., 2018).  It has been shown, that microglia can - via complement receptor 3 
(CR3) - internalize synaptic structures during the development of visual system. Numerous 
microglia were found to contain in their lysosomes fragments of presynaptic material during the 
period of circuitry refinement and synaptic pruning.  It was also demonstrated in the developing 
visual system that during the activity-dependent synaptic competition that microglia has preference 
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to less-active synapses (Schafer et al., 2012). The observed internalization of synaptic material by 
microglia significantly dropped after the circuitry refinement – synaptic pruning period was over, 
which highly suggests that microglial engulfment in synapse elimination mechanisms. In support of 
this is the fact that CR3 (CD11b/CD18, mac-1) expression in the brain is reserved solely to 
microglia (Presumey et al., 2017; Schafer et al., 2012). These data suggest that microglia mediate 
synaptic elimination via C3-tagging and CR3 and that this process is regulated through neural 
activity. In support of this is the observed increase in  synaptic engulfment by microglia during 
neural activity inhibition, suggesting that less active or “weak” synapses are those destined to be 
eliminated during development (Schafer et al., 2012). 
Although synaptic pruning mechanisms have been well studied and described during the 
development of visual system, synaptic elimination is poorly understood when it comes to 
developmental circuitry refinement in other CNS regions. In addition to visual system, recent 
studies have implicated synaptic engulfment by microglia in the visual cortex and hippocampus,  
but it remain unknown whether this circuitry remodeling is during different developmental stages 
complement dependent (Paolicelli et al., 2011; Tenner et al., 2018; Tremblay et al., 2010). 
Furthermore, all these studies focused on different brain regions, but it remains unknown whether 
spinal cord motor circuits undergo similar microglia and/or complement-mediated synaptic 
refinement and if so, how would impairment of these refinement mechanisms translate onto the 
complex motor behavior? Additionally, it is currently unknown whether microglia-mediated 
synaptic pruning is a shared characteristic of both development and the disease.   
Recent studies have implicated complement-mediated synapse elimination via microglia in 
early synaptic loss observed in Alzheimer’s disease (Hong et al., 2016).Similarly, complement-
microglia dependent synapse loss may be involved in other neurodegenerative diseases, in which 
synaptic loss is an early hallmark. In SMA, excitatory glutamatergic synapses are lost early in the 
disease process. However, it is currently unknown whether this is due to a developmental arrest or, 
are these synapses actively eliminated. Additionally, contribution of complement and microglia to 
the pathogenesis of disease is poorly understood. Beside their involvement in synaptic loss it would 
be essential to unravel whether complement has effect on synapse function or it is a sole mean of 
synaptic elimination. It is also critical to test whether inhibition of complement activation could 







The goal of this study is to investigate the mechanisms involved in spinal sensory-motor 
circuitry refinement during normal development, as well as the mechanisms that are responsible for 
sensory-motor circuitry dysfunction in the neurodegenerative disease spinal muscular atrophy 
(SMA). To achieve these, the following aims have been outlined:  
- Determine the molecular mechanisms involved in sensory-motor circuitry pathology in 
SMA and determine whether they are due to motor neuron autonomous defects or other non-
cell autonomous mechanisms. 
- Unravel the mechanisms involved in the reduction of proprioceptive synapses in SMA and 
differentiate between a potential developmental synaptic arrest versus an active synaptic 
elimination. 
- Discover to which extent complement proteins are involved in synaptic loss and dysfunction 
in SMA. 
- Characterize the source of C1q in the spinal cord. 
- Identify which cell(s) may mediate elimination of sensory synapses in SMA and determine 
whether there is selective synaptic vulnerability in the context of disease. 
- Determine whether C1q tagging of proprioceptive synapses is driven by SMN deficiency in 
proprioceptive neurons via cell autonomous mechanisms. 
- Demonstrate whether neutralization of C1q by in vivo treatment could prevent synaptic loss 
and confer behavioral benefit in SMA mice. 
- Find out if genetic deletion of C1q rescues proprioceptive synapse loss in SMA mice. 
- Conclude whether C1q plays a role during normal development and determine the potential 














3.1.1. Experimental Model – Mice  
 
Mice used in this study were housed in pathogen-free conditions.  All surgical procedures 
were performed on postnatal mice according to the National Institutes of Health Guidelines on the 
Care and Use of Animals. Columbia animal care and use committee (IACUC) approved all the 
performed procedures. Both sexes’ mice were used since previously published work in SMA mouse 
models and patient data do not demonstrate any sex-related difference neither in the onset nor in 
SMA severity. The original start breeding pairs of SMA mice used in this study (Smn+/–
/SMN2+/+/SMNΔ7+/+) were obtained from Jackson Mice (Jax stock #005025; background FVB). Dr. 
M. Botto (Imperial College London, UK) provided under an MTA agreement C1qa-/- mice 
(background C57BL6) as previously reported (Botto et al., 1998). C1qa-deficient mice (C57BL/6) 
lack C1q protein, thus have disrupted classical complement pathway (Botto et al., 1998). C3-/- mice 
(C57BL/6 background), deficient in C3 protein, were purchased from Jackson Laboratory (B6 
129S4-C3 < tmCrr > /J; stock No. 003641). In order to generate Smn+/-;SMN2+/+;SMND7+/+;C1qa-/- 
mice, C1qa-/- mice were crossed with SMA mice. To generate Pv-Cre+/-;SMN2+/+;SMNΔ7+/+ mice, 
SMA mice carrying Smn Cre-inducible allele (SmnRes; JAX stock #007951; (Lutz et al., 2011) were 
bred with PvCre (Jax stock #008069) mice. Cre- SMA mice lacked Cre, they were null for Smn 
allele and they carried SmnRes allele (SmnRes/–;SMN2+/+;SMNΔ7+/+). Cre+ SMA mice lacked 
endogenous mouse SMN, they carried one allele of SmnRes and they were heterozygous for PvCre 
(PVCre+/-;SmnRes/–;SMN2+/+;SMNΔ7+/+). WT mice were mice homozygous for wild-type allele in 
which Cre was absent (Smn+/+;SMN2+/+;SMNΔ7+/+). Similarly ChATCre mice were bred with mice 
carrying Smn Cre-inducible allele (SmnRes) to generate ChATCre+/-;Smn+/-;SMN2+/+;SMNΔ7+/+. 
Cre+ SMA mice carried one allele of SmnRes, they lacked endogenous mouse Smn and they were 
heterozygous for ChATCre (ChATCre+/-;SmnRes/-;SMN2+/+;SMNΔ7+/+). Additionally, PvCre and 
ChATCre mice were bred with mice carrying SmnRes to generate PVCre+/-;ChATCre+/-;SmnRes/-






3.1.2. Human Post-Mortem Tissue 
 
           Fresh frozen spinal cord tissue (lumbar segments) from one control patient - 3 years old male 
was obtained from the Brain Center (Columbia University), and fresh frozen spinal cord tissue 
(lumbar segments) from one SMA type I patient - 7 months old male, was kind gift from Dr. 






Polymerase chain reaction (PCR) genotyping from tail deoxyribonucleic acid (DNA) for SMA-Δ7, 
PvCre and C3-/- mice was performed following Jackson protocols as described on their website 
(https://www.jax.org). PCR reaction for the Smn, C3 PvCre and ChATCre alleles was used as follows: 
0.5 µl of each primer (25 µM; Sigma), 12.5 µl of GoTaq Hot Start Green Master Mix (Promega) 
and 4 µl of lysed tail DNA 1:20 diluted. Final volume of reaction - 25 µl was adjusted using 
ddH2O. Following thermal cycling protocol was used for the amplification of Smn and SmnRes 
alleles products: 95ºC for 2 minutes was followed by 35 cycles of 95ºC for 1 minute, 55ºC for 1 
minute, 72ºC for 1 minute, terminating with 72ºC for 5 minutes. Amplification of PvCre alleles 
products was done following next thermal cycling protocol: 94ºC for 3 minutes was followed by 34 
cycles of 94ºC for 30 seconds, 58ºC for 30 seconds, 72ºC for 1 minute and terminating with 72ºC 
for 5 minutes. Amplification of ChATCre allele products was done following next thermal cycling 
protocol: 95°C for 3 minutes, 97°C for 30 seconds; two step cycles 5 times: 95°C for 15 seconds, 
69°C for 1 minute; three step cycles 30 times: 95°C for 15 seconds, 60°C for 15 seconds, 68°C for 1 
minute and 68°C for 5 minutes. Amplification of C3 alleles products was performed following next 
thermal cycling protocol: 94ºC for 3 minutes was followed by 12 cycles of 94ºC for 20 seconds, 
64ºC for 30 seconds (0.5ºC increase per cycle), 72ºC for 35 seconds and then followed by 25 cycles 
of 94ºC for 20 seconds, 58ºC for 30 seconds and 72ºC for 35 seconds, and terminating reaction with 
72ºC for 2 minutes. Tail DNA extraction for C1q genotyping was done utilizing KAPA Biosystems 
Express Extract Kit (cat #KK7103). PCR reaction was performed as per following protocol: 25 µl 
of 2x Master Mix (2 mM; Promega #: M750B), 0.5 µl of tail DNA, 4 µl of MgCl2 (25 mM; 
Promega #: A351F), 1 µl of mC1qIN/1 primer, 2 µl of Neo30 primer and 1 µl  of mC1qA/50+ 
primer and adjusted to total volume of 50 µl with 16.5 µl of ddH2O. Amplification of the C1q 
alleles products was performed using the next thermal cycling protocol: 95ºC for 4 minutes, 94ºC 
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for 1 minute, and followed by 35 cycles of 94ºC for 1 minute, 57ºC for 30 seconds and 72ºC for 30 
seconds, terminating with 70ºC for 10 minutes. All custom-made primers are listed below (Table 1).  
 
Table 1. List of custom-made PCR primers. 
C1q knock-out allele forward primer GGGGATCGGCAATAAAAAGAC 
C1q wild-type allele forward primer GGGGCCTGTGATCCAGACAG 
C1q wild-type allele reverse primer ACCAATCGCTTCTCAGGACC 
uninverted SmnRes forward primer ACGCGTACCGTTCGTATAGC 
uninverted SmnRes reverse primer TGAGCACCTTCCTTCTTTTTG 
inverted SmnRes forward primer CAACCAGTTAAGTATGAGAATTC 
inverted SmnRes reverse primer GTTTGCAGAAGCGGTGGG 
PVCre wild-type allele reverse primer CGAGGGCCATAGAGGATGG 
PVCre allele reverse primer GCGGAATTCTTAATTAATCAGCG 
PVCre common forward primer GGATGCTTGCCGAAGATAAGAGTG 
ChATCre wild-type allele forward primer GTTTGCAGAAGCGGTGGG 
ChATCre allele forward primer TCGCCTTCTTGACGAGTTCTTCTG 
ChATCre common reverse primer GGCCACTTAGATAGATAATGAGGGGCTC 
 
 
3.2.2. Behavioral Analysis  
 
All experimental mice groups were monitored daily. Their body weight and righting time 
was recorded. Righting time was measured by placing a mouse on back and recording how long the 
pup needed to right itself back to an upright position, with cut off test time being 60 seconds to 
comply with IACUC guidelines. This was repeated 3 times and righting time was averaged for 
analysis. Mice were euthanized with carbon dioxide per IACUC guidelines if they had both lost 
25% of their body weight compared to previous day and were unable to right. Systemic 
administration anti-C1q antibody (ANX-M1, mouse anti-C1q antibody, Annexon Biosciences) or 
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its isotype control (mouse IgG1, Annexon Biosciences), was performed under an MTA agreement. 
Intraperitoneal (IP) injections were done in both WT and SMA mice every second 
day from birth (P0) and until death with a 100 mg/kg dose. Treated pups were monitored daily for 
righting times and body weight (average of three trials). Treatment was done in blind manner and 
mice were injected with either anti-C1q antibody or isotype control antibodies. Mice treated with 
PLX5622 IP solution were injected intraperitoneally two times a day starting from birth (P0) until 
P10/11 when tissue was harvested.  Systemic administration of PLX5622 IP solution was done at a 
dose of 50 mg/kg. Treated pups were monitored daily and body weight as well as righting times 
were analyzed. This treatment had maximal depletion of microglia but at low survival rate was 
observed in both WT and SMA mice.  
 
3.2.3. Physiology: Ex vivo Spinal Cord Preparation  
 
Mice were decapitated and spinal cord was dissected in cold oxygenated (12 ºC, 
95%O2/5%CO2) artificial cerebrospinal fluid (aCSF) which contained in mM: 4 KCl, 128.35 NaCl, 
0.58 NaH2PO4.H20, 30 D-Glucose, 21 NaHCO3, 1 MgSO4.7H20 and 1.5 CaCl2.H20. Isolated spinal 
cord was transferred to a custom-made recording chamber which was continuously perfused with 
oxygenated aCSF at the rate of 10 ml/min, at room temperature (21-24ºC). Ventral and dorsal roots 
were placed in suction electrodes for the stimulation and recording, respectively. Recordings from 
L1 or L2 ventral root were obtained in response to stimuli from homonymous L1 or L2 dorsal root, 
respectively. The stimulus threshold was defined as the minimal current which is necessary to 
evoke a response in homonymous ventral root, in 3 out of total 5 trials. Dorsal roots stimulations 
were performed at supramaximal intensity (0.2ms, 2-5x threshold) and delivered by constant current 
stimulus isolator (A365 - WPI, Sarasota, FL). Recordings were 1000x amplified (Cyberamp, 
Molecular Devices), fed to the A/D interface (Digidata 1320A, Molecular Devices) and acquired at 
50kHZ utilizing Clampex (V10, Molecular Devices). Data analysis was done offline using Clampfit 
(Molecular Devices). Amplitude measurements were obtained by averaging 10 single stimulations 
responses at 0.1 Hz. Following the recording session, in some experiments, tissue was collected for 
immunohistochemistry. Spinal cords were immersion fixed overnight in 4% PFA, and then 






3.2.4. Functional Assessment of NMJs 
 
Neuromuscular junctions (NMJs) of Quadratus Lumborum (QL) muscle were functionally 
assessed at P11. In order to do so a technique was developed in which axons of motor neurons in 
ventral root L2 (which innervate QL muscle) were stimulated by pulling the ventral root into the 
suction electrode while having removed spinal cord. The stimulation of L2 ventral root was 
performed with single stimulus (0.2 ms at supramaximal intensity), at different frequencies which 
were ranging from 0.1 Hz to 50 Hz to mimic physiological range for firing of neonatal motor 
neurons (Fletcher et al., 2017). Compound muscle action potentials (CMAPs) of Quadratus 
Lumborum were recorded utilizing a concentric bipolar electrode which was inserted in the muscle 
belly. The maximum CMAP amplitude, measured baseline-to-peak, was averaged from 10 
stimulations at 0.1 Hz. If tissue was collected for immunohistochemistry, upon the recording 
session, Quadratus Lumborum muscles were fixed for 20 minutes in 4% PFA and then transferred 
to PBS until processed for NMJ staining. 
 
3.3. Tracing and Immunohistochemistry  
 
Experimental mice [WT, SMA, SMA+a-C1q Ab, SMA+Ctr Ab, WT+PLX5622, 
SMA+PLX5622, C1q-/-, C3-/-, SMA+C1q-/-] were used in tracing and immunohistochemistry 
experiments at birth (P0), P4, or P11.  
 
3.3.1. Somatodendritic labeling of Motor Neurons 
 
The intact but isolated ex vivo spinal cord was hemisected to improve oxygenation (for P11 
spinal cords). The dissection chamber was perfused with cold oxygenated (10 ºC, 95% O2 / 5% 
CO2) aCSF (which contained in mM: 4 KCl, 128.35 NaCl, 21 NaHCO3, 0.58 NaH2PO4.H2O, 30 D-
Glucose, 2 MgSO4.7H2O and 0.1 CaCl2.H2O). The L1 or L2 (depending on experiment) ventral root 
was placed into the suction electrode which was then filled with the fluorescent dextran dye (Texas 
Red, Alexa Fluor 488 or Cascade Blue) allowing retrograde labeling of motor neurons. After 
allowing 14 – 20 hours for dye to fill motor neurons, the spinal cord was immersion fixed overnight 
in 4% paraformaldehyde and subsequently transferred to PBS until processed for 




3.3.2. Retrograde Labeling of Muscle-Identified Motor Neurons 
 
C1q-/- and WT motor neurons which supply Tibialis Anterior (TA) and Gastrocnemius (GA) 
muscles were in vivo retrogradely labeled by intramuscular Fluorescinated Dextran or CTb 
conjugated to Alexa 555 injections. Newborn mice (P0) were anesthetized utilizing isoflurane 
inhalation. Small incision was made in the right or left TA and GA area to access the muscles. GA 
muscles were injected with the fluorescinated dextran while TA muscles were injected 
with the 1 mL of 1% CTb-Alexa 555 in PBS. Injections were performed using a custom made, 
finely pulled glass micropipette. Dextran and CTb were delivered by pressure to a customized 
microsyringe. All incisions were sutured. Spinal cords were collected after 7 days (P7) and 
processed for immunohistochemistry. 
 
3.3.3. Tissue Collection 
 
Mice were anesthetized using 1.2% avertin (300mg/kg, intraperitoneal injection) and 
transcardially perfused with ice cold PBS to remove blood until tissue was cleared of blood (ie liver 
blanching). When fixation was required, mice were additionally perfused with 4% PFA. Spinal cord 
was carefully dissected after transcardial perfusion and immersion fixed in 4% PFA (4 hours to 
overnight). Subsequently, spinal cord was washed and stored in PBS until being processed for 
immunohistochemistry 
 
3.3.4. Immunohistochemistry  
 
Embedding of spinal cords was done in warm 5% Agar. Transverse serial sections from L1 
or L2 spinal segment (depending on experimental set up) were cut at 75 µm thickness using a 
Vibratome (Leica). Experiments in which anti-mouse antibodies were used, sections were pre-
incubated in M.O.M blocker (Vector Laboratories) for 1 hour, to block endogenous antigens. 
Blocking was done at room temperature for 1.5 hours using 10% normal donkey serum in 0.01M 
PBS, 0.1% Triton X-100 (PBS-T, pH 7.4). Following blocking, sections were incubated at room 
temperature overnight (for C1q antibody 24 hours) in different primary antibodies combinations 
diluted in PBS-T. The following day, washing was done in PBS-T, followed by 3h secondary 
antibody incubations at room temperature. Appropriate species-specific secondary antibodies were 
diluted in PBS-T. Subsequently, sections were washed in PBS, and mounting was done using 30% 
glycerol in PBS on glass slides and custom cover-slips. All antibodies, except VGluT1 (custom 
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made), Parvalbumin (custom made), and TMEM119 (Barres lab), were purchased from commercial 
sources. Production of VGluT1 anti-guinea pig antibody was done with the company Covance. 
Antibody was designed against the following epitope: (C)GATHSTVQPPRPPPP which is found 
within n-terminus of a mouse VGluT1 (Fletcher et al., 2017). Specificity of the VGluT1 antibody 
was confirmed in VGluT1 knock out tissue. Production of Parvalbumin anti-chicken antibody was 
done by Covance. Antibody was designed against full length bacterial fusion protein. The following 
primary antibodies were used at the indicated dilutions: rabbit monoclonal anti-C1q (1:1000; 
Abcam, ab182451), goat polyclonal anti-ChAT (1:100; Millipore, AB144P), rabbit polyclonal anti-
human C1q (1:500; Agilent, A013602), rat monoclonal anti-CD45 (1:1000; Millipore, 05-1416), 
rabbit polyclonal anti-C3d (1:500; Dako, A006302), rat monoclonal anti-CD68 (1:200; AbD 
Serotec, MCA1957GA), mouse monoclonal anti-GFAP (1:500; Sigma-Aldrich, G3893), rabbit 
polyclonal anti-GFAP (1:500; Dako, Z0334), goat polyclonal anti-Iba1 (1:500; Abcam, ab5076), 
rabbit polyclonal anti-Iba1 (1:500; Wako 019-19741), mouse monoclonal anti-NeuN (1:100; 
Millipore, MAB377) mouse monoclonal anti-TMEM119 (1:3; Barres lab), guinea pig polyclonal 
anti-Synaptophysin (1:500; Synaptic Systems, 101 004), guinea pig polyclonal anti-VGluT1 
(1:2000; custom made), guinea pig polyclonal anti-VGAT (1:200; Synaptic Systems, 131 004). 
Following are secondary antibodies used at the 1:250 dilution: Alexa Fluor 488 donkey anti-rabbit 
(Jackson ImmunoResearch, 711-545-152), Alexa Fluor 488 donkey anti-goat (Jackson 
ImmunoResearch, 705-545-003), Fluor 488 donkey anti—mouse (Jackson ImmunoResearh, 715-
545-150), Alexa Fluor 488 donkey anti-guinea pig (Jackson ImmunoResearch, 706-545-148), Alexa 
Donkey anti-guinea pig-Cy5 IgG (Jackson ImmunoResearch, 706-175-148), Donkey anti-mouse-
Cy5 IgG (Jackson ImmunoResearch, 715-175-151), Donkey anti-rabbit-Cy5 IgG (Jackson 
ImmunoResearch, 711-175-152), Donkey anti-rabbit-Cy3 IgG (Jackson ImmunoResearch, 711 165-
152), Donkey anti-goat-Cy3 IgG (Jackson ImmunoResearch, 705-165-147), Donkey anti-guinea 
pig-Cy3 IgG (Jackson ImmunoResearch, 706-165-148)  Donkey anti-rat-Rhodamine Red X IgG 
(Jackson ImmunoResearch, 712-295-153), Donkey anti-mouse-Cy3 IgG (Jackson 
ImmunoResearch, 715-165-150). 
 
3.3.5. Human Post-Mortem Tissue Staining 
 
Fresh frozen spinal cord tissue from the control patient (3 years old male) and from the 
SMA type I patient (7 months old male) was a kind gift from the Brain Center at Columbia 
University and Dr. Wendy Chung, respectively. Spinal cord tissue was cut on a cryostat at 20 µm 
thickness. Fixation was done for 2 minutes with 4% PFA upon which, sections were washed in PBS 
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and subsequently treated as described above. Sections were incubated overnight with primary 
antibodies against C1q - rabbit polyclonal anti-human (1:500; Dako, A013602-1) and against ChAT 
- goat polyclonal (1:100; Millipore, AB144P). Following day sections were washed and 
subsequently incubated with secondary antibodies: Donkey anti-rabbit-Cy3 (Jackson 
ImmunoResearch, 711-165-152) and Alexa Fluor 488 donkey anti-goat (Jackson ImmunoResearch, 
705-545-003). Sections were then washed and mounted using 30% glycerol in PBS. 
 
3.3.6. Staining in Dorsal Root Ganglions (DRGs) 
 
Mice were transcardially perfused at P11 with 2% PFA in a sodium acetate buffer (pH 6). 
Dorsal root ganglia were collected from L1-L3 spinal segments and immersion fixed for 2 hours. 
Tissue was cut with a vibratome at 100 µm thickness. Initial blocking was done in M.O.M. blocker 
(Vector Laboratories) diluted in PBS-T for an hour at room temperature, to prevent non-specific 
binding of secondary antibody to mouse antigens. Sections were then processed as described above, 
in previous immunohistochemistry protocol. Following primary antibodies were used:  mouse 
monoclonal anti-SMN (1:50; BD Biosciences, 610646) and chicken polyclonal anti-Parvalbumin 
(1:2000; custom made). Species specific secondary antibodies used were: donkey anti-mouse-Cy5 
IgG (Jackson ImmunoResearch, 715-175-151) and Alexa Fluor 488 donkey anti-chicken (Jackson 
ImmunoResearch, 703-545-155). Finally, sections were counter-stained with DAPI, washed and 
mounted using 30% glycerol in PBS. 
 
3.3.7. NMJ Staining 
 
Neuromuscular junctions (NMJs) were studied in the Quadratus Lumborum (QL) muscle. 
Muscles were collected from P11 mice (from each genotype) and for 20 minutes immersion fixed 
in 4% PFA which was followed by washing in PBS. Teasing of single fibers was done with fine 
forceps, which was followed by 30 minutes washing in PBS enriched with 0.1M glycine. Fibers 
were then incubated with alpha-bungarotoxin-555 for 20 minutes in order to stain postsynaptic part 
of neuromuscular endplates. Fibers were subsequently washed in PBS and permeabilized in ice cold 
methanol for 2 minutes. Following permeabilization fibers were washed in PBS and subsequently 
blocked for an hour with 10% Donkey Serum in 0.3% PBS-T prior to antibodies exposure. 
Following antibodies were used: guinea pig polyclonal anti-synaptophysin (1:500; Synaptic 
Systems, 101 004) and rabbit polyclonal anti-Neurofilament (1:500; Millipore). Primary antibodies 
were incubated overnight at 4 ºC. Following day, fibers were washed in PBS and secondary 
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antibodies exposure followed for one hour at room temperature. Following secondary antibodies 
were used: Donkey anti-guinea pig-Cy5 IgG (Jackson ImmunoResearch, 706-175-148) and Alexa 
Fluor 488 donkey anti-rabbit (Jackson ImmunoResearch, 711-545-152). Following the secondary 
antibody incubation, fibers were washed and mounting was done using 30% glycerol in PBS. 
 
3.4. Quantification and Data Analysis 
 
3.4.1. Imaging and Analysis 
 
Imaging was performed using the SP8 Leica confocal microscope. Off-line analysis of 
images was done using ImageJ (National Institutes of Health) and LASX (Leica Microsystems) 
software. For all immunohistochemistry experiments analysis, at least three mice from each 
genotype were used. Motor neuron counts were performed analyzing z-stacks images, which were 
acquired at 3 µm intervals and collected from each section containing fluorescent signal from L1 or 
L2 retrogradely labeled MNs and/or ChAT immunostained MNs, as previously described (Mentis et 
al., 2011; Fletcher et al., 2017). Sections for motor neuron counts were scanned with x20 dry 
objective. To avoid double counting of motor neurons (ChAT+) from the adjoining spinal cord 
sections, exclusively motor neurons containing the nucleus were counted. Quantitative analysis of 
VGluT1 synaptic densities at P11 were performed on L1 motor neurons using z-stacks of optical 
sections which were scanned with a x40 oil objective throughout the entire section thickness (at 
0.35 µm z-step size) in order to include the whole motor neuron cell body as well as proximal 
dendrites of ChAT+ and/or retrogradely labeled motor neurons. Density estimates were obtained by 
counting all VGluT1+ inputs on dendritic segments at sequential distances of 50 µm (0-50 µm and 
50-100 µm) from the cell body of motor neurons and dividing this number with the total linear 
length of all dendritic segments in every compartment, as described previously (Mentis et al., 2011; 
Fletcher et al., 2017). For VGluT1 counts on motor neuron cell bodies, only those motor neurons 
with an entire soma present within the analyzed z-stack were included. Gamma motor neurons were 
excluded from analysis, by counting only those motor neurons with a cell bodyperimeter greater 
than 400 µm2. 
 
3.4.2. SMN Quantification 
 
DRG sections were scanned throughout the whole section with x40 oil objective at 0.5 µm 
z-steps. For each studied genotype number of gem negative and positive proprioceptive neurons 
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was counted. For each genotype three mice were used with a minimum of 30 counted 
proprioceptive neurons per animal. 
 
3.4.3. NMJs Quantification 
 
The extent of NMJ innervations was determined by analyzing NMJ synapses for different 
experimental groups. Z stack images of NMJ synapses were acquired with x20 dry objective, 
scanning at 2 µm z-steps. Offline analysis of images was performed using LASAF software, 
counting numbers of innervated and denervated synapses. NMJ synapse was 
considered innervated only if the presynaptic nerve terminal was completely co-localizing with the 
postsynaptic endplate.  
 
3.4.4. Fluorescent In Situ Hybridization (FISH) combined with Immunohistochemistry 
 
Mice were transcardially perfused and spinal cords were isolated, post-fixed for 24 hours in 
4% PFA at 4 ºC, and subsequently cryopreserved overnight in 10%, followed by 20% and finally 
30% sucrose solutions. Spinal cord segments L1-L3 were sectioned using a cryostat (Leica) at 20 
µm thickness and mounted on super-frost slides. Fluorescent in situ hybridization (FISH) for C1qa 
was performed with RNAscope probe from Advanced Cell Diagnostics (ACD, #441221-C3) using 
the RNAscope Multiplex Fluorescent Reagent Kit V2 (ACD, #323110) and following 
the recommendations from manufacturer. HRPC1 signal was developed using TSA Plus Cyanine 5 
System (PerkinElmer, #NEL745E001KT). Slides with sections were briefly washed in PBS 
following the last wash in RNAscope protocol, and subsequently blocked in 10% normal donkey 
serum. Primary antibodies were incubated at room temperature overnight in wet chamber. Against 
ChAT goat polyclonal anti-ChAT antibody was used (1:100; Millipore, AB144P) and against Iba1 
rabbit polyclonal anti-Iba1 antibody (1:500; Wako 019-19741) was used. Sections were washed 
following day in PBS-T and incubated with secondary antibodies for 2 hours at room temperature. 







3.4.5. Quantification of Tagged Synapses 
 
Deposition of C1q and C3 on synapses was analyzed and quantified from single optical 
plane images which were acquired using a x63 oil or x40 oil objectives at resolution of 4096x4096 
DPI, using the SP8 Leica confocal microscope and LASX software from Leica Microsystems for 
subsequent deconvolution and the offline image analyses. Only synapses that were contacting motor 
neurons on either soma or on dendrites were analyzed. Synapse was defined as ‘‘tagged’’ only if 
C1q or C3 signal clearly colocalized with presynaptic signal. This colocalization was each time 
confirmed with intensity line profiling tool, where the intensity line profiles of C1q (or C3) and 
those of synaptic markers overlapped. To obtain percentage of tagged synapses all synaptic contacts 
were counted on soma and on dendrites of motor neurons and compared against the numbers of 
tagged synapses on motor neurons soma and on dendrites, respectively. 
 
3.4.6. C1q Binding Assay 
 
Black Costar 3925 plate from Corning was coated with human C1q (Complement 
Technology Inc) at the concentration of 2 µg/ml in bicarbonate buffer and incubated at 4 ºC 
overnight (100 µl/well). Next day, plate was 3x washed with 200 µl/well dPBS. Subsequent locking 
was done using 3% BSA in PBS, 200 µl/well, at room temperature, for 1 hour. Control isotype 
antibody or neutralizing anti-C1q antibody (Annexon Biosciences) was added in triplicate serial 
dilutions (8-12 point titration, 200-400 ng/ml) in dPBS with 0.3% BSA, 0.1% Tween buffer,50 
µL/well, and incubated at room temperature for 1 hour. Subsequently, goat anti-mouse-Fc-AP 
(Jackson ImmunoResearch) at 1:2000 dilution was added, 50 µl/well, diluted in PBS with 0.3% 
BSA, 0.1% Tween. Plate was then washed 3 times for 10 minutes, with dPBS 0.05%Tween 200 
µl/well. Incubation of AP substrate (CDP-Star) followed, for 20 minutes at room temperature. 
Infinite 200 PRO plate reader (Tecan Life Sciences) was used to read the plate. 
 
3.4.7. RNA Analysis 
 
Spinal segments L1-L2 were isolated at P4 and P11 from WT and SMA mice for RT-qPCR 
experiments. Phenol-free total RNA isolation was performed using the RNAqueous-Micro Kit 
(ThermoFisher Scientific). RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) 
was used for reverse transcription of RNA and Power SYBR Green PCR master mix (Applied 
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Biosystem) was used to perform triplicate reactions in a Realplex4 Mastercycler (Eppendorf). All 
primers designed for RT-qPCR experiments are listed below (Table 2). 
 
Table 2. List of custom-made primers used in RT-qPCR experiments. 
C1qA forward primer:  AAGGATGGGGCTCCAGGAAAT 
C1qA reverse primer:  TTCCCCTGGGTCTCCTTTAAAACCT 
C3 forward primer:  CCATCACAGTCCGCACCAAGAA 
C3 reverse primer:  GAGTTGTGCATAGTGCTGTAGGGA 
GAPDH forward primer:  AATGTGTCCGTCGTGGATCTGA 
GAPDH reverse primer:  GATGCCTGCTTCACCACCTTCT 
C5 forward primer:  CAGTAACAGTCACAGAATCTTCAGGT 
C5 reverse primer:  GGAGAGAGGACATATTTGACTCCA 
C5aR1 forward primer:  CCAGGACATGGACCCCATAGATA 
C5aR1 reverse primer:  CCATCCGCAGGTATGTTAGGA 
CD59b forward primer:  TCTCTATGCTGTAGCCGGAAG 
CD59b reverse primer:  TTGTATGCCTGCCACGTCTA 
IL-1β forward primer:  AGTTGACGGACCCCAAAAG 
IL-1β reverse primer:  AGCTGGATGCTCTCATCAGG 
IL-6 forward primer:  AGTCCGGAGAGGAGACTTCA 
IL-6 reverse primer:  GCCATTGCACAACTCTTTTCTCA 
TNF forward primer:  GTCCCCAAAGGGATGAGAAGTT 
TNF reverse primer:  TGTGAGGGTCTGGGCCATAG 
 
 
3.4.8. Western Blot Analysis 
 
WT, SMA+a-C1q antibody and SMA mice spinal cord segments L1–L3 (n = 2) were 
collected at P11 and homogenized in lysis buffer (150 mM NaCl, 1% Triton, 2 mM EDTA, 50 mM 
Tris, pH 7.4). Proteins were quantified with Bio-Rad protein assay. Protein extracts, in 
concentration of 30 µg, were run on 12% SDS–PAGE gels and subsequently transferred for probing 
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to PVDF membranes. Blocking was done for 1 hour, at room temperature, in 5% milk diluted in 
TBS/0.2% Tween. Membranes were probed with following primary antibodies: mouse monoclonal 
Anti-a-Tubulin (1:10000; Sigma-Aldrich, T9026) or mouse monoclonal anti-SMN (1:10000; BD 
Biosciences, 610646) which were diluted in blocking buffer (5% milk in TBS/0.2% Tween), and 
incubated at 4 ºC, overnight. Next day, membranes were 3 times washed in TBS/0.2% Tween and 
incubated at room temperature, for 1 hour, with following secondary antibody diluted in TBS/0.2% 
Twee: Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L) (Western Blot, 1:10000; Jackson 
ImmunoResearch, 115-035-003). Membranes were washed 3 times and visualized with enhanced 




PRISM (GraphPad Software, Prism Version 6.04.) was used to perform statistical analysis. 
Comparisons were performed using Student’s t test or One-Way ANOVA when normality and 
homoscedasticity conditions were respected. When violated, non-parametric Kruskal-Wallis and 
Mann–Whitney Wilcoxon tests were used. A p-value less than 0.05 (p < 0.05) was considered 

















4.1. The origin of sensory-motor circuitry pathology in SMA  
 
4.1.1. Selective restoration of SMN in proprioceptive neurons rescues synaptic loss  
 
In order to accurately quantify proprioceptive synapses on motor neurons across all studied 
experimental groups, a highly specific vesicular glutamate transporter 1 (VGluT1) antibody had to 
be produced as all commercially available antibodies were proven to be unreliable and inconsistent 
upon testing. VGluT1 antibody was designed against the epitope (C)GATHSTVQPPRPPPP on a 
mouse VGluT1 protein. Selected epitope is located within the n-terminus of a mouse VGluT1. 
Polyclonal anti-VGluT1 antibody was produced in guinea pig with the company Covance. After 
being injected with a designed peptide to elicit a primary immune response, guinea pig was given a 
secondary immunization to achieve higher antibody titers. After each immunization, guinea pig was 
bled and polyclonal antibodies were obtained straight from the serum and tested on P0, P4 and P11 
WT and SMA lumbar spinal cord sections at different serial dilutions, starting at 1:100 and ending 
at 1:20 000. Processed spinal cord sections were scanned within the 24 hours from the time serum 
was obtained and decision was made weather to immunize guinea pig again or if satisfied to 
perform terminal bleed. Specificity of the VGluT1 antibody was confirmed in VGluT1 knock out 
tissue. 
Previous experiments have demonstrated that the reduction of EPSP amplitude observed in SMA 
motor neurons is successfully restored in SMA+PvCre but not in SMA+ChATCre motor neurons 
(Fletcher et al., 2017) suggesting that motor neuron dysfunction is a consequence of SMN loss from 
proprioceptive neurons. To further examine whether this rescue of the EPSP amplitude in 
SMA+PvCre motor neurons was due to a rescue of the actual number of proprioceptive synapses, the 
number of VGluT1+ synapses on retrogradely filled motor neurons was quantified. A significant 
rescue of VGluT1 synapses was found on both soma and dendrites of motor neurons in SMA+PvCre 
mice at P4 (Figure 14, A-C), while no synaptic rescue was noted in SMA+ChATCre motor neurons 
(Fletcher et al., 2017) (Figure 14, A-C;). These results indicate that selective restoration of SMN in 
proprioceptive neurons rescues the number of synapses that are normally reduced under SMN 





Figure 14. Selective restoration of SMN in proprioceptive neurons in SMA rescues the 
number of synapses. (A) Z-stack projection of confocal images from L2 retrogradely labeled 
motor neurons (shown in blue) and VGluT1 immunoreactivity (shown in green) in WT, SMA, 
SMA+PvCre and SMA+ChATCre mice at P4. Insets show at higher magnification VGluT1 synaptic 
appositions on dendrites. The total distance in the z axis for all images was 7 μm (20 optical planes 
at 0.35 μm intervals) and 1.5 μm for the insets. (B) The average number of VGluT1 synapses on 
soma of L2 motor neurons in WT (n=17), SMA (n=14), SMA+PvCre (n=13) and SMA+ChATCre 
(n=15) mice. * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA, Tukey’s post hoc analysis. (C) 
VGluT1 synaptic density at 50 μm dendritic compartments from soma, for the same groups shown 
in (A) and (B). * P<0.05, ** P<0.01, *** P<0.001, one-way ANOVA, Tukey’s post hoc analysis. 
Adapted from (Fletcher et al., 2017). 
 
Additionally, the number of VGluT1 synapses in SMA+PvCre motor neurons remained 
comparable to those observed in WT mice motor neurons at a late stage of disease – P11 (Fletcher 
et al., 2017) (Figure 15, A-C;), which demonstrates that VGluT1 synapses continue to develop at 
older ages. Thus, SMN restoration in proprioceptive neurons rescues synaptic loss. Taken together 
with physiological findings (Fletcher et al., 2017), these results strongly argue that motor neuron 






Figure 15. Maintenance of rescued VGluT1 synapses at P11. (A) Z-stack projection of confocal 
images from L2 retrogradely labeled motor neurons (shown in blue) and VGluT1 immunoreactivity 
(shown in green) at P11 in WT, SMA, SMA+PvCre, SMA+ChATCre and SMA+(Pv+ChAT)Cre mice. 
The total distance in the z-axis for all images was 7 μm (20 optical planes at 0.35 µm intervals). (B) 
The average number of VGluT1 synapses on soma of L2 motor neurons at P11 in WT, SMA, 
SMA+PvCre, SMA+ChATCre and SMA+(Pv+ChAT)Cre mice. * P<0.05, ** P<0.01, *** P<0.001, 
one-way ANOVA, Tukey's post hoc analysis. (C) VGluT1 synaptic density at 50 μm dendritic 
compartments from soma, for the same groups as shown in (A) and (B). * P<0.05, ** P<0.01, 
***P<0.001, one-way ANOVA, Tukey's post hoc analysis. Adapted from(Fletcher et al., 2017). 
 
4.1.2. BDNF does not contribute to motor neuron dysfunction 
 
Fletcher et al addressed the possibility that other factors such as Brain-Derived Neurotrophic Factor 
(BDNF), which can be released by proprioceptive neurons (Betley et al., 2009; Mende et al., 2016) 
could also contribute to motor neuron dysfunction (Fletcher et al., 2017). Physiological assays 
revealed similar physiological properties in SMA motor neurons compared to SMA + BDNFproprio 
motor neurons (SMA motor neurons in mice in which BDNF was overexpressed in proprioceptive 
neurons) (Fletcher et al., 2017). To confirm BDNF release from proprioceptive SMA synapses upon 
the AAV9-GFPmBDNF based overexpression of BDNF (Fletcher et al., 2017), VGluT1, glutamic 
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acid decarboxylase 65-kilodalton isoform (GAD65) and 67-kilodalton isoform (GAD67) 
immunohistochemistry was performed (figure 16A, C). An increase in GAD65, and not GAD67 in 
Gamma-aminobutyric acid (GABA)pre synapses demonstrated that BDNF is released from SMA 
proprioceptive synapses (Figure 16B, D) similarly as what was previously reported for VGluT1−/− 
mice (Mende et al., 2016). 
 
Figure 16. BDNF is released from SMA proprioceptive synapses. (A) GAD65 immunoreactivity 
(shown in red) in GABApre terminals contacting VGluT1 (shown in green) proprioceptive afferent 
terminals in SMA and SMA+AAV9-BDNF mice at P5. GABApre terminals are indicated by 
arrows. (B) Synaptic marker intensity measurements (shown in arbitrary units) in GAD65+ 
GABApre terminals in mice at P5. (total numbers for GAD65: 39 terminals, n=3 mice per 
experimental group). *** P<0.001, Mann-Whitney test. (C) GAD67 immunoreactivity (shown in 
red) in GABApre terminals contacting VGluT1 (shown in green) proprioceptive afferent terminals 
in SMA and SMA+AAV9-BDNF mice at P5 mice. GABApre terminals are indicated by arrows. 
(D) Synaptic marker intensity measurements (shown in arbitrary units) in GAD67+ GABApre 
terminals in mice at P5. (total numbers for GAD67: 39 terminals, n=3 mice per experimental 
group). NS: not significant (P=0.72, Mann-Whitney test) Adapted from (Fletcher et al., 2017). 
 
Together with electrophysiological assays which revealed very similar physiological 
properties of SMA + BDNFproprio motor neurons compared to SMA motor neurons (Fletcher et al., 
2017) this data indicates that changes in SMA motor neuron function are unlikely mediated by 
release of BDNF from proprioceptive neurons. In summary, these results demonstrate that 
presynaptic impairment is responsible for motor neuron dysfunction in SMA further supporting that 






4.2. The mechanisms of synaptic loss in SMA 
 
4.2.1. Proprioceptive synapses are eliminated at the onset of SMA 
 
            Proprioceptive synapses reach motor neurons at late embryonic stages (Chen et al., 2003) 
and continue proliferating during postnatal development (Kudo and Yamada, 1987; Li and Burke, 
2002; Mentis et al., 2011). Proprioceptive synapses in SMA have reduced numbers compared to 
age-matched wild type (WT) mice at late stages of disease (Mentis et al., 2011). It is 
currently unknown whether this is due to synaptic arrest occurring during development, or are these 
synapses physically eliminated in SMA. This question was addressed by performing temporal 
analysis of the synaptic density of proprioceptive synapses on the somata and proximal dendrites in 
SMA motor neurons in the L1 spinal segment which is also a vulnerable spinal segment in SMA. 
Analyses were done on proximal dendrites (at distance  from soma 0-100μm) of motor neurons, as 
the large majority (>80%) of proprioceptive synapses expressing the vesicular glutamate transporter 
1 (VGluT1) are found on these sites (Fletcher et al., 2017; Rotterman et al., 2014). Analysis 
revealed that at birth (P0), there is no significant difference in the number of proprioceptive 
synapses between WT and SMA mice (Vukojicic et al., 2019) (Figure 17, A-C). This suggests that 
in SMA sensory synapses are formed normally. However, a significant progressive loss of SMA 
VGluT1+ synapses in proximal dendrites of motor neurons was observed at later ages, P11 and P13, 
compared to P4. Synaptic counts were analyzed at dendritic compartments 0-50μm and 50-100μm 
from the soma (Vukojicic et al., 2019) (Figure 17B, C).  
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Figure 17. Vulnerable proprioceptive synapses are actively eliminated in SMA. (A) z-stack 
projection of confocal images from L1 motor neurons (MNs) retrogradely labeled (shown in blue) 
and VGluT1 synapses (shown in green) in P11 WT and SMA mice. Total distance in the z axis: 6 
µm. (B) VGluT1+ synaptic density (number of synapses per 50 µm of dendritic length) in proximal 
dendritic compartments (0–50 µm) of WT (shown in blue) and SMA (shown in red) motor neurons 
at P0, P4, P11, and P13; N ≥ 3 mice per group. In WT number of dendrites: n = 11 (P0), n = 51 
(P4), n = 35 (P11), and n = 18 (P13); in SMA: n = 9 (P0), n = 42 (P4), n = 33 (P11), and n = 10 
(P13). (C) VGluT1+ synaptic density in 50–100 µm proximal dendritic compartments in WT 
(shown in blue) and in SMA (shown in red) motor neurons at P0, P4, P11, and P13; N ≥ 3 mice per 
group. In WT number of dendrites: n = 15 (P0), n = 44 (P4), n = 36 (P11), and n = 15 (P13); in 
SMA: n = 9 (P0), n = 34 (P4), n = 31 (P11), and n = 11 (P13). *p < 0.05, **p < 0.001, ***p < 
0.001; one-way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Intriguingly, there was no significant difference in the number of eliminated synapses on the 
soma of motor neurons at different ages in SMA (Vukojicic et al., 2019) (Figure 18), suggesting 
that the proprioceptive synapses on the soma may be more resilient to synaptic loss as compared to 





Figure 18. Proprioceptive synapses on the motor neurons soma may be more resilient to synaptic 
loss Graphs are showing temporal difference in the somatic number of VGluT1 synapses on L1 
motor neurons in WT (shown in blue) and SMA (shown in red) mice at P0, P4, P11 and P13. * 
p<0.05, ** p<0.001, *** p<0.001 with One-way ANOVA and Tukey’s test. Adapted from 
(Vukojicic et al., 2019).These results indicate that proprioceptive synapses in SMA are formed 
normally, but subsequently eliminated, starting at the onset of disease phenotype in mouse models 
of disease. 
 
4.2.2. C1q is expressed during normal spinal cord development and upregulated in SMA 
 
C1q, the initiating protein of the classical complement pathway, has been implicated in 
synapse elimination in Alzheimer’s disease models (Hong et al., 2016), in glaucoma (Howell et al., 
2011; Stevens et al., 2007), and frontotemporal dementia models (Lui et al., 2016). These 
observations have raised the possibility that classical complement pathway may also be involved in 
SMA. To investigate the molecular mechanisms underlying synaptic loss in SMA, the involvement 
of the C1q – the initiating protein of the classical cascade, was explored in this phenomenon. 
Immunoreactivity experiments revealed presence of C1q at similar levels in WT and SMA mice at 
birth (Vukojicic et al., 2019) (Figure 19). In striking contrast, a strong upregulation of C1q was 
observed in vulnerable SMA spinal cord segments at the onset of disease - (P4) and at late stages - 




Figure 19. Increased C1q expression coincides with the onset of SMA when vulnerable 
synapses are eliminated. Z stack projection of confocal images from L1 motor pools visualized 
with ChAT (shown in blue) and C1q (shown in red) immunoreactivity from P0, P4, and P11 WT 
and SMA mice. Total distance in the z axis: 4.9 µm. Adapted from (Vukojicic et al., 2019). 
 
An increased C1q immunoreactivity was noted around, but not within motor neurons 
(Vukojicic et al., 2019) (Figure 20), suggesting that C1q was not expressed in motor neurons. 
 
 
Figure 20. C1q is found around but not within motor neurons. Confocal images of motor 
neurons (ChAT: shown in blue) and C1q (shown in red) immunoreactivity in WT and SMA mice at 




 Importantly, C1q antibody specificity was validated in C1q knockout (C1q-/-) mice 
(Vukojicic et al., 2019) (Figure 21). 
 
Figure 21. Validation of C1q antibody specificity. Z-stack projection of confocal images from the 
L1 spinal cord segment of C1q-/- mice showing motor neurons labeled with ChAT in blue and C1q 
in red. Total distance in the z-axis: 9.1 μm. Adapted from (Vukojicic et al., 2019) 
 
Furthermore, quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
experiments revealed that C1qA mRNA was also significantly increased at the onset of disease - P4 
in vulnerable SMA spinal segments L1-L2 compared to those in WT mice (Vukojicic et al., 2019) 
(Figure 22A).  
 
Figure 22. C1qA gene expression is increased at the onset of disease while the main 
proinflammatory cytokines remain unchanged. (A) qRT-PCR analysis of C1qA mRNA levels at 
P4 in the spinal cord segments L1–L2 of WT (n = 3, shown in blue) and SMA (n = 3, shown in red) 
mice. *p < 0.05; t test. (B) RT-qPCR analysis of IL-1β, IL-6 and TNF mRNA levels at P4, in the 
spinal cord segments L1-L2 of WT (n=3, shown in blue) and SMA (n=3, shown in red) mice. No 




While C1q levels were elevated, there was no significant difference in the mRNA levels of 
the proinflammatory cytokines tumor necrosis factor (TNF), interleukin 1 beta (IL-1β), and 
interleukin 6 (IL-6) in WT and SMA L1-2 spinal cords at P4 (Vukojicic et al., 2019) (Figure 22B) 
suggesting that increased C1q expression in SMA was not associated with the activation of 
inflammatory pathways as seen in neuroinflammatory diseases or in CNS injury. In addition to the 
increase in a mouse model of SMA, increased C1q immunoreactivity was also observed in human 
post-mortem spinal cord tissue from SMA Type I patient compared to a control (Vukojicic et al., 
2019) (Figure 23), suggesting that similar mechanisms operate in both animal models and in SMA 
patients.  
 
Figure 23. C1q expression is increased in SMA Type I human spinal cord. Z-stack projection of 
confocal images visualized with ChAT (shown in blue) and C1q (shown in red) immunoreactivity 
from post-mortem control and SMA patient’s spinal cord lumbar segment. Total distance in the z-
axis: 6μm. Adapted from (Vukojicic et al., 2019). 
 
Taken together, these results suggest that there is a local production of C1q in close 
proximity to motor neurons and demonstrate a transient expression of C1q during early normal 
postnatal development in WT spinal cords as well as an aberrant upregulation of C1q at the onset of 
SMA. 
 
4.2.3. Vulnerable SMA synapses are tagged by C1q and C3 
 
To determine C1q localization at the synaptic level and particularly whether it is associated with 
proprioceptive sensory synapses, putative interactions between VGluT1+ synapses and C1q were 
investigated using confocal microscopy and high resolution imaging, followed by deconvolution 
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and image analysis in WT and SMA spinal cords at P4. Analysis revealed a close association of 
C1q with VGluT1synapses in both WT and SMA mice (Vukojicic et al., 2019) (Figure 24, A-D). 
However, this “tagging” of proprioceptive synapses occurred at significantly higher percentage 
(~25%) on proximal dendrites of L1 motor neurons in SMA compared to WT counterparts (~4%) 
(Vukojicic et al., 2019) (Figure 24E), which is in correlation with previously described findings that 
proprioceptive synapses are actively lost from proximal dendrites but not form the soma of 
vulnerable L1 motor neurons. Intensity line profiling was used as a quantifiable measure for overlap 
between the two signals (C1q and VGluT1) to confirm each tagging event (Vukojicic et al., 2019) 
(Figure 24C,D). 
Figure 24. C1q tags vulnerable VGluT1 SMA synapses at the onset of disease. (A and B) 
Confocal images of ChAT (shown in blue), C1q (shown in red), and VGluT1 synapses (shown in 
green), at P4 in WT and SMA mice. Arrows indicate tagged synapses. (B) Higher magnification of 
dotted-line box from (A). (C) Higher magnification of the dotted-line box in (B), indicating the line 
in which the fluorescence profile is measured. (D) Fluorescence intensity profile (arbitrary units) for 
C1q signal (shown in red) and VGluT1 signal (shown in green) across the line which is shown in 
(C). (E) Percentage of VGluT1 synapses tagged by C1q on the soma and dendrites of spinal 
segment L1 motor neurons in WT (2,170 synapses from 76 motor neurons) and SMA (1,580 
synapses from 86 motor neurons) at P4. ***p < 0.001; t test. Adapted from (Vukojicic et al., 2019). 
 
To address whether C1q tagging is a selective event targeting specific synapses or 
alternatively all synapses indiscriminately in the context of the neurodegenerative disease, 
immunohistochemistry was employed against a pan-synaptic marker – synaptophysin. A 
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widespread C1q tagging of SMA synapses contacting MNs was discovered (Vukojicic et al., 2019) 
(Figure 25A, B) suggesting possibly C1q tagging beyond proprioceptive synapses in SMA.  
 
                
Figure 25. C1q might be tagging different types of synapses. (A) Confocal images of ChAT 
(shown in blue), Synaptophysin (shown in green) and C1q (shown in red) at P4 in WT and SMA 
motor neurons. (B) Higher magnification images of synaptophysin (shown in green) and C1q 
(shown in red) in WT and SMA spinal cords. Adapted from (Vukojicic et al., 2019). 
 
To explore the possibility that C1q tagging is random in SMA and irrespective of the 
utilized synaptic neurotransmitter immunohistochemical experiments using antibodies against 
inhibitory synapses were performed. GABAergic synapses were labeled with the vesicular 
GABAergic transporter (VGAT). There was no difference between WT and SMA mice in the 
extent of C1q tagged synapses (Vukojicic et al., 2019) (Figure 26A, B). These results are in 
agreement with previous reports that GABAergic and glycinergic synapses are not affected in SMA 
(Ling et al., 2010a; Mentis et al., 2011). 
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Figure 26. C1q does not preferentially tag inhibitory synapses in SMA. (A) Confocal images of 
ChAT (shown in blue), VGAT (shown in green) and C1q (shown in red) immunoreactivity at P4 in 
WT and SMA motor neurons. (B) Percentage of VGAT synapses tagged by C1q on the soma and 
dendrites in WT (shown in blue, n=55) and SMA (shown in red, n = 29) L1 motor neurons at P4. 
Adapted from (Vukojicic et al., 2019). 
 
These results point out that increased synaptic tagging by C1q is specific for excitatory 
proprioceptive synapses, the numbers of which are significantly reduced in SMA (Mentis et al., 
2011). Therefore, these results suggest that C1q might be tagging those synapses destined to be 
eliminated in the context of SMA. 
At birth (P0) aberrant tagging of proximal proprioceptive synapses in SMA was not evident 
(Vukojicic et al., 2019) (Figure 27), which was in agreement with the finding that there was no 
statistical difference in the number of proprioceptive synapses on motor neurons between WT and 
SMA mice.  
                                                              
Figure 27. At birth aberrant tagging of SMA synapses is absent. Percentage of C1q-tagged 
VGluT1 synapses on the soma and dendrites of L1 motor neurons in WT (shown in blue, 454 
synapses from 56 MNs) and SMA (shown in red, 487 synapses from 46 MNs) mice at birth (P0). 
Adapted from (Vukojicic et al., 2019). 
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These results indicate that in SMA, aberrant C1q tagging occurs after birth, at the onset of 
the disease which correlates with the time synaptic loss occurs, suggesting C1q involvement in 
synaptic elimination. 
            To test whether C1q deposition on synapses, triggers classical complement pathway 
activation, localization and the expression of the downstream complement component 
C3 was next investigated. A significant increase in C3 gene expression in SMA compared to WT 
spinal cords at P4 (Vukojicic et al., 2019) (Figure 28A) was revealed with RT-qPCR experiments. 
Additionally, immunohistochemistry against C3 was performed, followed by high resolution 
confocal imaging, deconvolution and image analysis, to determine C3 localization in the context of 
vulnerable synapses in SMA. Analysis showed that C3 associates with WT and SMA VGluT1+ 
synapses (Vukojicic et al., 2019) (Figure 28B, C). However, in SMA mice, C3 is associated with a 
significantly higher number of proprioceptive synapses compared to WT controls (Vukojicic et al., 
2019) (Figure 28D).              
                  
Figure 28. Aberrantly increased C3 tags vulnerable synapses in SMA. (A) qRT-PCR analysis of 
C3 mRNA levels at P4 in the spinal cord L1–L2 segments of WT (shown in blue, n = 3) and SMA 
(shown in red, n = 3) mice. *p < 0.05; t test. (B) Confocal images of motor neurons visualized with 
ChAT (shown in blue), C3 (shown in red), and VGluT1 synapses (shown in green) 
immunoreactivity at P4 in WT and SMA mice. The arrows indicate C3 deposited on synapses. (C) 
Confocal image at a higher magnification of a C3 (shown in red) deposited on a VGluT1 synapse 
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(shown in green) indicated by the dotted-line box in (B; SMA image). (D) Percentage of VGluT1 
C3-tagged synapses on the soma and the proximal dendrites of L1 motor neurons in WT (1,155 
synapses from 27 MNs) and SMA (1,305 synapses from 22 MNs) mice at P4. *p < 0.05; t test. 
Adapted from (Vukojicic et al., 2019). 
 
C3immunoreactivity specificity was validated in C3-/- (C3 knockout) mice (Vukojicic et al., 
2019) (Figure 29). 
 
Figure 29. Validation of C3 antibody specificity. Z-stack projections of confocal images of motor 
neurons visualized with ChAT (shown in blue) and C3 (shown in red) immunoreactivity in L1 
motor neurons of C3-/- at P4. Total distance in the z-axis: 9.1 μm. Adapted from (Vukojicic et al., 
2019). 
 
Together, these results indicate that similar percentage of proprioceptive synapses on 
proximal dendrites associated with C3 to those observed with C1q tagging, suggesting that early in 
the disease process the classical complement pathway is triggered and activated. 
 
4.2.4. Microglia are responsible for synaptic removal in the spinal cord 
 
Microglia have been implicated in synaptic pruning through the complement receptor 3 
(Schafer et al., 2012; Stevens et al., 2007; Wu et al., 2015) which is the major phagocytic receptor 
on microglia (Ehlers, 2000). To determine the cell type responsible for the synapse elimination in 
SMA, the presence of microglia was investigated initially, since they express complement receptor 
3 (CR3) (Tremblay et al., 2011). Immunohistochemistry utilizing ionized calcium-binding adapter 
molecule 1 (Iba1) as a marker for microglia revealed increased presence of Iba1+ cells in SMA 
mice, within the motor neuron nucleus, compared to the WT mice at P4 (Vukojicic et al., 2019) 
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(Figure 30A and 34B). Importantly, VGluT1+ synapses remnants were found within microglia 
profiles in WT and SMA motor neuron pools (Vukojicic et al., 2019) (insets in Figure 30A). 
However, quantification of the number of VGluT1+ synapses remnants within microglia revealed 
significantly higher incidence in SMA mice (Vukojicic et al., 2019) (Figure 30B).  
 
Figure 30. VGluT1+ synapse remnants are found within microglia suggesting of microglia-
mediated synaptic elimination. (A) Z-stack projections of confocal images of motor neurons with 
ChAT (shown in blue), VGluT1 (shown in green), and Iba1 (shown in red) immunoreactivity at P4 
in WT and SMA L1 motor neuron pools. Total distance in the z-axis: 10 µm. Insets show single 
optical planes in which areVGluT1 remnants (indicated by arrows) found within Iba1+ cells. (B) 
Percentage of VGluT1 synapses engulfed by microglia at P4 in WT and SMA mice. *p < 0.001; t 
test (n = 3). Adapted from (Vukojicic et al., 2019). 
 
Most of the VGluT1 remnants within microglia were localized within the internal lysosomal 
compartments labeled by CD68 (Cluster of Differentiation 68) antibody (Vukojicic et al., 2019) 
(Figure 31) suggesting active phagocytosis of engulfed synapses. 
 
Figure 31. VGluT1 remnants are found within microglia lysosomes. Single optical plane 
confocal images of SMA microglia within the L1 spinal segment motor neuron nucleus at P4, 
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visualized by Iba1 (shown in red) and CD68 (shown in blue) as well as VGluT1 (shown in green) 
immunoreactivity. VGluT1 signal within microglial lysosome is indicated by arrows. Adapted from 
(Vukojicic et al., 2019). 
 
 Additionally, in both WT and SMA, every Iba1+ cell revealed low expression of cluster of 
differentiation 45 (CD45). At the same time CD45+/Iba1- cells were not observed, suggesting that 
there is no infiltration of leukocytes (Vukojicic et al., 2019) (Figure 32) which further supports that, 
beside complement activation, other inflammatory pathways are likely not activated. 
 
Figure 32. Low CD45 expression in WT and SMA spinal cord is restricted to Iba1+ cells. (B) 
Z-stack projections of confocal images of WT and SMA spinal cord L1 segments visualized by 
CD45 (shown in red), Iba1 (shown in green) and ChAT (shown in blue) immunoreactivity at P4. 
Total distance in the z-axis: 5.4 μm. Dotted boxes are shown at higher magnification on the right 
side for CD45 (shown in red) immunoreactivity in WT and SMA (a’ and a’’) and for Iba1 (shown in 
green) immunoreactivity in WT and in SMA (b’ and b’’). Adapted from (Vukojicic et al., 2019). 
 
Collectively, these results suggest that VGluT1 synapses are phagocytosed by resident 
macrophages within the central nervous system – microglia, upon activation of the classical 
complement cascade. 
To test whether activation of other components of the classical complement pathway occurs, 
gene expression level of the downstream C5 and its receptor C5aR1 was tested in WT and SMA 
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mice at P4, when complement tagging of vulnerable synapses has been initiated. RT-qPCR 
experiments revealed no difference between WT and SMA L1-2 spinal cord mRNA levels of either 
C5 or C5aR1 (Vukojicic et al., 2019) (Figure 33A,B). Additionally, potential differences in the 
expression of membrane attack complex (MAC) inhibitor - CD59b between WT and SMA mice 
were tested since studies in Amyotrophic Lateral Sclerosis and Alzheimer’s disease noted low 
expression of CD59 coupled with high levels of downstream complement component (Lee et al., 
2013; Yang et al., 2000). It has been demonstrated that CD59b is a key complement regulator in 
mice (Qin  et al., 2003).WT and SMA mice, L1-2 spinal segments, at P4 revealed no difference in 
CD59b expression (Vukojicic et al., 2019) (Figure 33C). 
 
 
Figure 33. The downstream classical complement components are not activated in SMA mice. 
RT-qPCR analysis of C5 (A), C5aR1 (B) and CD59b (C) mRNA levels at P4 in the spinal cord L1-
L2 segments of WT (shown in blue, n=3) and SMA (shown in red, n=3) mice. No significant 
difference was observed, t-test. Adapted from (Vukojicic et al., 2019). 
 
The gene expression experiments for C5, C5aR1 and CD59b in WT and SMA suggest that 
the activation of the downstream components of the classical complement pathway and the 
membrane attack complex (MAC) is unlikely to be involved in synaptic elimination in SMA. These 
results suggest that resident microphage of CNS – microglia are responsible for synapse elimination 
in SMA mice. Collectively, this data indicates that vulnerable SMA synapses are removed upon 
complement tagging and classical pathway activation via microglia-mediated mechanisms which 





4.2.5. Depletion of microglia rescues vulnerable synapses in SMA mice 
 
            To provide the evidence that microglia are causally responsible for synaptic elimination in 
SMA, both WT and SMA mice were treated with PLX5622 – a drug that inhibits the colony 
stimulating factor 1 receptor (CSF1R) (Elmore et al., 2018). Microglia originate from stem cells in 
the yolk sac (Kierdorf et al., 2013). These pluripotent cells develop into microglia precursor cells 
that will migrate to CNS and become microglia. Their development depends on Pu.1 and Irf8 
(Kierdorf et al., 2013) and on the CSF1R (Elmore et al., 2014; Erblich et al., 2011; Ginhoux et al., 
2010). Genetic evidence indicate that CSF1R plays a role in regulating the proliferation, viability 
and density of microglia (Cecchini et al., 1994; Michell-Robinson et al., 2015; Oosterhof et al., 
2018). In adult mice treatment with selective CSF1R inhibitors eliminate up to ∼99% of microglia 
brain-wide (Elmore et al., 2014; Elmore et al., 2018; Najafi et al., 2018; Spangenberg et al., 2019), 
confirming high efficacy of the drug and that microglia physiologically depend on CSF1R signaling 
in adult brain. While adult mice are treated with CSF1R inhibitor enriched breeder chow, SMA and 
WT mice were treated two times a day from birth  until P10 with 50 mg/kg of PLX5622, as 
recommended by the provider - Plexxikon Inc. Morphological analysis of the untreated SMA and 
WT mice ventral horn revealed significantly higher number of microglia in SMA mice compared to 
age-matched WT controls (Vukojicic et al., 2019) (Figure 34A and B) an active proliferation of 
microglia in the close proximity to SMN-deficient motor neurons. In addition to this, microglia 
surrounding motor neurons in SMA mice appeared “activated” as indicated by larger cell body with 
strong Iba-1 immunoreactivity and thicker shorter processes (Davis et al., 1994). In support of this 
is the observation from another study in which increased association of activated microglia with 
motor neurons in SMAΔ7 mice has been reported (Ling et al., 2010a). PLX5622 treatment during 
the first 10 postnatal days resulted in approximately 90% reduction of microglia in WT as well as in 
SMA mice (Vukojicic et al., 2019) (Figure 34B) confirming that administration of PLX5622 




Figure 34. Microglia is successfully depleted from WT and SMA mice upon treatment with PLX5622. 
(A) Confocal images of motor neurons within L1 motor neuron nuclei labeled with ChAT (shown 
in blue) and microglia labeled with Iba1 (shown in red) in WT, SMA, WT+PLX5622 and 
SMA+PLX5622 at P11. (B) Total number of microglia (Iba1+ cells) per 145x103 μm2 area  and 
within motor neuron area in WT (shown in blue, n=5), WT+PLX5622 (shown in light blue, n=3), 
SMA (shown in red, n=7) and SMA+PLX5622 (shown in purple, n=3) mice at P11. *** p<0.001, 
One-way ANOVA, with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Strikingly, microglia depletion correlated with a significant rescue of VGluT1+ proprioceptive 
synapses on proximal dendrites of motor neurons in SMA mice treated with PLX5622 compared to 
untreated ones (Vukojicic et al., 2019) (Figure 35C,D). No difference was observed in somatic 
synaptic counts, supporting the observation that proprioceptive synapses contacting soma of motor 




38. Depletion of microglia in SMA mice rescues vulnerable synapses. (A) Z-stack projections of 
confocal images of motor neurons at P11, labeled with ChAT (shown in blue) and VGluT1 
synapses (shown in white) from untreated SMA and PLX5622-treated SMA mice. Total z stack 
distance: 20 µm. (B) VGluT1 synaptic density - number of synapses in 50-µm from soma dendritic 
compartments at P11 for WT (shown in blue, n = 41), WT+PLX5622 (shown in light blue, n = 17), 
SMA (shown in red, n = 43), and SMA+PLX5622 (shown in purple, n = 9) dendrites. *p < 0.05, 
***p < 0.001; One-way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
To test whether the rescue of synapses had any effect on behavior, the righting reflex was 
monitored daily in SMA and WT mice treated with PLX5622 In addition to synaptic rescue, a 
significant behavioral benefit correlated with the depletion of microglia in SMA treated mice, 
shown by a gradual improvement in time mice take to right after being placed on their back 
(righting time) (Vukojicic et al., 2019) (Figure 36).  
             
Figure 36. Depletion of microglia in SMA mice leads to motor behavior improvement. 
Righting times for WT (shown in blue, n = 10), WT+PLX5622 (shown in light blue, n = 9), SMA 
(shown in red, n = 8), and SMA+PLX5622 (shown in purple, n = 18) mice. *p < 0.05, **p < 0.01, 
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***p < 0.001; t test for SMA versus SMA+PLX5622 for individual ages. Adapted from (Vukojicic 
et al., 2019). 
 
Control experiments showed that PLX5622 treated WT and SMA mice had no significant 
differences in body weight gain (Figure 37A) but a significant improvement in righting behavior in 
SMA, but not WT mice (Figure 36) (Vukojicic et al., 2019).  
 
Figure 37. Depletion of microglia in SMA does not affect body weight nor does it rescue motor 
neurons from dying. (A) Body weights for WT (shown in blue, n=10), WT+PLX5622 (shown in 
light blue, n=9), SMA (shown in red, n=8) and SMA+PLX5622 (shown in purple, n=18) mice. (B) 
Total number of motor neurons in spinal L1 segment for WT (shown in blue, n = 3), SMA (shown 
in red, n = 4), and SMA+PLX5622 (shown in purple, n = 3) mice, at P11. **p < 0.01; one-way 
ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
PLX5622 treatment did not rescue motor neuron death in SMA mice (Figure 37B), which is 
consistent with previous results which demonstrate that motor neuron death and synaptic loss as 
well as dysfunction are two independent events (Fletcher et al., 2017). While motor neuron loss is 
driven by SMN deficiency in motor neurons per se, which leads to activation of intrinsic 
mechanisms responsible for their degeneration (Simon et al., 2017; Van Alstyne et al., 2018),  
sensory motor circuitry dysfunction and synaptic loss are consequence of SMN deficiency in 
proprioceptive neurons (Fletcher et al., 2017). Taken together, these results provide the evidence 
that microglia play an important role in the pathogenesis of SMA. These data demonstrate that 
activated and aberrantly increased microglia are responsible for synaptic elimination in SMA, 
potentially providing another therapeutic target point.  
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4.2.6. SMN deficiency in proprioceptive neurons drives C1q tagging of proprioceptive 
synapses 
 
            In order to identify what triggers C1q deposition at VGluT1 synapses, SMN was selectively 
restored in proprioceptive neurons in SMA mice. An SMA mouse model harboring two transgenic 
alleles and a single targeted mutation which resuls in the following genotype 
Smn+/Res;SMN2+/+;SMNΔ7+/+was used (Fletcher et al., 2017). The allele that carries targeted 
mutation (SmnRes) reverts to a fullyfunctional Smnallele consequent to Cre-mediated recombination 
(Cre+/-;SmnRes/-;SMN2+/+;SMNΔ7+/+) (Lutz et al., 2011).SMN2 is the human gene whereasSMNΔ7is 
the human SMN cDNA without exon 7. These mice have phenotype similar to the SMNΔ7 SMA 
mice in the absence of the Crerecombinase (Cre-/-;SmnRes/-;SMN2+/+;SMNΔ7+/+) (Fletcher et al., 
2017). In order to restore SMN protein selectively inproprioceptive neurons these conditional 
inversion SMA mice were crossed with Parvalbumin::Cre (PvCre) mice as has mentioned before, 
which label only proprioceptive neurons(during the first 10 postnatal days), as previously shown 
(Fletcher et al., 2017;Mendelsohn et al., 2015). SMA::PvCremice show significant reduction of C1q 
deposition on VGluT1+ proprioceptive synapses located at the proximal dendrites of SMA 
vulnerable motor neurons (Vukojicic et al., 2019) (Figure 38A,B). Previous results have 
demonstrated that loss of SMN from proprioceptive neurons drives sensory-motor circuitry 
dysfunction and synaptic loss (Fletcher et al., 2017). Now, results of these experiments indicate that 
upon specific restoration of SMN in proprioceptive neurons, C1q tagging of VGluT1 synapses in 
SMA is comparable to that in WT mice (Vukojicic et al., 2019), suggesting that presynaptic SMN 
deficiency drives C1q-mediated mechanisms of synaptic loss in SMA.  
    
Figure 38. Selective restoration of SMN in proprioceptive neurons prevents C1q-tagging 
proprioceptive synapses. (A) z stack projection of confocal images of motor neurons retrogradely 
labeled (shown in blue), VGluT1 synapses (shown in green), and C1q (shown in red) from a P4 
SMA::PvCre motor neuron pool. Total distance in the z-axis: 4.2 µm. (B) Percentage of C1q-tagged 
VGluT1 synapses on the soma and dendrites of spinal segment L1 motor neurons in WT (shown in 
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blue, 2,170 synapses from 76 MNs), SMA (shown in red, 1,580 synapses from 86 MNs), and 
SMA::PvCre (shown in yellow, 921 synapses from 52 MNs) at P4. ***p < 0.001; one-way 
ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
4.2.7. The local source of C1q in spinal cord are microglia 
 
            Possible local source of C1q in spinal cord was next investigated considering that 
previous results suggest that there is no infiltration of leukocytes in SMA spinal cord as well as the 
fact that through transcardial perfusion preceded all immunohistochemical experiments, meaning all 
blood derived complement was eliminated. Since C1q signal was not present within motor neurons 
and morphology of large C1q accumulations resembled the shape of microglia, 
immunohistochemistry experiments utilizing C1q antibody in combination with the antibodies 
against transmembrane protein 119 (TMEM119) and Iba1 were performed. While Iba1 labels 
microglia and microphages and is upregulated during the activation of these cells (Ohsawa et al., 
2004), TMEM119 is a specific marker for microglia only and it is not expressed by macrophages or 
other neuronal or immune cell types (Bennett et al., 2016). All double positive Iba1+/TMEM119+ 
cells (n=128 from 3 WT mice n=215 from 3 SMA mice) showed a strong C1q signal in both WT 
and SMA mice (Vukojicic et al., 2019) (Figure 39A, B). These results suggest that C1q in spinal 
cord could be produced locally by microglia.  
     
Figure 39. All spinal cord microglia expresses C1q.  Z-stack projections of confocal images of 
C1q (shown in red), TMEM119 (shown in blue), and Iba1 (shown in green) in P4 SMA (upper 
images) and WT (lower images) in the L1 spinal ventral horn. Total distance in the z-axis: 5.25 µm. 
The circled area indicates the motor neuron nucleus. The area shown in the insets is indicated by 
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dotted-line box The insets show at higher magnification the colocalization of microglia 
(Iba1+/TMEM119+ cells) and C1q. Adapted from (Vukojicic et al., 2019). 
 
Additionally, all Iba1+ cells (n=135 from 3 WT mice; n=252 from 3 SMA mice) were positive for 
cluster of differentiation 68 (CD68) (Vukojicic et al., 2019) which is highly expressed by the 
monocyte lineage cells and by both circulating and tissue macrophages and microglia (Holness and 
Simmons, 1993). This result together with the previous observation that all Iba1+ cells were 
TMEM119+, suggests that infiltration of macrophages or monocytes does not occur in WT or SMA 
mice, further supporting idea that C1q is locally produced by microglia. Additionally, these data 
also support previous observation that in SMA spinal cord there is no leukocyte infiltration as seen 
in classically defined neuroinflammatory conditions (e.g. multiple sclerosis) or after CNS injury. 
Importantly, to probe further whether C1q is produced by microglia, fluorescent in situ 
hybridization (FISH) in combination with immunohistochemistry was performed.  
  
Figure 40. Microglia are the source of C1q in the spinal cord. Single optical plane confocal 
images from FISH C1q mRNA (shown in red) combined with Iba1 (shown in green) and ChAT 
(shown in blue) immunoreactivity at P4 in WT, SMA and C1q-/- mice. Dotted boxes are presented 
at higher magnification on the right side for C1q mRNA (shown in red) and Iba1 (shown in green) 
immunoreactivity in WT, SMA and C1q-/- mice. Adapted from (Vukojicic et al., 2019). 
 
These experiments revealed C1qA mRNA presence within Iba1-antibody labeled microglia, 
but not inside motor neurons, which were labeled with ChAT antibody (Vukojicic et al., 2019) 
(Figure 40). FISH results confirmed that indeed microglia produces C1q both during normal 
development and in SMA. While all Iba1+ cells expressed C1qA, none was found inside of motor 
neurons. Additionally, SMN deficient microglia had significantly higher expression of C1qA which 
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is in correlation with previous results that C1q has increased expression in SMA mice compared to 
WT (Vukojicic et al., 2019). Together, these results demonstrate that during early development the 
major source of C1q in the spinal cord is microglia.  
 
4.2.8. Postnatal neutralization of C1q tagging confers synaptic rescue and behavioral benefit 
in SMA mice 
             
            To further confirm the role of C1q in synaptic loss in SMA, mouse monoclonal anti-
C1qantibody (a-C1q) (Lansita et al., 2017) was used to block postnatally C1q in SMA mice. The 
globular domain of C1q which is responsible for the recognition properties of C1q has compact, 
close to spherical heterotrimeric assembly of C1qA, C1qB and C1qC. This organization of subunits 
appears to be responsible for C1q’s wide recognition properties (Gaboriaud et al., 2003). The exact 
binding target of C1q on a synapse is unknown. It is also not known which C1q subunit(s) are 
involved in its synaptic localization. The neutralizing a-C1q antibody binds to a conformational 
epitope which spans two of the three subunits of C1q globular head domains. It has been 
demonstrated that a-C1q antibody blocks interaction between C1q and diverse ligands, including 
phosphatidyl serine, IgM and CRP. Additionally, Lansita and colleagues (Lansita et al., 2017) 
showed in multiple animal species that functional activation of the classical pathway can be fully 
blocked by a-C1q antibody. Efficient C1q blockage by a-C1q antibody was also shown in animal 
models of antibody-independent neurodegeneration (Dejanovic et al., 2018; Hong et al., 2016) and 
antibody-mediated disease (McGonigal et al., 2016). C1q binding assay, utilizing plate coated with 
human C1q and both C1q neutralizing and control antibody in triplicate serial dilutions, was used to 
validate the specificity and affinity of the a-C1q antibody versus the isotype control – mouse 
immunoglobulin G1 (mIgG1) (Vukojicic et al., 2019) (Figure 41). This result confirmed high 
specificity and affinity of neutralizing a-C1q antibody used in in vivo experiments. SMA mice were 
treated from birth (P0) with either a-C1q antibody or isotype control antibody at a dose of 




Figure 41. Validation of the specificity and affinity of the a-C1q antibody. C1q binding assay – 
ELISA of anti-C1q neutralizing antibody (shown in black), and Isotype control antibody (shown in 
gray) to human C1q. Adapted from (Vukojicic et al., 2019). 
 
SMA mice which were treated with a-C1q antibody (SMA+a-C1q Ab) had a significant increase in 
VGluT1+ synapses on both soma and proximal dendrites of L1 MNs at P10.  SMA mice treated 
with control antibody (SMA+Ctr Ab) did not show any increase in VGluT1+ synapses (Vukojicic et 
al., 2019) (Figure 42A-C). Additionally, there was no difference in VGluT1 synaptic density 
between isotype control treated and untreated SMA mice (Vukojicic et al., 2019) (Figure 42B, C). 
Strikingly, in a-C1q treated SMA mice, nearly complete synaptic rescue of VGluT1+ synapses on 
proximal dendrites of MNs was observed (Vukojicic et al., 2019) (Figure 42C).  
   
Figure 42. Postnatal in vivo neutralization of C1q in SMA mice rescues VGluT1 synapses (A) 
Z-stack projections of confocal images of L1 moto neurons retrogradely labeled (shown in blue) 
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and VGluT1 (shown in white) in SMA mice treated with isotype control antibody (left) and with 
anti-C1q antibody (right) at P11. Total distance in the z axis: 22.4 µm. Higher-magnification 
confocal images of individual motor neuron dendrites with VGluT1 synapses are shown at right. 
(B) The total number of VGluT1 synapses on the entire soma in WT (shown in blue, n = 10), SMA 
(shown in red, n = 10), SMA+Ctr Ab (shown in orange, n = 10), and SMA+a-C1q Ab (shown in 
black, n = 6) L1 motor neurons. *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA with 
Tukey’s test. (C) Synaptic density in 50-µm from the soma dendritic compartments in WT (shown 
in blue, n = 41), SMA (shown in red, n = 43), SMA+Ctr Ab (shown in orange, n = 31), and 
SMA+a-C1q Ab (shown in black, n = 54) L1 motor neurons . ***p < 0.001; One-way ANOVA 
with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
To test whether treatment with a-C1q antibody upregulated SMN in spinal cord, western 
blot was used to asses SMN levels in spinal cords from treated SMA mice compared to untreated 
WT and SMA mice.  Results of these experiments revealed that SMN levels remain unchanged in 
SMA mouse spinal cord upon a-C1q antibodies treatment (Vukojicic et al., 2019) (Figure 43A). To 
also address this possibility of SMN upregulation in DRGs upon treatment, immunohistochemistry 
against SMN and parvalbumin was performed. Similarly to spinal cord observations, SMN levels 
did not increase in DRGs upon treatment, as no increase of Gems (nuclear structures containing 
SMN) (Liu and Dreyfuss, 1996) was observed in proprioceptive neurons (Vukojicic et al., 2019) 
(Figure 43 B, C).  
 
Figure 43. Postnatal in vivo neutralization of C1q in SMA mice does not upregulate SMN 
protein. (A) Western blot analysis for SMN and β-tubulin protein expression from L1-L3 spinal 
cord segments of two WT, two SMA and two SMA+a-C1q Ab at P11. (B) Confocal images of 
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Parvalbumin (shown in green), SMN (shown in white) and nuclei stained with 4′,6-diamidino-2-
phenylindole (DAPI, shown in blue) in P11 DRGs from WT, SMA and SMA+a-C1q Ab. Arrow 
points on gem, visualized by SMN (shown in white) immunoreactiity. (C) Percentage of 
parvalbumin neurons containing gems in P11 DRGs from WT (shown in blue, n=50), SMA (shown 
in red, n=50) and SMA+a-C1q Ab (shown in orange, n=50). *** p<0.01, One-way ANOVA with 
Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Furthermore, to test whether a-C1q antibody treatment rescues motor neurons, all L1 spinal 
segment motor neurons were counted in untreated WT and SMA mice and compared against treated 
SMA mice. SMA mice treated with a-C1q antibody did not have any rescue of SMA motor neurons 
(Vukojicic et al., 2019) (Figure 44), suggesting that C1q does not play a role in motor neuron death. 
This is not surprising as it has been demonstrated that motor neuron death is cell autonomous event 
driven by SMN deficiency which leads to activation of intrinsic mechanisms responsible for motor 
neurons degeneration (Simon et al., 2017; Van Alstyne et al., 2018). Additionally, previous results 
show that synaptic loss and sensory motor circuitry dysfunction are due to SMN deficiency in 
proprioceptive neurons (Fletcher et al., 2017), indicating that these events are independent from 
motor neuron death. 
 
Figure 44. Postnatal in vivo neutralization of C1q in SMA mice does not rescue motor neurons 
from dying. Total number of L1 motor neurons at P11 in WT (shown in blue, n = 3), SMA (shown 
in red, n = 4), SMA+Ctr Ab (shown in orange, n = 5), and SMA+a-C1q Ab (shown in black, n = 8) 
mice. ***p < 0.001; one-way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Furthermore, to test whether neutralization of C1q has any effects on neuromuscular junction 
(NMJ) denervation, the extent of denervation was investigated in the vulnerable muscle Quadratus 




Figure 45. Postnatal in vivo neutralization of C1q in SMA mice does not rescue NMJs. (A) Z-
stack projections of confocal images of synaptophysin (shown in green), neurofilament (NF) 
(shown in blue) and a-bungarotoxin (BTX) (shown in red) to label pre- and postsynaptic elements 
of neuromuscular junctions (NMJs) in the QL muscle at P11 in WT, SMA, SMA+Ctr Ab, and 
SMA+a-C1q Ab mice. The arrows indicate denervated NMJ. total distance in thez-axis:7 µm. (B) 
Percentage extent of QL muscle innervation in WT (shown in blue, n = 3 mice), SMA (shown in 
blue, n = 3), SMA+Ctr Ab (shown in orange, n = 3), and SMA+a-C1q Ab (showan in black, n = 5). 
***p < 0.001; One-way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
No difference was found between isotype control-treated, untreated SMA and SMA mice treated 
with a-C1q antibody (Vukojicic et al., 2019) (Figure 45A, B). This is most likely due to the absence 
of C1q  around neuromuscular junctions (NMJs), as no C1q signal was detected  in close proximity 
to NMJs of vulnerable QL muscle in SMA mice (Vukojicic et al., 2019) (Figure 46A,B). Although 
the number of NMJ synapses was not rescued, to further investigate whether anti-C1q antibody 
treatment had any physiological benefit in vulnerable muscle performance, in collaboration with Dr. 
Nicolas Delestree in the Mentis Lab, physiological assays were performed on vulnerable QL 
muscles. Following stimulation of the L1 ventral root, tested compound muscle action potentials 
(CMAPs) in QL muscle of SMA a-C1q antibody treated mice did not reveal any improvement 
compared to isotype control treated or untreated SMA mice (Vukojicic et al., 2019) (Figure 46C). 




Figure 46. C1q does not tag NMJs and postnatal in vivo neutralization of C1q in SMA mice 
does not have any effect on NMJ denervation and function.  Z-stack projections of confocal 
images of NMJs from the Quadratus Lumborum (QL) muscle visualized with α-bungarotoxin 
(BTX, shown in red), synaptophysin and neurofilalment (shown in green) and C1q (shown in white) 
immunoreactivity at P5 in WT (A) and SMA (B) mice. Total z stac distance: 7 μm. (C) Schematic 
illustration of ex vivo experimental setup for assessment of Compound Muscle Action Potentials 
(CMAPs) in the QL muscle in mice. Superimposed traces of the 1st (shown in black) and 25th 
(shown in red) CMAPs during 25 Hz stimulation of the L2 ventral root in WT, SMA and SMA+a-
C1qAb mice. Graph shows the percentage change in CMAP amplitude (baseline-to-peak) of the 
25th response normalized to the 1st CMAP following 25 Hz stimulation of the ventral root in WT 
(shown in blue, n=5), SMA (shown in red, n=5) and SMA+a-C1qAb (shown in back, n=5) mice. *  
p<0.05, One-way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Collectively, these results demonstrate that while C1q is involved in central synapse 
elimination, it plays no role in peripheral synapse elimination in SMA. Importantly, to address 
whether rescued VGluT1+ synapses in SMA mice treated with a-C1q antibody were functional, the 
ex vivo spinal cord preparation (Vukojicic et al., 2019) (Figure 47) was employed and dorsal-to 





Figure 47. The ex vivo spinal cord physiological assay. Schematic illustration of the ex vivo 
spinal cord physiological assessment. Stimulation of the L1 dorsal root elicits a response on the 
homonymous L1 ventral root. Adapted from (Vukojicic et al., 2019). 
 
In SMA mice treated with a-C1q antibody the amplitude of the reflex response showed a 
significant increase compared to isotype control treated or untreated SMA mice (Vukojicic et al., 
2019) (Figure 48A, B,). These results indicate that more motor neurons can be activated following 
proprioceptive synapse activation in those mice treated with C1q neutralizing antibody. In addition, 
to test synaptic reliability of the synapses rescued by treatment, we challenged proprioceptive 
synapses at different frequencies in order to investigate presynaptic from postsynaptic mechanisms. 
These experiments demonstrated that synaptic reliability of rescued synapses in treated mice  is 
similar to synaptic reliability of WT mice, following the high frequency stimulation (20Hz) 
(Vukojicic et al., 2019) (Figure 48C). Thus, although the number of motor neurons in treated SMA 
mice remains similar to the one in untreated, their function and output are significantly improved 
due to the restoration of sensory-motor circuitry. Importantly, the synaptic reliability test does not 
depend on the number of synapses present nor on the number of MNs present, since the motor 
neuron response amplitude at high frequency is normalized to the first stimulus, meaning that 




Figure 48. Postnatal in vivo neutralization of C1q in SMA mice improves motor output by 
rescuing synaptic function. (A) Ventral root responses to L1 dorsal root stimulation in WT, SMA, 
SMA+Ctr Ab, and SMA+aC1q Ab at P10. The dotted line indicates baseline. The arrowheads point 
to the stimulus artifacts. The arrows indicate the maximal amplitude of the monosynaptic responses. 
(B) The maximum amplitude of the monosynaptic response in WT (shown in blue, n = 6), SMA 
(shown in red, n = 9), SMA+Ctr Ab (shown in orange, n = 7), and SMA+a-C1q Ab (shown in 
black, n = 7) mice. *p < 0.05, ***p < 0.001; One-way ANOVA with Tukey’s test. (C) Percentage 
of the amplitude change for the 5th response (normalized to the 1st) following 20-Hz stimulation in 
WT (shown in blue, n = 6), SMA (shown in red n = 9), SMA+Ctr Ab (shown in orange, n = 7), and 
SMA+aC1q Ab (shown in black, n = 7) mice at P11. ***p < 0.001; One-way ANOVA with 
Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
Together, these results demonstrate that in vivo neutralization of C1q by a-C1q antibody 
treatment from birth results in increased number and function of proprioceptive synapses in SMA 
mice. This suggests that beside the role for complement in selective synaptic elimination, 
complement also play a role early in synaptic dysfunction. To test whether all these observations 
upon a-C1q antibody treatment translate into behavioral improvement, body weight and righting 
time were monitored daily in the isotype control treated, untreated SMA and a-C1q antibody treated 
SMA mice. SMA mice treated with a-C1q antibody showed a significant improvement in the 
survival by the lifespan increase of ~25 % (Figure 49A), but minimal body weight gain (Figure 
49B) (Vukojicic et al., 2019). 
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Figure 49. Postnatal in vivo neutralization of C1q in SMA mice improves survival but results 
in minimal body weight gain. (A) Lifespan of SMA+Ctr Ab (n = 8) compared to SMA+a-C1q Ab 
(n = 10) mice. **p < 0.01; t test. (B) Body weights gain in WT (shown in blue), SMA (shown in 
red), SMA+Ctr. Ab (shown in orange) and SMA+a-C1q Ab (shown in black) mice. Adapted from 
(Vukojicic et al., 2019). 
 
 Importantly, a-C1q antibody treated SMA mice showed a significant improvement in 
righting time compared to controls (Vukojicic et al., 2019) (Figure 50). This improvement in treated 
SMA mice was improving progressively over time, with the striking ability to right and even walk 
in second postnatal week.  
                
Figure 50. Postnatal in vivo neutralization of C1q in SMA mice has a striking effect on motor 
behavior. Righting times of WT (shown in blue, n = 10), SMA (shown in red, n = 9), SMA+Ctr Ab 
(shown in orange, n = 15), and SMA+a-C1q Ab (shown in black, n = 24). *p < 0.05, **p < 0.01; t 
test for individual ages. Adapted from (Vukojicic et al., 2019). 
 
Collectively, these results demonstrate that in vivo postnatal treatment of SMA mice with a-
C1q antibody rescues both number and the function of proprioceptive synapse which further 
confirms the essential role for C1q in active synaptic elimination in SMA mice. Importantly, 
rescued synaptic function indicates that C1q does not tag dysfunctional synapses and suggests 
involvement of complement proteins in synaptic dysfunction. Furthermore, synaptic rescue and 
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improved sensory-motor circuitry function in treated mice provided remarkable behavioral benefit, 
underlying importance of contribution of other neuronal types to motor neuron dysfunction and 
motor deficit seen in SMA. Thus, neutralization of C1q could be a potential therapeutic approach 
combinatorial to SMN upregulation in SMA patients. 
 
4.2.9. Genetic deletion of C1q in SMA mice rescues proprioceptive synapses 
 
            To test whether complete elimination of C1q during embryonic development might also be 
beneficial, since postnatal neutralization of C1q resulted in significant synaptic rescue and 
behavioral benefit, C1q was removed from SMA mice through genetic manipulations. This was 
achieved by crossing mice harboring ubiquitous deletion of C1qa (Botto, 1998) with SMA mice. 
SMA::C1q-/- mice showed significant rescue of proprioceptive synapses on the somata as well as 
on proximal dendrites of L1 motor neurons in comparison to SMA mice at P10 (Vukojicic et al., 
2019) (Figure 51A-C). 
 
                                                  
Figure 51. Genetic deletion of C1q in SMA mice rescues proprioceptive synapses. (A) z-stack 
projections of confocal images motor neurons visualized with ChAT (shown in blue) and VGluT1 
(shown in white) immunoreactivity in SMA and SMA::C1q-/- motor neurons at P11. Total distance 
in the z-axis: 22.4 µm. Inset shows at higher magnification motor neuron dendrites (shown in blue) 
with VGluT1 synapses (shown in white). (B) The total number of VGluT1 synapses on the entire 
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soma in WT (shown in dark blue, n = 10), SMA (shown in red, n = 10), and SMA::C1q-/- (shown in 
light blue, n = 10) L1 motor neurons at P11. *p < 0.05, **p < 0.01, ***p < 0.01; One-way ANOVA 
with Tukey’s test. (C) VGluT1 synaptic density – number of synapses in 50-µm from the soma 
dendritic compartments for WT (shown in dark blue, n = 41), SMA (shown in red, n = 43), and 
SMA::C1q-/- (shown in light blue, n = 29) motor neurons. *p < 0.05, **p < 0.01, ***p < 0.01; one-
way ANOVA with Tukey’s test. Adapted from (Vukojicic et al., 2019). 
 
            Similar to C1q neutralization, there was no rescue of L1 motor neurons in SMA::C1q-/- 
mice (Vukojicic et al., 2019) (Figure 52), further supporting that C1q does not play a role in motor 
neuron death. These results are not surprising considering recent studies demonstrating that motor 
neuron death is a cell autonomous event in which SMN deficiency leads to activation of intrinsic 
mechanisms involved in motor neuron degeneration (Simon et al., 2017; Van Alstyne et al., 2018). 
Additionally, since previous results demonstrated that synaptic loss is not due to cell-autonomous 
mechanisms but rather due to proprioceptive-autonomous mechanisms (Fletcher et al., 2017), it is 
expected that synaptic rescue and motor neuron death are independent events in SMA::C1q-/- mice. 
 
Figure 52. Genetic deletion of C1q in SMA mice does not rescue motor neurons. Total number 
of L1 motor neurons in WT (shown in dark blue, n = 3), SMA (shown in red, n = 4), and 
SMA::C1q-/- (shown in light blue, n = 4) mice. ***p < 0.01; one-way ANOVA with Tukey’s test. 
Adapted from (Vukojicic et al., 2019). 
 
To address whether rescued synapses are functional,  in collaboration with Dr. Delestree the 
ex vivo spinal cord preparation was utilized to measure the monosynaptic reflex amplitude recorded 
in the L1 ventral root upon the stimulation of the L1 dorsal root  SMA::C1q-/- mice showed a 
significant increase in the reflex amplitude compared to the age matched SMA mice (Vukojicic et 




     
Figure 53. Genetic deletion of C1q in SMA mice improves motor output by rescuing synaptic 
function. (A) The monosynaptic response (indicated with arrows) in SMA and SMA::C1q-/- mice at 
P10 are shown. The arrowheads indicate stimulus artifacts. (B) The amplitude of the monosynaptic 
reflex responses at P10, in SMA (shown in red, n = 9) and in SMA::C1q-/- (shown in light blue, n = 
4) mice. **p < 0.01; t test. (C) The latency of the monosynaptic response onset for the same groups. 
Adapted from (Vukojicic et al., 2019). 
 
 These results demonstrate that genetic removal of C1q in SMA mice rescues number and 
the function of proprioceptive synapses which indicates that C1q mediated synaptic elimination is 
an active aberrant pathogenic process. 
 
4.3. C1q mediates sensory-motor circuits refinement during normal development 
 
Surprisingly, genetic removal of C1q, unlike postnatal C1q neutralization with anti-C1q 
antibody, did not result in any behavioral improvement in SMA mice, despite very similar rescue of 
proprioceptive synapses. While SMA mice treated with a-C1q antibody from birth had striking 
improvement in time to right  SMA::C1q-/- mice lacked any  improvement in righting reflex 
(Vukojicic et al., 2019) (Figure 54A). Their body weight gain and time to right across all ages were 
comparable to those of SMA mice (Vukojicic et al., 2019) (Figure 54B,A). These results were 
intriguing considering a seeming sensory-motor circuitry restoration, as both synapse numbers and 
function were rescued. These results opened the possibility of C1q involvement in synaptic 
elimination during the spinal sensory-motor circuit refinement during the prenatal development. 
Proprioceptive neurons synapse onto motor neurons innervating the homonymous muscle, but not 
the antagonistic muscle. However, during early development motor neurons do receive 
proprioceptive inputs originating from antagonistic muscles (Seebach and Ziskind-Conhaim, 1994), 
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that will be eliminated at postnatal ages (Poliak et al., 2016) to achieve proper motor function. The 
molecular mechanisms involved in this sensory-motor circuitry refinement are currently unknown. 
 
Figure 54. Genetic deletion of C1q in SMA mice does not confer behavioral benefit. (B) 
Righting time and (B) body weight gain during postnatal development in SMA (shown in red, n=9) 
and SMA::C1q-/- (shown in light blue, n=10) mice. Adapted from (Vukojicic et al., 2019). 
 
To explore whether C1q is involved in synaptic refinement early during development, the 
synaptic numbers of VGluT1+ proprioceptive synapses on soma and proximal dendrites of motor 
neurons in C1q-/- mice were investigated. Synaptic density analysis revealed ~25%  of excessive 
VGluT1 synapses, on the soma and proximal dendrites of C1q-/-  motor neurons in comparison to 
WT counterparts at P11 (Vukojicic et al., 2019) (Figure 55A-C).  
 
Figure 55. Genetic deletion of C1q in SMA mice results in an increased number of 
proprioceptive synapses during normal development. (A) Z-stack projections of confocal images 
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of L1 motor neurons visualized with ChAT (shown in blue) and VGluT1 synapses (shown in white) 
in WT and C1q-/- mice at P11. Total distance in the z-axis: 25.2 µm. Circled areas indicate MN 
nuclei. Higher magnification images (right) of z stack projections from single motor neurons in WT 
and C1q-/- mice. Total distance in the z-axis: 2.1 µm. (B) The total number of VGluT1 synapses on 
the entire soma from WT (shown in blue, n = 10) and C1q-/- (n = 12) L1 motor neurons. **p < 0.01; 
t test. (C) VGluT1 synaptic density – number of synapses in 50-µm from the soma dendritic 
compartments in WT (shown in blue, n = 41) and C1q-/- (shown in green, n = 35) motor neurons. 
**p < 0.01, ***p < 0.001; t test. Adapted from (Vukojicic et al., 2019). 
 
To test whether these supernumerary synapses were functional, in collaboration with Dr. 
Delestree, dorsal root-to-ventral root reflexes were measured in the L1 lumbar segment, ex vivo, at 
P11.The monosynaptic reflex amplitude was significantly increased compared to WT counterparts 
(Vukojicic et al., 2019) (Figure 56A, B). Furthermore, to probe the synaptic efficacy of these 
excessive synapses in C1q-/- mice, synaptic neurotransmission was challenged under high 
frequency (20Hz) stimulation. Electrophysiological recordings revealed that the change in reflex 
amplitude during repetitive stimulation, was similar to the one observed in WT mice (Vukojicic et 
al., 2019) (Figure 56C, D).  
 
Figure 56. Supernumerary synapses in C1q-/- mice are functional. (A) Ventral root responses to 
supramaximal stimulation of the homonymous L1 dorsal root in WT and C1q-/- spinal cords at P10. 
The arrowheads indicate the stimulus artifacts. (B) The amplitude of the monosynaptic reflex 
responses for WT (n = 6) and C1q-/- (n = 7) mice at P11. *p < 0.05; t test. (C) Superimposed traces 
of the 1st (shown in black) and 5th (shown in red) responses following 20-Hz stimulation of the 
dorsal root in WT and C1q-/- mice. (D) Percentage of the amplitude change of the 5th response 
normalized to the 1st response, following a 20-Hz stimulation in WT (n = 6) and C1q-/- (n = 7) mice. 




Additionally, there was no difference in the numbers of motor neurons in WT and C1q-/- 
mice (Vukojicic et al., 2019) (Figure 57A,B) which together with previous observation indicates 
that supernumerary synapses in C1q-/- mice are functional. 
  
Figure 57. Genetic deletion of C1q does not result in motor neuron death. (A) Confocal images 
of L1 motor neurons labeled with ChAT (shown in blue) in WT and C1q-/- mice at P11. (B) The 
total number of L1 spinal segment motor neurons in WT (shown in blue) and C1q-/- (shown in 
green) mice. Adapted from (Vukojicic et al., 2019). 
 
Behavioral analysis revealed a mild underweight condition for C1q-/- mice compared to the WT 
controls (Vukojicic et al., 2019) (Figure 58).  
 
                                        
 
Figure 58. Genetic deletion of C1q results in mild under-weight gain. Body weight gain in WT 





Strikingly, C1q-/- mice exhibited remarkable differences in time they took to right (Vukojicic 
et al., 2019) (Figure 59). They showed a significant delay in righting, very prominent at birth and 
with progressive improvement during the second postnatal week (Vukojicic et al., 2019) (Figure 
59). This is not surprising as previous results demonstrated involvement of proprioceptive sensory 
synapses in the righting ability during the first postnatal week (Fletcher et al., 2017). In the second 
postnatal week, however, descending pathways mature and especially vestibulospinal pathways 
play a more prominent role in the righting reflex. This could explain why sensory-motor circuitry 
perturbations caused by the lack of C1q will not have strong effect after the first postnatal week.  
 
                    
 
Figure 59. C1q-/- mice show a significant delay in righting. Righting times in WT (n = 10) and 
C1q-/- (n = 18) mice during the first 12 postnatal days. ***p < 0.001; t test for the individual ages.  
Adapted from (Vukojicic et al., 2019). 
 
The righting inability of C1q-/- mice coupled with the increased numbers of proprioceptive 
synapses on MNs raised the question whether sensory motor circuits may have been inadequately 
established during the late embryonic and early postnatal development. Therefore, the connectivity 
pattern between two antagonistic motor pools, Gastrocnemius (Gastro) and the Tibialis Anterior 
(TA) muscles were investigated. An assay that utilizes the transganglionic transport properties of 
cholera toxin β-subunit (CTb) conjugated to Alexa-555 was used. Upon muscle injection, CTb 
accumulates in approximately 40% of proprioceptive synapses, which can be independently and 
selectively marked by the presynaptic VGluT1 expression (Mendelsohn et al., 2015). The TA 
muscle was injected with CTb-Alexa-555 which labels TA motor neurons as well as proprioceptive 
synapses. At the same time Gastro muscle was injected with fluorescein dextran (Dext) which 
labels only motor neurons (Vukojicic et al., 2019) (Figure 60A, B). This distinction allowed binary 
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density comparison of proprioceptive synapses labeled with CTb in contact with either 
homonymous CTb-labeled or Dextran labeled antagonistic MNs (Mendelsohn et al., 2015).  
 
         
 
Figure 60. Experimental set up for binary density comparison of proprioceptive synapses in 
contact with either homonymous CTb-labeled or Dextran labeled antagonistic motor neurons.  
(A) Schematic illustration for retrograde labeling of Tibialis Anterior (TA) motor neurons and their 
proprioceptive synapses with CTb-555 (shown in red) and gastrocnemius (Gastro) motor neurons 
only with fluorescinated dextran (shown in green). The dotted red line indicates inappropriate 
Tibialis Anterior synapses onto gastrocnemius motor neurons. (B) Tibialis Anterior and 
gastrocnemius motor neuronss labeled with CTb-555 and fluorescinated dextran correspondingly. 
Adapted from (Vukojicic et al., 2019). 
 
Synaptic density was analyzed 6-7 days after injection which is the minimum time needed 
for labeling both motor neurons and proprioceptive synapses (Mendelsohn et al., 2015). C1q-/- mice 
had approximately 22% of Gastro motor neurons which received inappropriate sensory synapses 
originating from proprioceptive neurons in antagonistic TA muscle compared to none in WT mice 





Figure 61. C1q mediates sensory-motor circuitry refinement during normal development. (A) 
Single optical planes of confocal images with the tracers fluorescinated dextran (shown in green), 
CTb-555 (shown in red) and VGluT1 (shown in blue) immunoreactivity from gastrocnemius motor 
neurons in a WT and a C1-/- mouse at P7. Inset shows an example of inappropriate synapse – tibialis 
anterior-originating proprioceptive synapse (arrow) on a gastrocnemius motor neuron. (B) 
Percentage of motor neurons receiving inappropriate synapses in WT (n = 3) and C1q-/- mice (n = 
4). *p < 0.05; t test. Adapted from (Vukojicic et al., 2019). 
 
These results provide evidence that sensory-motor circuitry refinement occurs early during 
development, likely during late embryonic and early postnatal period, and that it is C1q-dependent. 
Although these data demonstrate that ~ 22% of Gastro motor neurons receives inappropriate 
sensory synapses, this percentage is likely higher but due to experimental limitations cannot be 
assessed prior to P7. These results may also offer the explanation for the lack of motor 
improvement in SMA::C1q-/- mice, as these inappropriate synapses contributed to seemingly 
rescued VGgluT1 density on vulnerable SMA motor neurons in the absence of C1q. Importantly, 
these results indicate a major role for C1q in the refinement of spinal sensory-motor circuits during 










5.1. Sensory-motor circuitry dysfunction in SMA is driven by non-motor neuron 
autonomous mechanisms  
 
Dysfunction and death of vulnerable neurons are common characteristics of 
neurodegenerative diseases. Behavioral deficits are often thought to be due to dysfunction 
of vulnerable neurons driven by cell-autonomous mechanisms. Deciphering the mechanisms behind 
these events is key in understanding and determining their contribution to pathology of disease. 
Importantly, since vulnerable neurons are located within neuronal circuits, the mechanisms by 
which their synaptic partners contribute to the disease process may play important roles in disease 
pathology. Neuronal dysfunction is often described by changes in physiological properties in 
disease vulnerable neurons (Kuo et al., 2004; Mentis et al., 2011). 
This study confirms, in a mouse model of spinal muscular atrophy (SMA), that non-cell 
autonomous mechanisms drive motor neuron dysfunction. It has been shown that the reduction of 
EPSP amplitude observed in SMA motor neurons is restored in SMA+PvCre  (restoration of SMN in 
proprioceptive neurons only) but not in SMA+ChATCre motor neurons (Fletcher et al., 2017) 
indicating that motor neuron dysfunction is a consequence of SMN loss from proprioceptive 
neurons. Following SMN restoration in proprioceptive neurons (SMA+PvCre), synaptic loss is 
rescued. Taken together with physiological findings (Fletcher et al., 2017), this suggests that SMN-
deficiency from proprioceptive neurons causes sensory-derived motor neuron dysfunction leading 
to motor behavior impairments.  
Motor neuron dysfunction can be seen as a non-motor neuron autonomous consequence of 
SMN deficiency in proprioceptive neurons which is further exacerbated at later stages by 
progressive synaptic loss from motor neuron dendrites (Redman, 1979), which comprise nearly 
80% of the total synaptic number (Rotterman et al., 2014). Dendritic synapses are also largely 
responsible for the activation of motor neurons (Redman, 1979). Thus, to decipher the mechanisms 






5.2. Loss of vulnerable synapses in SMA is induced by aberrantly activated classical 
complement pathway 
 
Results of this study in neurodegenerative disease SMA indicate involvement of C1q in 
synaptic dysfunction and its role in selective elimination of proprioceptive synapses. Dysfunction of 
the vulnerable motor neuron synapses is coupled with deposition of C1q and the subsequent 
activation of classical complement cascade, which leads to progressive microglia-mediated synaptic 
elimination in SMA. Inhibition of classical complement pathway after birth with an anti-C1q 
antibody in vivo treatment, rescues the number and the function of vulnerable synapses, while also 
extending moderately the lifespan and conferring significant behavioral benefit in a mouse model of 
SMA. Thus, protecting vulnerable synapses from elimination by neutralizing aberrant C1q may 
serve as an applicable therapeutic approach complementary to upregulation of SMN. This study 
uncovers previously unknown roles for classical complement pathway in synaptic pathology of 
SMA. 
SMA is a neurodegenerative disease in which a deficiency in the SMN protein leads to 
selective loss of motor neurons, but the course of disease does not involve CNS injury. 
Additionally, there is a limited knowledge on neuroinflammation, if any present, in either human 
patients or mouse models of disease (Deguise et al., 2017; Papadimitriou et al., 2010). Furthermore, 
the loss of blood-brain barrier integrity has not been reported in SMA patients or in mouse models 
of SMA, nor the influx of lymphocytes and myeloid cells, which would be the case in classically 
defined neuroinflammatory conditions such as multiple sclerosis or during CNS infections or 
following CNS injury. Importantly, results from this study demonstrate absence of infiltrating 
macrophages in SMA mouse spinal cord tissue , since all Iba1+ cells were positive for TMEM119, 
a marker specific to microglia but not expressed by either macrophages or other immune or 
neuronal cell types (Bennett et al., 2016). Furthermore, in CD68 experiments, all Iba1+ cells were 
positive for CD68, suggesting that there is no infiltration of monocytes or macrophages.  
Additionally, immunohistochemistry against CD45 in L1 spinal cords of WT and SMA mice at P4 
– when complement proteins are highly expressed and synaptic tagging occurs, revealed low 
expression of CD45, while no CD45+/Iba1- cells were observed, suggesting that there is no 
infiltration of leukocytes. Although influx of leukocytes was not observed, it is possible that 
microglia as well as astrocytes and endothelial cells could locally produce cytokines in response to 
homeostatic imbalance in SMA, as seen in some neurodegenerative diseases. However, gene 
expression levels of few important pro-inflammatory cytokines (IL-1β, IL-6 and TNF) from mouse 
L1/L2 spinal segments - which show significant pathological changes early in the course of disease, 
showed no significant difference between WT and SMA at the onset of the disease when synaptic 
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loss occurs and complement proteins are highly expressed. All these observations, suggest that the 
aberrant upregulation of C1q by local microglia production does not occur in response to activation 
of inflammatory pathways but as a direct consequence of SMN-deficient conditions which are 
driving neurodegeneration in SMA. How does loss of SMN leads to increased C1q expression is an 
intriguing question left to be solved. Several genes have been recently implicated in the sensory 
neuron dysfunction in SMA (Ackermann et al., 2013; Shorrock et al., 2018). However, a precise 
mechanistic bridge that connects the loss of SMN with the increased C1q expression reported in this 
study remains unknown. It is possible that microglia under its own SMN deficient conditions 
changes gene expression profile, which includes upregulation of C1q. However, since this 
upregulation happens at specific time point, around the time when synaptic loss occurs, it is more 
likely that microglia is upregulating C1q in response to signals from other SMN deficient cell 
type(s). SMN deficiency in motor neurons leads to their dysfunction which could cause a release of 
yet unknown factor(s) from motor neurons, that could be recognized either directly by microglia or 
through signals from other glial cell(s) triggering the overexpression of C1q in microglia. Overall, 
there has been very limited information on the contribution of glia to SMA pathology. However, 
some reports have highlighted the involvement of astrocytes in the disease. Increased astrogliosis 
was observed in postmortem tissues of SMA patients (Dachs et al., 2011; Kuru et al., 2009; Rindt et 
al., 2015; Tarabal et al., 2014) and in the SMA-Δ7 mouse model at both early and late disease 
stages (McGivern et al., 2013). Astrocytes are known to control formation, maturation and function 
of synapses through various contact-mediated and secreted signals (Clarke and Barres, 2013). It is 
possible therefore that astrocytes “sense” SMN deficient synapses and then signal to microglia 
which in turn upregulates expression of C1q, an initiating protein that mediates synaptic elimination 
in SMA.  
SMA has been used as a model disease which allows studying the role of synaptic 
dysfunction in neurodegenerative diseases (Shorrock et al., 2019; Tisdale and Pellizzoni, 2015). It 
has been shown that loss of motor neurons follows sensory synapse dysfunction (Mentis et al., 
2011). Additionally, restoration of SMN selectively in proprioceptive sensory neurons, restores 
number of sensory synapses as well as their function, which results in the spiking frequency 
improvement of SMA motor neurons, while not having an effect on the survival of motor neurons 
(Fletcher et al., 2017).  This finding revealed that in SMA, motor neuron survival and synaptic 
dysfunction are two independent events (Fletcher et al., 2017). Similarly, SMN restoration in spinal 
interneurons and sensory neurons in Drosophila models of SMA was reported to improve 
behavioral phenotype (Imlach et al., 2012). All these studies had one thing in common - sensory 
synapses were identified as primary neuronal target which contributes to the disease phenotype. 
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However, the mechanisms by which sensory synapses are lost in SMA remained elusive. Results of 
this study demonstrate that synaptic loss in SMA is due to an active elimination of proprioceptive 
sensory synapses contacting motor neurons. These vulnerable synapses are tagged by the imitating 
protein of classical complement pathway - C1q, as well as with the downstream C3 protein, both of 
which are aberrantly expressed in SMA. C1q and C3 are found to localize to proprioceptive 
synapses both in WT and in SMA mice, but to a significantly higher extent in SMA. Furthermore, 
VGluT1 remnants found within microglia suggest that upon C1q deposition on proprioceptive 
synapses activation of the classical complement pathway is triggered leading to their subsequent 
elimination. Microglia mediates synaptic elimination likely via complement receptor 3 (CR3) 
considering that C3 deposits on synapses and that microglia are the only cell type in CNS carrying 
receptor for cleaved C3 protein. Additionally, results of this study show that microglia have another 
important role in developing and diseased spinal cord. C1q production in the spinal cord of WT and 
SMA mice is reserved exclusively to microglia, which is also consistent with a recent study in the 
brain (Fonseca et al., 2017). Importantly, C1q protein as well as C1q mRNA were not observed 
within motor neurons, as previously suggested (Zhang et al., 2013). Considering these findings 
microglia may be an important target in combinatorial SMA therapy. Pharmacological 
neutralization of C1q or genetic ablation in SMA mice results in a rescue of vulnerable synapses, 
which indicates that dominant mechanism of synaptic elimination in SMA is activation of the 
classical complement pathway. Additionally, microglia depletion in vivo with PLX5622 from birth, 
resulted in a significant synaptic rescue in treated SMA mice. Coupled with the rescue of vulnerable 
synapses was a significant phenotypic benefit observed in these mice, further confirming the role 
for C1q and microglia in synaptic elimination. The focus of this study was the loss of VGluT1+ 
synapses, but VGluT2+ synapses have also been reported to be reduced in SMA (Ling et al., 2010b; 
Simon et al., 2016). Although not investigated, complement proteins and microglia could also be 
involved in their removal. This study therefore demonstrates that aberrant activation of classical 
complement cascade triggers loss of proprioceptive synapses and indicates that microglia are 
responsible for elimination of synapses in SMA. However, what is the trigger for this selective 
elimination of proprioceptive synapses in SMA, remains to be answered.  
It is unlikely that preferential C1q tagging of glutamatergic synapses in SMA is due to the 
type of neurotransmitter, since inhibitory synapses are selectively removed via C1q in a mouse 
model of FTD (Lui et al., 2016). It is possible that neuronal activity may be a driving factor for the 
selective elimination of synapses. It has been shown (Fletcher et al., 2017) that in SMA, 
proprioceptive synapses dysfunction to a certain extent very early (P2) in the disease process. It is 
possible that C1q can ‘‘sense’’ these early synaptic changes, tag synapses and further propagate 
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their dysfunction leading to demise of motor function. Furthermore, if SMN is selectively restored 
in proprioceptive neurons or if neuronal activity is pharmacologically induced, synaptic function 
will be rescued and synaptic elimination is prevented in SMA mice (Fletcher et al., 2017). Results 
of this study demonstrate that restoration of SMN selectively in proprioceptive neurons of SMA 
mice abrogates synaptic tagging by C1q to nearly WT levels. This is in the support of the idea that 
C1q somehow senses changes in synaptic activity and that tagging by C1q is mediated by synaptic 
mechanisms that arise from proprioceptive neurons. Considering the tagging role for C1q in 
synaptic elimination, there must be a way for tight regulation of this process, by which all properly 
active synapses remain protected from complement proteins. It has been reported that CD47 is 
localized at synapses (Mi et al., 2000; Toth et al., 2013). CD47, also termed integrin-associated 
protein (IAP), is widely expressed transmembrane protein which provides a “do not eat me” signal. 
It has been demonstrated recently that in the developing lateral geniculate nucleus (LGN) CD47 
localizes preferentially in more active synapses, to which it may provide protective signal against 
the complement proteins. Therefore, microglia get to eliminate dysfunctional or weak synapses 
(Lehrman et al., 2018). It is possible that vulnerable proprioceptive synapses in SMA, may have 
downregulated CD47 expression, thus became available to complement and microglia-mediated 
elimination.  
 
5.3. The role of the C1q in the Normal Development of Spinal Sensory-Motor Circuits 
 
This study has uncovered a previously unknown role for the C1q and classical complement 
pathway in the refinement of spinal sensory-motor circuit during normal development. The 
monosynaptic spinal sensory-motor arc reflex includes proprioceptive sensory neurons which 
directly synapse onto motor neurons which innervate homonymous muscle. It has been shown 
during embryonic development that 30% of motor neurons are being innervated by proprioceptive 
afferents originating from antagonistic muscles (Seebach and Ziskind-Conhaim, 1994). 
Additionally, it has been demonstrated that this persists during the first postnatal week (Poliak et 
al., 2016). However, proprioceptive afferents which connect motor neurons that supply antagonistic 
muscles are being removed during postnatal development (Mears and Frank, 1997; Mendelsohn et 
al., 2015). However, molecular mechanisms behind elimination of these inappropriate synapses had 
long remained elusive. This study shows that removal of these inappropriate synapses requires C1q 
and likely the activation of the classical complement cascade. Results of this study demonstrate that 
genetic removal of C1q from WT mice results in increased number of proprioceptive synapses, for 
approximately 25%, on both soma and proximal dendrites of WT motor neurons. These results 
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indicate that in the absence of C1q 25% of proprioceptive synapses fail to be pruned and suggest its 
involvement in sensory-motor circuitry refinement. Additionally, tracing experiments demonstrate 
involvement of C1q in refinement of proprioceptive synapses which contact motor neurons that 
originate from antagonistic muscles. This result reveals a C1q-mediated mechanism behind the 
synaptic refinement in developing spinal cord. During this early postnatal period, proprioceptive 
synapses play a major role in righting behavior (Fletcher et al., 2017). It has been demonstrated that 
descending pathways, such as vestibule-spinal inputs have more impact in this behavior than 
proprioceptive after the first postnatal week (Bignall, 1974; Pellis and Pellis, 1994; ten Donkelaar, 
2000). The amplitude increase of the homonymous dorsal to ventral root reflex in C1q-/- mice 
compared to WT mice revealed that supernumerary synapses in C1q deficient mice are functional. 
However, observed deficits in motor behavior which are illustrated through the impaired righting 
behavior during the first postnatal week could be explained by the absence of pruning of 
inappropriate synapses. In support of this are also the results from SMA mice in which C1q was 
removed genetically. Unlike postnatal neutralization of C1q with anti-C1q antibody, there was no 
behavioral benefit in SMA mice lacking C1q, despite the similar level of synaptic rescue. 
Furthermore, results of this study show an increased C1q expression at birth compared to later 
postnatal days. Taken together, these results suggest the role for C1q in pruning of inappropriate 
proprioceptive synapses during development. However, the intriguing question is how does C1q 
mediate elimination of inappropriate proprioceptive synapses? The assembly of selective 
connections between sensory and motor neurons has been demonstrated to depend on their surface 
recognition features as well as on the position at which will motor neurons settle in ventral spinal 
cord (Fukuhara et al., 2013; Pecho-Vrieseling et al., 2009; Surmeli et al., 2011). Microglia are 
known to interact with synapses as a response to sensory experience or neurotransmitter 
release (Nimmerjahn et al., 2005; Ransohoff and Perry, 2009; Wake et al., 2009). In addition, it has 
been demonstrated that early during development, microglia engulf synapses in lateral geniculate 
nucleus. This engulfment is dependent on neural activity and complement tagging, and it is 
mediated through microglia-specific CR3 (Schafer et al., 2012). It is likely that inappropriate 
proprioceptive synapses are being less active, which could be sensed by microglia, leading to C1q 
deposition, subsequent activation of the classical complement cascade and finally microglia-
mediated elimination of improper synapses via CR3. In support of this are following observations: 
C1q and C3 tagging of VGluT1 synapses early in postnatal WT mice and VGluT1 remnants within 
microglia. This suggest that a portion, if not all, inappropriate proprioceptive synapses tagged by 
C1q are eliminated via classical complement cascade and microglia-mediated mechanism and 




In summary, this study shows that refinement of spinal sensory-motor circuits during 
early development is mediated by C1q-depndent mechanisms. In neurodegenerative disease SMA 
aberrantly activated classical complement cascade contributes to the synaptic dysfunction 
and induces elimination of proprioceptive synapses early in the disease pathology, propagating the 
demise of motor function. Future studies should determine whether pruning of 
other synapses in the spinal motor circuit is mediated by similar mechanisms during their 
developmental refinement. It will be also interesting to resolve mechanism behind the C1q 
upregulation in SMA and to answer the intriguing question of what exactly C1q binds to on the 
synapse. Importantly, future work should examine the therapeutic potential of C1q neutralization in 























Based on the results of this study, the following conclusions can be drawn: 
1.) This study confirms, utilizing a mouse model of spinal muscular atrophy (SMA), that 
presynaptic impairment driven by SMN deficiency in proprioceptive neurons is responsible 
for motor neuron dysfunction in SMA. Thus, results of this study indicate that non-cell 
autonomous mechanisms drive motor neuron dysfunction. 
2.) Proprioceptive synapses in SMA have significantly reduced numbers compared to age-
matched WT mice at late stages of disease. Results of this study demonstrate that this is not 
due to synaptic arrest occurring during development and that synapses in SMA are formed 
normally, but subsequently eliminated, starting at the onset of diseases phenotype in SMA 
mice. 
3.) Results of this study demonstrate a transient expression of C1q during early normal 
postnatal development in WT spinal cords as well as an aberrant upregulation of C1q at the 
onset of SMA in both mouse model and human tissue.  
4.) In a mouse model of SMA, C1q aberrantly tags vulnerable proprioceptive synapses at the 
onset of the disease, which correlates with the time synaptic loss occurs, suggesting 
involvement in synaptic elimination. Furthermore, similar percentage of proprioceptive 
synapses on proximal dendrites were tagged by a downstream complement component C3, 
suggesting that early in the disease process the classical complement pathway is triggered 
and activated. 
5.) While C1q aberrantly tags vulnerable excitatory synapses in SMA, there was no significant 
difference in C1q tagged inhibitory synapses between WT and SMA mice. Additionally, 
C1q was not found in the periphery, on NMJs, suggesting that complement proteins are not 
involved in the denervation of NMJs.  
6.) Proprioceptive synapses are eliminated by resident macrophages within the central nervous 
system – microglia, upon the activation of the classical complement cascade, in a mouse 
model of SMA.  
7.) Microglia are the major and likely the sole source of C1q in the spinal cord during normal 
early development as well as in SMA. 
8.) Pharmacological depletion of microglia by PLX5622 in vivo treatment of SMA mice, 
revealed that depletion of microglia, rescued synapses that are eliminated in SMA. This 
pharmacological approach conferred significant behavioral benefit in SMA mice. 
97 
 
9.) Experiments in which SMN was selectively restored in proprioceptive neurons revealed that 
SMN deficiency in proprioceptive neurons drives C1q-tagging of proprioceptive synapses. 
10.) The number and the function of proprioceptive synapses in SMA mice can be rescued with 
in vivo postnatal neutralization of C1q by a-C1q antibody treatment, demonstrating that C1q 
also plays a role early in synaptic dysfunction. Treatment with a-C1q antibody provided 
remarkable behavioral benefit, underling its significance as a potential combinatorial 
therapeutic approach in SMA patients. 
11.) Genetic removal of C1q in SMA mice rescues number and the function of proprioceptive 
synapses which indicates that C1q mediated synaptic elimination is an active aberrant 
pathogenic process. 
12.) This study uncovers previously unknown role for the C1q in the refinement of spinal 
sensory-motor circuit during normal development. In this process C1q mediates elimination 






























Abraira, V.E., and Ginty, D.D. (2013). The sensory neurons of touch. Neuron 79, 618-639. 
Ackermann, B., Krober, S., Torres-Benito, L., Borgmann, A., Peters, M., Hosseini Barkooie, S.M., 
Tejero, R., Jakubik, M., Schreml, J., Milbradt, J., et al. (2013). Plastin 3 ameliorates spinal 
muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. 
Human molecular genetics 22, 1328-1347. 
Akay, T., Tourtellotte, W.G., Arber, S., and Jessell, T.M. (2014). Degradation of mouse locomotor 
pattern in the absence of proprioceptive sensory feedback. Proceedings of the National Academy of 
Sciences of the United States of America 111, 16877-16882. 
Allan, D.W., and Greer, J.J. (1997). Development of phrenic motoneuron morphology in the fetal 
rat. The Journal of comparative neurology 382, 469-479. 
Altman, J., Bayer, SA.  (1997). Development of the cerebellar system (New York: CRC Press;). 
Arber, S., Ladle, D.R., Lin, J.H., Frank, E., and Jessell, T.M. (2000). ETS gene Er81 controls the 
formation of functional connections between group Ia sensory afferents and motor neurons. Cell 
101, 485-498. 
Arkblad, E., Tulinius, M., Kroksmark, A.K., Henricsson, M., and Darin, N. (2009). A population-
based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta 
paediatrica (Oslo, Norway : 1992) 98, 865-872. 
Arnold, W.D., and Burghes, A.H. (2013). Spinal muscular atrophy: development and 
implementation of potential treatments. Annals of neurology 74, 348-362. 
Arnold, W.D., Kassar, D., and Kissel, J.T. (2015). Spinal muscular atrophy: diagnosis and 
management in a new therapeutic era. Muscle & nerve 51, 157-167. 
Bennett, M.L., Bennett, F.C., Liddelow, S.A., Ajami, B., Zamanian, J.L., Fernhoff, N.B., 
Mulinyawe, S.B., Bohlen, C.J., Adil, A., Tucker, A., et al. (2016). New tools for studying microglia 
in the mouse and human CNS.  113, E1738-E1746. 
Betley, J.N., Wright, C.V., Kawaguchi, Y., Erdelyi, F., Szabo, G., Jessell, T.M., and Kaltschmidt, 
J.A. (2009). Stringent specificity in the construction of a GABAergic presynaptic inhibitory circuit. 
Cell 139, 161-174. 
Bignall, K.E. (1974). Ontogeny of levels of neural organization: The righting reflex as a model. 
Experimental Neurology 42, 566-573. 
Botto, M. (1998). C1q knock-out mice for the study of complement deficiency in autoimmune 
disease. Exp Clin Immunogenet 15, 231-234. 
99 
 
Botto, M., Dell'Agnola, C., Bygrave, A.E., Thompson, E.M., Cook, H.T., Petry, F., Loos, M., 
Pandolfi, P.P., and Walport, M.J. (1998). Homozygous C1q deficiency causes glomerulonephritis 
associated with multiple apoptotic bodies. Nature genetics 19, 56-59. 
Brennan, F.H., Lee, J.D., Ruitenberg, M.J., and Woodruff, T.M. (2016). Therapeutic targeting of 
complement to modify disease course and improve outcomes in neurological conditions. Semin 
Immunol 28, 292-308. 
Brodsky-Doyle, B., Leonard, K.R., and Reid, K.B. (1976). Circular-dichroism and electron-
microscopy studies of human subcomponent C1q before and after limited proteolysis by pepsin. 
The Biochemical journal 159, 279-286. 
Brown, A.G. (1981). Organization in the Spinal Cord. New York: Springer. 
Brown, A.G., and Fyffe, R.E. (1979). The morphology of group Ib afferent fibre collaterals in the 
spinal cord of the cat. The Journal of physiology 296, 215-226. 
Burghes, A.H., and Beattie, C.E. (2009). Spinal muscular atrophy: why do low levels of survival 
motor neuron protein make motor neurons sick? Nature reviews Neuroscience 10, 597-609. 
Burke, R.E., Strick, P.L., Kanda, K., Kim, C.C., and Walmsley, B. (1977). Anatomy of medial 
gastrocnemius and soleus motor nuclei in cat spinal cord. Journal of neurophysiology 40, 667-680. 
Butchbach, M.E. (2016). Copy Number Variations in the Survival Motor Neuron Genes: 
Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Frontiers in 
molecular biosciences 3, 7. 
Carroll, M.C., and Isenman, D.E. (2012). Regulation of humoral immunity by complement. 
Immunity 37, 199-207. 
Castro, D., and Iannaccone, S.T. (2014). Spinal muscular atrophy: therapeutic strategies. Current 
treatment options in neurology 16, 316. 
Catela, C., Shin, M.M., and Dasen, J.S. (2015). Assembly and function of spinal circuits for motor 
control. Annual review of cell and developmental biology 31, 669-698. 
Cecchini, M.G., Dominguez, M.G., Mocci, S., Wetterwald, A., Felix, R., Fleisch, H., Chisholm, O., 
Hofstetter, W., Pollard, J.W., and Stanley, E.R. (1994). Role of colony stimulating factor-1 in the 
establishment and regulation of tissue macrophages during postnatal development of the mouse. 
Development 120, 1357-1372. 
Chen, H.H., Hippenmeyer, S., Arber, S., and Frank, E. (2003). Development of the monosynaptic 
stretch reflex circuit. Current opinion in neurobiology 13, 96-102. 
Chiriboga, C.A. (2017). Nusinersen for the treatment of spinal muscular atrophy. Expert review of 
neurotherapeutics 17, 955-962. 
Cho, K. (2019). Emerging Roles of Complement Protein C1q in Neurodegeneration. Aging and 
disease 10, 652-663. 
100 
 
Chu, Y., Jin, X., Parada, I., Pesic, A., Stevens, B., Barres, B., and Prince, D.A. (2010). Enhanced 
synaptic connectivity and epilepsy in C1q knockout mice. Proceedings of the National Academy of 
Sciences of the United States of America 107, 7975-7980. 
Clarke, L.E., and Barres, B.A. (2013). Emerging roles of astrocytes in neural circuit development. 
Nature reviews Neuroscience 14, 311-321. 
Coovert, D.D., Le, T.T., McAndrew, P.E., Strasswimmer, J., Crawford, T.O., Mendell, J.R., 
Coulson, S.E., Androphy, E.J., Prior, T.W., and Burghes, A.H. (1997). The survival motor neuron 
protein in spinal muscular atrophy. Human molecular genetics 6, 1205-1214. 
Corey, D.R. (2017). Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. 
Nature neuroscience 20, 497-499. 
Coulthard, L.G., Hawksworth, O.A., and Woodruff, T.M. (2018). Complement: The Emerging 
Architect of the Developing Brain. Trends Neurosci 41, 373-384. 
Dachs, E., Hereu, M., Piedrafita, L., Casanovas, A., Caldero, J., and Esquerda, J.E. (2011). 
Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal 
muscular atrophy. Journal of neuropathology and experimental neurology 70, 444-461. 
Darras, B.T. (2015). Spinal Muscular Atrophies. Pediatric Clinics of North America 62, 743-766. 
Dasen, J.S. (2009). Transcriptional networks in the early development of sensory-motor circuits. 
Curr Top Dev Biol 87, 119-148. 
Dasen, J.S., and Jessell, T.M. (2009). Hox networks and the origins of motor neuron diversity. Curr 
Top Dev Biol 88, 169-200. 
Davis, E.J., Foster, T.D., and Thomas, W.E. (1994). Cellular forms and functions of brain 
microglia. Brain research bulletin 34, 73-78. 
Degn, S.E., Thiel, S., and Jensenius, J.C. (2007). New perspectives on mannan-binding lectin-
mediated complement activation. Immunobiology 212, 301-311. 
Deguise, M.-O., De Repentigny, Y., McFall, E., Auclair, N., Sad, S., and Kothary, R. (2017). 
Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. 
Human molecular genetics 26, 801-819. 
Dejanovic, B., Huntley, M.A., De Maziere, A., Meilandt, W.J., Wu, T., Srinivasan, K., Jiang, Z., 
Gandham, V., Friedman, B.A., Ngu, H., et al. (2018). Changes in the Synaptic Proteome in 
Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100, 1322-
1336.e1327. 
DiDonato, C.J., Chen, X.N., Noya, D., Korenberg, J.R., Nadeau, J.H., and Simard, L.R. (1997). 
Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of 
the spinal muscular atrophy-determining gene. Genome research 7, 339-352. 
101 
 
Dunkelberger, J.R., and Song, W.C. (2010). Complement and its role in innate and adaptive 
immune responses. Cell Res 20, 34-50. 
Eccles, J.C., Eccles, R.M., Iggo, A., and Lundberg, A. (1960). Electrophysiological studies on 
gamma motoneurones. Acta physiologica Scandinavica 50, 32-40. 
Eccles, J.C., Eccles, R.M., and Lundberg, A. (1957). The convergence of monosynaptic excitatory 
afferents on to many different species of alpha motoneurones. The Journal of physiology 137, 22-
50. 
Edens, B.M., Ajroud-Driss, S., Ma, L., and Ma, Y.-C. (2015). Molecular mechanisms and animal 
models of spinal muscular atrophy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of 
Disease 1852, 685-692. 
Ehlers, M.R. (2000). CR3: a general purpose adhesion-recognition receptor essential for innate 
immunity. Microbes Infect 2, 289-294. 
Elmore, M.R., Najafi, A.R., Koike, M.A., Dagher, N.N., Spangenberg, E.E., Rice, R.A., Kitazawa, 
M., Matusow, B., Nguyen, H., West, B.L., et al. (2014). Colony-stimulating factor 1 receptor 
signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult 
brain. Neuron 82, 380-397. 
Elmore, M.R.P., Hohsfield, L.A., Kramar, E.A., Soreq, L., Lee, R.J., Pham, S.T., Najafi, A.R., 
Spangenberg, E.E., Wood, M.A., West, B.L., et al. (2018). Replacement of microglia in the aged 
brain reverses cognitive, synaptic, and neuronal deficits in mice. Aging cell 17, e12832. 
Erblich, B., Zhu, L., Etgen, A.M., Dobrenis, K., and Pollard, J.W. (2011). Absence of colony 
stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory 
deficits. PloS one 6, e26317. 
Fagan, K., Crider, A., Ahmed, A.O., and Pillai, A. (2017). Complement C3 Expression Is 
Decreased in Autism Spectrum Disorder Subjects and Contributes to Behavioral Deficits in 
Rodents. Molecular neuropsychiatry 3, 19-27. 
Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T.F., and Wirth, B. (2002). Quantitative 
analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier 
testing and prediction of severity of spinal muscular atrophy. American journal of human genetics 
70, 358-368. 
Fetcho, J.R. (1987). A review of the organization and evolution of motoneurons innervating the 
axial musculature of vertebrates. Brain research 434, 243-280. 
Fletcher, E.V., and Mentis, G.Z. (2017). Motor Circuit Dysfunction in Spinal Muscular Atrophy. In 
Spinal Muscular Atrophy, pp. 153-165. 
102 
 
Fletcher, E.V., Simon, C.M., Pagiazitis, J.G., Chalif, J.I., Vukojicic, A., Drobac, E., Wang, X., and 
Mentis, G.Z. (2017). Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 
in spinal muscular atrophy. Nat Neurosci 20, 905-916. 
Fonseca, M.I., Chu, S.H., Hernandez, M.X., Fang, M.J., Modarresi, L., Selvan, P., MacGregor, 
G.R., and Tenner, A.J. (2017). Cell-specific deletion of C1qa identifies microglia as the dominant 
source of C1q in mouse brain. Journal of neuroinflammation 14, 48. 
Friese, A., Kaltschmidt, J.A., Ladle, D.R., Sigrist, M., Jessell, T.M., and Arber, S. (2009). Gamma 
and alpha motor neurons distinguished by expression of transcription factor Err3.  106, 13588-
13593. 
Füger, P., Hefendehl, J.K., Veeraraghavalu, K., Wendeln, A.-C., Schlosser, C., Obermüller, U., 
Wegenast-Braun, B.M., Neher, J.J., Martus, P., Kohsaka, S., et al. (2017). Microglia turnover with 
aging and in an Alzheimer's model via long-term in vivo single-cell imaging. Nature neuroscience 
20, 1371-1376. 
Fujita, T. (2002). Evolution of the lectin-complement pathway and its role in innate immunity. Nat 
Rev Immunol 2, 346-353. 
Fukuhara, K., Imai, F., Ladle, D.R., Katayama, K., Leslie, J.R., Arber, S., Jessell, T.M., and 
Yoshida, Y. (2013). Specificity of monosynaptic sensory-motor connections imposed by repellent 
Sema3E-PlexinD1 signaling. Cell reports 5, 748-758. 
Gaboriaud, C., Frachet, P., Thielens, N.M., and Arlaud, G.J. (2011). The human c1q globular 
domain: structure and recognition of non-immune self ligands. Front Immunol 2, 92. 
Gaboriaud, C., Juanhuix, J., Gruez, A., Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-
Camps, J.C., and Arlaud, G.J. (2003). The crystal structure of the globular head of complement 
protein C1q provides a basis for its versatile recognition properties. The Journal of biological 
chemistry 278, 46974-46982. 
Garber, K. (2016). Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nature 
biotechnology 34, 1002-1003. 
Gavrilina, T.O., McGovern, V.L., Workman, E., Crawford, T.O., Gogliotti, R.G., DiDonato, C.J., 
Monani, U.R., Morris, G.E., and Burghes, A.H. (2008). Neuronal SMN expression corrects spinal 
muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic 
effect. Human molecular genetics 17, 1063-1075. 
Ghebrehiwet, B. (2018). Chapter 3 - C1q. In The Complement FactsBook (Second Edition), S. 
Barnum, and T. Schein, eds. (Academic Press), pp. 23-32. 
Gilliam, T.C., Brzustowicz, L.M., Castilla, L.H., Lehner, T., Penchaszadeh, G.K., Daniels, R.J., 
Byth, B.C., Knowles, J., Hislop, J.E., Shapira, Y., et al. (1990). Genetic homogeneity between acute 
and chronic forms of spinal muscular atrophy. Nature 345, 823-825. 
103 
 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, S.J., 
Ng, L.G., Stanley, E.R., et al. (2010). Fate mapping analysis reveals that adult microglia derive 
from primitive macrophages. Science (New York, NY) 330, 841-845. 
Gogliotti, R.G., Quinlan, K.A., Barlow, C.B., Heier, C.R., Heckman, C.J., and Didonato, C.J. 
(2012). Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor 
defects are a consequence, not a cause, of motor neuron dysfunction. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 32, 3818-3829. 
Goulding, M., and Pfaff, S.L. (2005). Development of circuits that generate simple rhythmic 
behaviors in vertebrates. Current opinion in neurobiology 15, 14-20. 
Goulet, B.B., Kothary, R., and Parks, R.J. (2013). At the "junction" of spinal muscular atrophy 
pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression. Current 
molecular medicine 13, 1160-1174. 
Grillner, S., and Jessell, T.M. (2009). Measured motion: searching for simplicity in spinal 
locomotor networks. Current opinion in neurobiology 19, 572-586. 
Gutman, C.R., Ajmera, M.K., and Hollyday, M. (1993). Organization of motor pools supplying 
axial muscles in the chicken. Brain research 609, 129-136. 
Hancock, M.B., and Peveto, C.A. (1979). Preganglionic neurons in the sacral spinal cord of the rat: 
an HRP study. Neuroscience letters 11, 1-5. 
Heier, C.R., Satta, R., Lutz, C., and DiDonato, C.J. (2010). Arrhythmia and cardiac defects are a 
feature of spinal muscular atrophy model mice. Human molecular genetics 19, 3906-3918. 
Hoheisel U, L.-W.E., Mense S.   (1989). Termination patterns of identified group II and III 
afferent fibres from deep tissues in the spinal cord of the cat. Neuroscience 28:495–507. 
Holness, C., and Simmons, D. (1993). Molecular cloning of CD68, a human macrophage marker 
related to lysosomal glycoproteins. Blood 81, 1607-1613. 
Hong, S., Beja-Glasser, V.F., Nfonoyim, B.M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.M., 
Shi, Q., Rosenthal, A., Barres, B.A., et al. (2016). Complement and microglia mediate early 
synapse loss in Alzheimer mouse models. Science (New York, NY) 352, 712-716. 
Howell, G.R., Macalinao, D.G., Sousa, G.L., Walden, M., Soto, I., Kneeland, S.C., Barbay, J.M., 
King, B.L., Marchant, J.K., Hibbs, M., et al. (2011). Molecular clustering identifies complement 
and endothelin induction as early events in a mouse model of glaucoma. The Journal of clinical 
investigation 121, 1429-1444. 
Hsieh-Li, H.M., Chang, J.G., Jong, Y.J., Wu, M.H., Wang, N.M., Tsai, C.H., and Li, H. (2000). A 
mouse model for spinal muscular atrophy. Nature genetics 24, 66-70. 
104 
 
Hua, J.Y., and Smith, S.J. (2004). Neural activity and the dynamics of central nervous system 
development. Nature neuroscience 7, 327-332. 
Imai, F., and Yoshida, Y. (2018). Molecular mechanisms underlying monosynaptic sensory-motor 
circuit development in the spinal cord. Developmental dynamics : an official publication of the 
American Association of Anatomists 247, 581-587. 
Imlach, W.L., Beck, E.S., Choi, B.J., Lotti, F., Pellizzoni, L., and McCabe, B.D. (2012). SMN is 
required for sensory-motor circuit function in Drosophila. Cell 151, 427-439. 
Janeway, T.P., Walport M, et al. (2001). The complement system and innate immunity. 
Immunobiology: The Immune System in Health and Disease. , Vol 5th edition. (New York: Garland 
Science). 
Jessell, T.M. (2000). Neuronal specification in the spinal cord: inductive signals and transcriptional 
codes. Nature reviews Genetics 1, 20-29. 
Jung, H., and Dasen, J.S. (2015). Evolution of patterning systems and circuit elements for 
locomotion. Developmental cell 32, 408-422. 
Kang, Y.S., Do, Y., Lee, H.K., Park, S.H., Cheong, C., Lynch, R.M., Loeffler, J.M., Steinman, 
R.M., and Park, C.G. (2006). A dominant complement fixation pathway for pneumococcal 
polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125, 47-58. 
Kanning, K.C., Kaplan, A., and Henderson, C.E. (2010). Motor neuron diversity in development 
and disease. Annual review of neuroscience 33, 409-440. 
Kariya, S., Park, G.H., Maeno-Hikichi, Y., Leykekhman, O., Lutz, C., Arkovitz, M.S., Landmesser, 
L.T., and Monani, U.R. (2008). Reduced SMN protein impairs maturation of the neuromuscular 
junctions in mouse models of spinal muscular atrophy. Human molecular genetics 17, 2552-2569. 
Kashima, T., Rao, N., David, C.J., and Manley, J.L. (2007). hnRNP A1 functions with specificity in 
repression of SMN2 exon 7 splicing. Human molecular genetics 16, 3149-3159. 
Katz, L.C., and Shatz, C.J. (1996). Synaptic Activity and the Construction of Cortical Circuits. 
Science (New York, NY) 274, 1133-1138. 
Kierdorf, K., Erny, D., Goldmann, T., Sander, V., Schulz, C., Perdiguero, E.G., Wieghofer, P., 
Heinrich, A., Riemke, P., Holscher, C., et al. (2013). Microglia emerge from erythromyeloid 
precursors via Pu.1- and Irf8-dependent pathways. Nature neuroscience 16, 273-280. 
Kilchherr, E., Hofmann, H., Steigemann, W., and Engel, J. (1985). Structural model of the collagen-
like region of C1q comprising the kink region and the fibre-like packing of the six triple helices. 
Journal of molecular biology 186, 403-415. 




Kishore, U., Gupta, S.K., Perdikoulis, M.V., Kojouharova, M.S., Urban, B.C., and Reid, K.B.M. 
(2003). Modular Organization of the Carboxyl-Terminal, Globular Head Region of Human C1q A, 
B, and C Chains.  171, 812-820. 
Kishore, U., and Reid, K.B. (2000). C1q: structure, function, and receptors. Immunopharmacology 
49, 159-170. 
Kjaeldgaard, A.L., Pilely, K., Olsen, K.S., Pedersen, S.W., Lauritsen, A.O., Moller, K., and Garred, 
P. (2018). Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis. Mol 
Immunol 102, 14-25. 
Knobel, H.R., Villiger, W., and Isliker, H. (1975). Chemical analysis and electron microscopy 
studies of human C1q prepared by different methods. European journal of immunology 5, 78-82. 
Kong, L., Wang, X., Choe, D.W., Polley, M., Burnett, B.G., Bosch-Marce, M., Griffin, J.W., Rich, 
M.M., and Sumner, C.J. (2009). Impaired synaptic vesicle release and immaturity of neuromuscular 
junctions in spinal muscular atrophy mice. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 29, 842-851. 
Korinthenberg, R., Sauer, M., Ketelsen, U.P., Hanemann, C.O., Stoll, G., Graf, M., Baborie, A., 
Volk, B., Wirth, B., Rudnik-Schoneborn, S., et al. (1997). Congenital axonal neuropathy caused by 
deletions in the spinal muscular atrophy region. Annals of neurology 42, 364-368. 
Kudo, N., and Yamada, T. (1987). Morphological and physiological studies of development of the 
monosynaptic reflex pathway in the rat lumbar spinal cord. The Journal of physiology 389, 441-
459. 
Kuffler, S.W., Hunt, C.C., and Quilliam, J.P. (1951). Function of medullated small-nerve fibers in 
mammalian ventral roots; efferent muscle spindle innervation. Journal of neurophysiology 14, 29-
54. 
Kuo, J.J., Schonewille, M., Siddique, T., Schults, A.N., Fu, R., Bar, P.R., Anelli, R., Heckman, C.J., 
and Kroese, A.B. (2004). Hyperexcitability of cultured spinal motoneurons from presymptomatic 
ALS mice. Journal of neurophysiology 91, 571-575. 
Kuru, S., Sakai, M., Konagaya, M., Yoshida, M., Hashizume, Y., and Saito, K. (2009). An autopsy 
case of spinal muscular atrophy type III (Kugelberg-Welander disease). Neuropathology : official 
journal of the Japanese Society of Neuropathology 29, 63-67. 
Landmesser, L. (1978). The distribution of motoneurones supplying chick hind limb muscles. The 
Journal of physiology 284, 371-389. 
Lansita, J.A., Mease, K.M., Qiu, H., Yednock, T., Sankaranarayanan, S., and Kramer, S. (2017). 
Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of 
Autoimmune and Neurodegenerative Diseases. International journal of toxicology 36, 449-462. 
106 
 
Le, T.T., Pham, L.T., Butchbach, M.E., Zhang, H.L., Monani, U.R., Coovert, D.D., Gavrilina, T.O., 
Xing, L., Bassell, G.J., and Burghes, A.H. (2005). SMNDelta7, the major product of the 
centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular 
atrophy and associates with full-length SMN. Human molecular genetics 14, 845-857. 
Lee, Y.I., Mikesh, M., Smith, I., Rimer, M., and Thompson, W. (2011). Muscles in a mouse model 
of spinal muscular atrophy show profound defects in neuromuscular development even in the 
absence of failure in neuromuscular transmission or loss of motor neurons. Developmental biology 
356, 432-444. 
Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, 
C., Millasseau, P., Zeviani, M., et al. (1995). Identification and characterization of a spinal 
muscular atrophy-determining gene. Cell 80, 155-165. 
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Munnich, A., Dreyfuss, G., and Melki, 
J. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. Nature 
genetics 16, 265-269. 
Lehrman, E.K., Wilton, D.K., Litvina, E.Y., Welsh, C.A., Chang, S.T., Frouin, A., Walker, A.J., 
Heller, M.D., Umemori, H., Chen, C., et al. (2018). CD47 Protects Synapses from Excess 
Microglia-Mediated Pruning during Development. Neuron 100, 120-134.e126. 
Li, Y., and Burke, R.E. (2002). Developmental changes in short-term synaptic depression in the 
neonatal mouse spinal cord. Journal of neurophysiology 88, 3218-3231. 
Ling, K.K., Lin, M.Y., Zingg, B., Feng, Z., and Ko, C.P. (2010a). Synaptic defects in the spinal and 
neuromuscular circuitry in a mouse model of spinal muscular atrophy. PloS one 5, e15457. 
Ling, K.K.Y., Lin, M.-Y., Zingg, B., Feng, Z., and Ko, C.-P. (2010b). Synaptic Defects in the 
Spinal and Neuromuscular Circuitry in a Mouse Model of Spinal Muscular Atrophy. PloS one 5, 
e15457. 
Lipton, A.M., Cullum, C.M., Satumtira, S., Sontag, E., Hynan, L.S., White, C.L., 3rd, and Bigio, 
E.H. (2001). Contribution of asymmetric synapse loss to lateralizing clinical deficits in 
frontotemporal dementias. Archives of neurology 58, 1233-1239. 
Liu, Q., and Dreyfuss, G. (1996). A novel nuclear structure containing the survival of motor 
neurons protein. Embo j 15, 3555-3565. 
Loeffler, D.A., Camp, D.M., and Conant, S.B. (2006). Complement activation in the Parkinson's 
disease substantia nigra: an immunocytochemical study. Journal of neuroinflammation 3, 29. 
Lorson, C.L., and Androphy, E.J. (2000). An exonic enhancer is required for inclusion of an 
essential exon in the SMA-determining gene SMN. Human molecular genetics 9, 259-265. 
Louveau, A., Harris, T.H., and Kipnis, J. (2015). Revisiting the Mechanisms of CNS Immune 
Privilege. Trends in immunology 36, 569-577. 
107 
 
Louveau, A., Herz, J., Alme, M.N., Salvador, A.F., Dong, M.Q., Viar, K.E., Herod, S.G., Knopp, J., 
Setliff, J.C., Lupi, A.L., et al. (2018). CNS lymphatic drainage and neuroinflammation are regulated 
by meningeal lymphatic vasculature. Nature neuroscience 21, 1380-1391. 
Lui, H., Zhang, J., Makinson, S.R., Cahill, M.K., Kelley, K.W., Huang, H.Y., Shang, Y., Oldham, 
M.C., Martens, L.H., Gao, F., et al. (2016). Progranulin Deficiency Promotes Circuit-Specific 
Synaptic Pruning by Microglia via Complement Activation. Cell 165, 921-935. 
Lutz, C.M., Kariya, S., Patruni, S., Osborne, M.A., Liu, D., Henderson, C.E., Li, D.K., Pellizzoni, 
L., Rojas, J., Valenzuela, D.M., et al. (2011). Postsymptomatic restoration of SMN rescues the 
disease phenotype in a mouse model of severe spinal muscular atrophy. The Journal of clinical 
investigation 121, 3029-3041. 
Mailman, M.D., Heinz, J.W., Papp, A.C., Snyder, P.J., Sedra, M.S., Wirth, B., Burghes, A.H., and 
Prior, T.W. (2002). Molecular analysis of spinal muscular atrophy and modification of the 
phenotype by SMN2. Genetics in medicine : official journal of the American College of Medical 
Genetics 4, 20-26. 
Mallucci, G.R. (2009). Prion neurodegeneration: starts and stops at the synapse. Prion 3, 195-201. 
Malone, D.C., Dean, R., Arjunji, R., Jensen, I., Cyr, P., Miller, B., Maru, B., Sproule, D.M., Feltner, 
D.E., and Dabbous, O. (2019). Cost-effectiveness analysis of using onasemnogene abeparvocec 
(AVXS-101) in spinal muscular atrophy type 1 patients. Journal of market access & health policy 7, 
1601484. 
Maretina, M.A., Zheleznyakova, G.Y., Lanko, K.M., Egorova, A.A., Baranov, V.S., and Kiselev, 
A.V. (2018). Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible 
Disease-modifying Candidates. Current genomics 19, 339-355. 
Martinez, T.L., Kong, L., Wang, X., Osborne, M.A., Crowder, M.E., Van Meerbeke, J.P., Xu, X., 
Davis, C., Wooley, J., Goldhamer, D.J., et al. (2012). Survival motor neuron protein in motor 
neurons determines synaptic integrity in spinal muscular atrophy. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 32, 8703-8715. 
McGonigal, R., Cunningham, M.E., Yao, D., Barrie, J.A., Sankaranarayanan, S., Fewou, S.N., 
Furukawa, K., Yednock, T.A., and Willison, H.J. (2016). C1q-targeted inhibition of the classical 
complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. 
Acta Neuropathol Commun 4, 23. 
Mears, S.C., and Frank, E. (1997). Formation of specific monosynaptic connections between 
muscle spindle afferents and motoneurons in the mouse. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 17, 3128-3135. 
Medzhitov, R., and Janeway, C., Jr. (2000). Innate immunity. The New England journal of 
medicine 343, 338-344. 
108 
 
Medzhitov, R., and Janeway, C.A., Jr. (2002). Decoding the patterns of self and nonself by the 
innate immune system. Science (New York, NY) 296, 298-300. 
Melki, J., Abdelhak, S., Sheth, P., Bachelot, M.F., Burlet, P., Marcadet, A., Aicardi, J., Barois, A., 
Carriere, J.P., Fardeau, M., et al. (1990). Gene for chronic proximal spinal muscular atrophies maps 
to chromosome 5q. Nature 344, 767-768. 
Mende, M., Fletcher, E.V., Belluardo, J.L., Pierce, J.P., Bommareddy, P.K., Weinrich, J.A., Kabir, 
Z.D., Schierberl, K.C., Pagiazitis, J.G., Mendelsohn, A.I., et al. (2016). Sensory-Derived Glutamate 
Regulates Presynaptic Inhibitory Terminals in Mouse Spinal Cord. Neuron 90, 1189-1202. 
Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., 
Alfano, L., Berry, K., Church, K., et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal 
Muscular Atrophy. The New England journal of medicine 377, 1713-1722. 
Mendelsohn, A.I., Simon, C.M., Abbott, L.F., Mentis, G.Z., and Jessell, T.M. (2015). Activity 
Regulates the Incidence of Heteronymous Sensory-Motor Connections. Neuron 87, 111-123. 
Mentis, G.Z., Blivis, D., Liu, W., Drobac, E., Crowder, M.E., Kong, L., Alvarez, F.J., Sumner, C.J., 
and O'Donovan, M.J. (2011). Early functional impairment of sensory-motor connectivity in a 
mouse model of spinal muscular atrophy. Neuron 69, 453-467. 
Mentis, G.Z., Diaz, E., Moran, L.B., and Navarrete, R. (2007). Early alterations in the 
electrophysiological properties of rat spinal motoneurones following neonatal axotomy. The Journal 
of physiology 582, 1141-1161. 
Mi, Z.P., Jiang, P., Weng, W.L., Lindberg, F.P., Narayanan, V., and Lagenaur, C.F. (2000). 
Expression of a synapse-associated membrane protein, P84/SHPS-1, and its ligand, IAP/CD47, in 
mouse retina. The Journal of comparative neurology 416, 335-344. 
Michell-Robinson, M.A., Touil, H., Healy, L.M., Owen, D.R., Durafourt, B.A., Bar-Or, A., Antel, 
J.P., and Moore, C.S. (2015). Roles of microglia in brain development, tissue maintenance and 
repair. Brain : a journal of neurology 138, 1138-1159. 
Monani, U.R., Sendtner, M., Coovert, D.D., Parsons, D.W., Andreassi, C., Le, T.T., Jablonka, S., 
Schrank, B., Rossoll, W., Prior, T.W., et al. (2000). The human centromeric survival motor neuron 
gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal 
muscular atrophy. Human molecular genetics 9, 333-339. 
Montes, J., Gordon, A.M., Pandya, S., De Vivo, D.C., and Kaufmann, P. (2009). Clinical outcome 
measures in spinal muscular atrophy. Journal of child neurology 24, 968-978. 
Mortensen, S.A., Sander, B., Jensen, R.K., Pedersen, J.S., Golas, M.M., Jensenius, J.C., Hansen, 
A.G., Thiel, S., and Andersen, G.R. (2017). Structure and activation of C1, the complex initiating 




Mostacciuolo, M.L., Danieli, G.A., Trevisan, C., Muller, E., and Angelini, C. (1992). Epidemiology 
of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology 11, 34-38. 
Murray, L.M., Comley, L.H., Thomson, D., Parkinson, N., Talbot, K., and Gillingwater, T.H. 
(2008). Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic 
pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human 
molecular genetics 17, 949-962. 
Najafi, A.R., Crapser, J., Jiang, S., Ng, W., Mortazavi, A., West, B.L., and Green, K.N. (2018). A 
limited capacity for microglial repopulation in the adult brain. Glia 66, 2385-2396. 
Nayak, D., Roth, T.L., and McGavern, D.B. (2014). Microglia Development and Function. Annual 
Review of Immunology 32, 367-402. 
Neniskyte, U., and Gross, C.T. (2017). Errant gardeners: glial-cell-dependent synaptic pruning and 
neurodevelopmental disorders. Nature reviews Neuroscience 18, 658-670. 
Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo. Science (New York, NY) 308, 1314-1318. 
Noris, M., and Remuzzi, G. (2013). Overview of complement activation and regulation. Semin 
Nephrol 33, 479-492. 
Ohsawa, K., Imai, Y., Sasaki, Y., and Kohsaka, S. (2004). Microglia/macrophage-specific protein 
Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem 88, 844-856. 
Oosterhof, N., Kuil, L.E., van der Linde, H.C., Burm, S.M., Berdowski, W., van Ijcken, W.F.J., van 
Swieten, J.C., Hol, E.M., Verheijen, M.H.G., and van Ham, T.J. (2018). Colony-Stimulating Factor 
1 Receptor (CSF1R) Regulates Microglia Density and Distribution, but Not Microglia 
Differentiation In Vivo. Cell reports 24, 1203-1217.e1206. 
Oskoui, M., Darras, B.T., and De Vivo, D.C. (2017). Chapter 1 - Spinal Muscular Atrophy: 125 
Years Later and on the Verge of a Cure. In Spinal Muscular Atrophy, C.J. Sumner, S. Paushkin, and 
C.-P. Ko, eds. (Academic Press), pp. 3-19. 
Oskoui, M., Levy, G., Garland, C.J., Gray, J.M., O'Hagen, J., De Vivo, D.C., and Kaufmann, P. 
(2007). The changing natural history of spinal muscular atrophy type 1. Neurology 69, 1931-1936. 
Ottesen, E.W. (2017). ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy. 
Translational neuroscience 8, 1-6. 
Ozaki, S., and Snider, W.D. (1997). Initial trajectories of sensory axons toward laminar targets in 
the developing mouse spinal cord. The Journal of comparative neurology 380, 215-229. 
Palop, J.J., and Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's 
disease: from synapses toward neural networks. Nature neuroscience 13, 812-818. 
110 
 
Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., 
Ferreira, T.A., Guiducci, E., Dumas, L., et al. (2011). Synaptic pruning by microglia is necessary 
for normal brain development. Science (New York, NY) 333, 1456-1458. 
Papadimitriou, D., Le Verche, V., Jacquier, A., Ikiz, B., Przedborski, S., and Re, D.B. (2010). 
Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiology of Disease 37, 
493-502. 
Park, G.H., Maeno-Hikichi, Y., Awano, T., Landmesser, L.T., and Monani, U.R. (2010). Reduced 
survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously 
to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 30, 12005-12019. 
Pecho-Vrieseling, E., Sigrist, M., Yoshida, Y., Jessell, T.M., and Arber, S. (2009). Specificity of 
sensory-motor connections encoded by Sema3e-Plxnd1 recognition. Nature 459, 842-846. 
Pellis, S.M., and Pellis, V.C. (1994). Development of righting when falling from a bipedal standing 
posture: Evidence for the dissociation of dynamic and static righting reflexes in rats. Physiology & 
Behavior 56, 659-663. 
Pellizzoni, L., Baccon, J., Rappsilber, J., Mann, M., and Dreyfuss, G. (2002). Purification of native 
survival of motor neurons complexes and identification of Gemin6 as a novel component. The 
Journal of biological chemistry 277, 7540-7545. 
Plant, G.W., Weinrich, J.A., and Kaltschmidt, J.A. (2018). Sensory and descending motor circuitry 
during development and injury. Current opinion in neurobiology 53, 156-161. 
Poliak, S., Norovich, A.L., Yamagata, M., Sanes, J.R., and Jessell, T.M. (2016). Muscle-type 
Identity of Proprioceptors Specified by Spatially Restricted Signals from Limb Mesenchyme. Cell 
164, 512-525. 
Powis, R.A., and Gillingwater, T.H. (2016). Selective loss of alpha motor neurons with sparing of 
gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular 
atrophy. Journal of anatomy 228, 443-451. 
Prasad, A., and Hollyday, M. (1991). Development and migration of avian sympathetic 
preganglionic neurons. The Journal of comparative neurology 307, 237-258. 
Presumey, J., Bialas, A.R., and Carroll, M.C. (2017). Complement System in Neural Synapse 
Elimination in Development and Disease. Adv Immunol 135, 53-79. 
Price, S.R., and Briscoe, J. (2004). The generation and diversification of spinal motor neurons: 
signals and responses. Mechanisms of development 121, 1103-1115. 
Qin, X., Krumrei, N., Grubissich, L., Dobarro, M., Aktas, H., Perez, G., and Halperin, J.A. (2003). 
Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic 
anemia with platelet activation and progressive male infertility. Immunity 18, 217-227. 
111 
 
Rademakers, R., Neumann, M., and Mackenzie, I.R. (2012). Advances in understanding the 
molecular basis of frontotemporal dementia. Nature reviews Neurology 8, 423-434. 
Ransohoff, R.M., and Perry, V.H. (2009). Microglial physiology: unique stimuli, specialized 
responses. Annu Rev Immunol 27, 119-145. 
Redman, S. (1979). Junctional mechanisms at group Ia synapses. Prog Neurobiol 12, 33-83. 
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for 
immune surveillance and homeostasis. Nat Immunol 11, 785-797. 
Rindt, H., Feng, Z., Mazzasette, C., Glascock, J.J., Valdivia, D., Pyles, N., Crawford, T.O., 
Swoboda, K.J., Patitucci, T.N., Ebert, A.D., et al. (2015). Astrocytes influence the severity of spinal 
muscular atrophy. Human molecular genetics 24, 4094-4102. 
Rochette, C.F., Gilbert, N., and Simard, L.R. (2001). SMN gene duplication and the emergence of 
the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet 108, 
255-266. 
Romanes, G.J. (1951). The motor cell columns of the lumbo-sacral spinal cord of the cat. The 
Journal of comparative neurology 94, 313-363. 
Rotterman, T.M., Nardelli, P., Cope, T.C., and Alvarez, F.J. (2014). Normal distribution of 
VGLUT1 synapses on spinal motoneuron dendrites and their reorganization after nerve injury. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 34, 3475-3492. 
SA., S. (1992). Sensory Neurons: Diversity, Development, and Plasticity. New York: Oxford Univ 
Press. 
Schafer, D.P., Lehrman, E.K., Kautzman, A.G., Koyama, R., Mardinly, A.R., Yamasaki, R., 
Ransohoff, R.M., Greenberg, M.E., Barres, B.A., and Stevens, B. (2012). Microglia sculpt postnatal 
neural circuits in an activity and complement-dependent manner. Neuron 74, 691-705. 
Schrank, B., Gotz, R., Gunnersen, J.M., Ure, J.M., Toyka, K.V., Smith, A.G., and Sendtner, M. 
(1997a). Inactivation of the survival motor neuron gene, a candidate gene for human spinal 
muscular atrophy, leads to massive cell death in early mouse embryos. Proceedings of the National 
Academy of Sciences of the United States of America 94, 9920-9925. 
Schrank, B., Götz, R., Gunnersen, J.M., Ure, J.M., Toyka, K.V., Smith, A.G., and Sendtner, M. 
(1997b). Inactivation of the survival motor neuron gene, a candidate gene for human spinal 
muscular atrophy, leads to massive cell death in early mouse embryos.  94, 9920-9925. 
Seebach, B.S., and Ziskind-Conhaim, L. (1994). Formation of transient inappropriate sensorimotor 
synapses in developing rat spinal cords. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 14, 4520-4528. 
112 
 
Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., 
Presumey, J., Baum, M., Van Doren, V., et al. (2016). Schizophrenia risk from complex variation of 
complement component 4. Nature 530, 177-183. 
Selkoe, D.J. (2002). Alzheimer's disease is a synaptic failure. Science (New York, NY) 298, 789-
791. 
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E.S., 
Burtscher, I., Mowla, S.J., and Lickert, H. (2019). Development and Clinical Translation of 
Approved Gene Therapy Products for Genetic Disorders. Front Genet 10, 868-868. 
Shneider, N.A., Brown, M.N., Smith, C.A., Pickel, J., and Alvarez, F.J. (2009). Gamma motor 
neurons express distinct genetic markers at birth and require muscle spindle-derived GDNF for 
postnatal survival. Neural development 4, 42. 
Shorrock, H.K., Gillingwater, T.H., and Groen, E.J.N. (2019). Molecular Mechanisms Underlying 
Sensory-Motor Circuit Dysfunction in SMA. Frontiers in Molecular Neuroscience 12. 
Shorrock, H.K., van der Hoorn, D., Boyd, P.J., Llavero Hurtado, M., Lamont, D.J., Wirth, B., 
Sleigh, J.N., Schiavo, G., Wishart, T.M., Groen, E.J.N., et al. (2018). UBA1/GARS-dependent 
pathways drive sensory-motor connectivity defects in spinal muscular atrophy. Brain : a journal of 
neurology 141, 2878-2894. 
Simic, G., Seso-Simic, D., Lucassen, P.J., Islam, A., Krsnik, Z., Cviko, A., Jelasic, D., Barisic, N., 
Winblad, B., Kostovic, I., et al. (2000). Ultrastructural analysis and TUNEL demonstrate motor 
neuron apoptosis in Werdnig-Hoffmann disease. Journal of neuropathology and experimental 
neurology 59, 398-407. 
Simon, C.M., Dai, Y., Van Alstyne, M., Koutsioumpa, C., Pagiazitis, J.G., Chalif, J.I., Wang, X., 
Rabinowitz, J.E., Henderson, C.E., Pellizzoni, L., et al. (2017). Converging Mechanisms of p53 
Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy. Cell reports 21, 3767-
3780. 
Simon, C.M., Janas, A.M., Lotti, F., Tapia, J.C., Pellizzoni, L., and Mentis, G.Z. (2016). A Stem 
Cell Model of the Motor Circuit Uncouples Motor Neuron Death from Hyperexcitability Induced 
by SMN Deficiency. Cell reports 16, 1416-1430. 
Smith, R., Brundin, P., and Li, J.Y. (2005). Synaptic dysfunction in Huntington's disease: a new 
perspective. Cellular and molecular life sciences : CMLS 62, 1901-1912. 
Somers, E., Lees, R.D., Hoban, K., Sleigh, J.N., Zhou, H., Muntoni, F., Talbot, K., Gillingwater, 
T.H., and Parson, S.H. (2016). Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular 
Atrophy. Annals of neurology 79, 217-230. 
113 
 
Sontheimer, R.D., Racila, E., and Racila, D.M. (2005). C1q: Its Functions within the Innate and 
Adaptive Immune Responses and its Role in Lupus Autoimmunity. Journal of Investigative 
Dermatology 125, 14-23. 
Spangenberg, E., Severson, P.L., Hohsfield, L.A., Crapser, J., Zhang, J., Burton, E.A., Zhang, Y., 
Spevak, W., Lin, J., Phan, N.Y., et al. (2019). Sustained microglial depletion with CSF1R inhibitor 
impairs parenchymal plaque development in an Alzheimer's disease model. Nat Commun 10, 3758. 
Stephan, A.H., Barres, B.A., and Stevens, B. (2012). The complement system: an unexpected role 
in synaptic pruning during development and disease. Annual review of neuroscience 35, 369-389. 
Stevens, B., Allen, N.J., Vazquez, L.E., Howell, G.R., Christopherson, K.S., Nouri, N., Micheva, 
K.D., Mehalow, A.K., Huberman, A.D., Stafford, B., et al. (2007). The classical complement 
cascade mediates CNS synapse elimination. Cell 131, 1164-1178. 
Sumner, C.J., and Fischbeck, K.H. (2007). 44 - Spinal Muscular Atrophy. In Neurobiology of 
Disease, S. Gilman, ed. (Burlington: Academic Press), pp. 501-511. 
Surmeli, G., Akay, T., Ippolito, G.C., Tucker, P.W., and Jessell, T.M. (2011). Patterns of spinal 
sensory-motor connectivity prescribed by a dorsoventral positional template. Cell 147, 653-665. 
Takeoka, A., Vollenweider, I., Courtine, G., and Arber, S. (2014). Muscle spindle feedback directs 
locomotor recovery and circuit reorganization after spinal cord injury. Cell 159, 1626-1639. 
Tarabal, O., Caraballo-Miralles, V., Cardona-Rossinyol, A., Correa, F.J., Olmos, G., Llado, J., 
Esquerda, J.E., and Caldero, J. (2014). Mechanisms involved in spinal cord central synapse loss in a 
mouse model of spinal muscular atrophy. Journal of neuropathology and experimental neurology 
73, 519-535. 
ten Donkelaar, H.J. (2000). Descending Pathways to the Spinal Cord in Tetrapods: A Brief Outline. 
In Development and Regenerative Capacity of Descending Supraspinal Pathways in Tetrapods: A 
Comparative Approach, H.J. ten Donkelaar, ed. (Berlin, Heidelberg: Springer Berlin Heidelberg), 
pp. 9-13. 
Tenner, A.J., Stevens, B., and Woodruff, T.M. (2018). New tricks for an ancient system: 
Physiological and pathological roles of complement in the CNS. Mol Immunol 102, 3-13. 
Tisdale, S., and Pellizzoni, L. (2015). Disease mechanisms and therapeutic approaches in spinal 
muscular atrophy. J Neurosci 35, 8691-8700. 
Toth, A.B., Terauchi, A., Zhang, L.Y., Johnson-Venkatesh, E.M., Larsen, D.J., Sutton, M.A., and 
Umemori, H. (2013). Synapse maturation by activity-dependent ectodomain shedding of 
SIRPalpha. Nature neuroscience 16, 1417-1425. 
Tremblay, M.-È., Stevens, B., Sierra, A., Wake, H., Bessis, A., and Nimmerjahn, A. (2011). The 
Role of Microglia in the Healthy Brain. The Journal of Neuroscience 31, 16064-16069. 
114 
 
Tremblay, M.E., Lowery, R.L., and Majewska, A.K. (2010). Microglial interactions with synapses 
are modulated by visual experience. PLoS Biol 8, e1000527. 
Umemiya, M., Araki, I., and Kuno, M. (1993). Electrophysiological properties of axotomized facial 
motoneurones that are destined to die in neonatal rats. The Journal of physiology 462, 661-678. 
Van Alstyne, M., Simon, C.M., Sardi, S.P., Shihabuddin, L.S., Mentis, G.Z., and Pellizzoni, L. 
(2018). Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in 
spinal muscular atrophy. Genes Dev 32, 1045-1059. 
Vanderhorst, V.G., and Holstege, G. (1997). Organization of lumbosacral motoneuronal cell groups 
innervating hindlimb, pelvic floor, and axial muscles in the cat. The Journal of comparative 
neurology 382, 46-76. 
Verret, L., Mann, E.O., Hang, G.B., Barth, A.M., Cobos, I., Ho, K., Devidze, N., Masliah, E., 
Kreitzer, A.C., Mody, I., et al. (2012). Inhibitory interneuron deficit links altered network activity 
and cognitive dysfunction in Alzheimer model. Cell 149, 708-721. 
Viollet, L., Bertrandy, S., Bueno Brunialti, A.L., Lefebvre, S., Burlet, P., Clermont, O., Cruaud, C., 
Guenet, J.L., Munnich, A., and Melki, J. (1997). cDNA isolation, expression, and chromosomal 
localization of the mouse survival motor neuron gene (Smn). Genomics 40, 185-188. 
von Gontard, A., Zerres, K., Backes, M., Laufersweiler-Plass, C., Wendland, C., Melchers, P., 
Lehmkuhl, G., and Rudnik-Schoneborn, S. (2002). Intelligence and cognitive function in children 
and adolescents with spinal muscular atrophy. Neuromuscular disorders : NMD 12, 130-136. 
Vukojicic, A., Delestree, N., Fletcher, E.V., Pagiazitis, J.G., Sankaranarayanan, S., Yednock, T.A., 
Barres, B.A., and Mentis, G.Z. (2019). The Classical Complement Pathway Mediates Microglia-
Dependent Remodeling of Spinal Motor Circuits during Development and in SMA. Cell reports 29, 
3087-3100.e3087. 
Wadman, R.I., Vrancken, A.F., van den Berg, L.H., and van der Pol, W.L. (2012). Dysfunction of 
the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 79, 2050-2055. 
Wake, H., Moorhouse, A.J., Jinno, S., Kohsaka, S., and Nabekura, J. (2009). Resting microglia 
directly monitor the functional state of synapses in vivo and determine the fate of ischemic 
terminals. The Journal of neuroscience : the official journal of the Society for Neuroscience 29, 
3974-3980. 
Waldrop, M.A., and Kolb, S.J. (2019). Current Treatment Options in Neurology-SMA 
Therapeutics. Current treatment options in neurology 21, 25. 
Werneburg, S., Buettner, F.F., Erben, L., Mathews, M., Neumann, H., Muhlenhoff, M., and 
Hildebrandt, H. (2016). Polysialylation and lipopolysaccharide-induced shedding of E-selectin 
ligand-1 and neuropilin-2 by microglia and THP-1 macrophages. Glia 64, 1314-1330. 
115 
 
Westbury, D.R. (1982). A comparison of the structures of alpha and gamma-spinal motoneurones of 
the cat. The Journal of physiology 325, 79-91. 
Williams, P.A., Tribble, J.R., Pepper, K.W., Cross, S.D., Morgan, B.P., Morgan, J.E., John, 
S.W.M., and Howell, G.R. (2016). Inhibition of the classical pathway of the complement cascade 
prevents early dendritic and synaptic degeneration in glaucoma. Molecular Neurodegeneration 11, 
26. 
Windhorst, U. (2007). Muscle proprioceptive feedback and spinal networks. Brain research bulletin 
73, 155-202. 
Wirth, B., Schmidt, T., Hahnen, E., Rudnik-Schoneborn, S., Krawczak, M., Muller-Myhsok, B., 
Schonling, J., and Zerres, K. (1997). De novo rearrangements found in 2% of index patients with 
spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications 
for genetic counseling. American journal of human genetics 61, 1102-1111. 
Woodruff, T.M., Crane, J.W., Proctor, L.M., Buller, K.M., Shek, A.B., de Vos, K., Pollitt, S., 
Williams, H.M., Shiels, I.A., Monk, P.N., et al. (2006). Therapeutic activity of C5a receptor 
antagonists in a rat model of neurodegeneration. Faseb j 20, 1407-1417. 
Wu, Y., Dissing-Olesen, L., MacVicar, B.A., and Stevens, B. (2015). Microglia: Dynamic 
Mediators of Synapse Development and Plasticity. Trends Immunol 36, 605-613. 
Yamada, T., McGeer, P.L., and McGeer, E.G. (1992). Lewy bodies in Parkinson's disease are 
recognized by antibodies to complement proteins. Acta Neuropathol 84, 100-104. 
Yona, S., Kim, K.W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., 
Guilliams, M., Misharin, A., et al. (2013). Fate mapping reveals origins and dynamics of monocytes 
and tissue macrophages under homeostasis. Immunity 38, 79-91. 
Zanetta, C., Riboldi, G., Nizzardo, M., Simone, C., Faravelli, I., Bresolin, N., Comi, G.P., and 
Corti, S. (2014). Molecular, genetic and stem cell-mediated therapeutic strategies for spinal 
muscular atrophy (SMA). Journal of cellular and molecular medicine 18, 187-196. 
Zerres, K., and Davies, K.E. (1999). 59th ENMC International Workshop: Spinal Muscular 
Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The 
Netherlands. Neuromuscular disorders : NMD 9, 272-278. 
Zerres, K., and Rudnik-Schoneborn, S. (1995). Natural history in proximal spinal muscular atrophy. 
Clinical analysis of 445 patients and suggestions for a modification of existing classifications. 
Archives of neurology 52, 518-523. 
Zerres, K., Rudnik-Schoneborn, S., Forrest, E., Lusakowska, A., Borkowska, J., and Hausmanowa-
Petrusewicz, I. (1997). A collaborative study on the natural history of childhood and juvenile onset 
proximal spinal muscular atrophy (type II and III SMA): 569 patients. Journal of the neurological 
sciences 146, 67-72. 
116 
 
Zhang, Z., Pinto, A.M., Wan, L., Wang, W., Berg, M.G., Oliva, I., Singh, L.N., Dengler, C., Wei, 
Z., and Dreyfuss, G. (2013). Dysregulation of synaptogenesis genes antecedes motor neuron 
pathology in spinal muscular atrophy. Proceedings of the National Academy of Sciences of the 
United States of America 110, 19348-19353. 
Zheng, Y., Liu, P., Bai, L., Trimmer, J.S., Bean, B.P., and Ginty, D.D. (2019). Deep Sequencing of 
Somatosensory Neurons Reveals Molecular Determinants of Intrinsic Physiological Properties. 
Neuron 103, 598-616.e597. 
Zipfel, P.F., and Skerka, C. (2009). Complement regulators and inhibitory proteins. Nat Rev 


















Aleksandra Vukojičić was born on December 23rd, 1986 in Belgrade, Serbia. She received a 
bachelor’s degree in Biology (module: Molecular Biology and Physiology) from Faculty of 
Biology, University of Belgrade in 2012. Same year she started master studies in Molecular 
Biology and Physiology (module: Immunobiology) at the Faculty of Biology, University of 
Belgrade. She carried out experimental part of her master studies in the lab of dr Monika Bradl, in 
the Center for Brain Research, dept. of Neuroimmunology, at the Medical University of Vienna, 
where she studied autoreactive antibodies involved in the pathogenesis of autoimmune disease 
neuromyelitis optica. She received a master’s degree in 2013 and same year started Ph.D studies in 
Biology (module: Immunobiology) at the Faculty of Biology, University of Belgrade.  
In November 2013, Aleksandra joined dr George Z. Mentis lab, at the Center for Motor Neuron 
Biology and Disease at Columbia University. Aleksandra carried out entire experimental part of her 
doctoral studies in dr Mentis lab, where she studied the molecular, cellular and neuronal circuit 
mechanisms involved in the dysfunction and elimination of synapses on motor neurons at the onset 
of the neurodegenerative disease spinal muscular atrophy (SMA). She has uncovered the role of the 
classical complement pathway in synaptic dysfunction and elimination of proprioceptive synapses 
in a mouse model of SMA, as well as the role of complement proteins in sensory-motor circuitry 
refinement during normal development.  
Aleksandra Vukojičić has authored one and co-authored two more peer-reviewed papers in top 
international journals (category M21). She has given talks at six international meetings and one at a 
national meeting. Additionally, she had four poster presentations at international meetings and one 
at a national meeting. In 2017, Aleksandra was awarded F1000 prize for an outstanding presentation 










Изјава о ауторству 
 
 
Потписани-a   Александра Вукојичић 




да је докторска дисертација под насловом  
 
Комплемент и микроглија као посредници губитка сензорно-моторних синапси 
током нормалног развића и у спиналној мишићној атрофији 
 
• резултат сопственог истраживачког рада, 
• да предложена дисертација у целини ни у деловима није била предложена за добијање 
било које дипломе према студијским програмима других високошколских установа, 
• да су резултати коректно наведени и  
• да нисам кршио/ла ауторска права и користио интелектуалну својину других лица.  
 
 
            Потпис aутора 
 








Прилог 2.  
 
Изјава о истоветности штампане и електронске верзије 
докторског рада 
 
Име и презиме аутора Александра Вукојичић 
Број индекса   Б3004/2013 
Студијски програм   Биологија 
Наслов рада   Комплемент и микроглија као посредници губитка сензорно-
моторних синапси током нормалног развића и у спиналној мишићној атрофији 
Ментор dr. George Z. Mentis и др Биљана Божић Недељковић  
 
Потписани/а Александра Вукојичић 
 
Изјављујем да је штампана верзија мог докторског рада истоветна електронској верзији коју 
сам предао/ла за објављивање на порталу Дигиталног репозиторијума Универзитета у 
Београду.  
Дозвољавам да се објаве моји лични подаци везани за добијање академског звања доктора 
наука, као што су име и презиме, година и место рођења и датум одбране рада.  
Ови лични подаци могу се објавити на мрежним страницама дигиталне библиотеке, у 
електронском каталогу и у публикацијама Универзитета у Београду. 
 
            Потпис аутора  
 








Прилог 3.  
 
Изјава о коришћењу 
 
Овлашћујем Универзитетску библиотеку „Светозар Марковић“ да у Дигитални 
репозиторијум Универзитета у Београду унесе моју докторску дисертацију под насловом: 
 
Комплемент и микроглија као посредници губитка сензорно-моторних синапси 
током нормалног развића и у спиналној мишићној атрофији 
која је моје ауторско дело.  
Дисертацију са свим прилозима предао/ла сам у електронском формату погодном за трајно 
архивирање.  
Моју докторску дисертацију похрањену у Дигитални репозиторијум Универзитета у 
Београду могу да користе сви који поштују одредбе садржане у одабраном типу лиценце 
Креативне заједнице (Creative Commons) за коју сам се одлучио/ла. 
1. Ауторство 
2. Ауторство – некомерцијално 
3. Ауторство – некомерцијално – без прераде 
4. Ауторство – некомерцијално – делити под истим условима 
5. Ауторство – без прераде 
6. Ауторство – делити под истим условима 
(Молимо да заокружите само једну од шест понуђених лиценци, кратак опис лиценци дат је 
на полеђини листа). 
                     Потпис аутора 
 
 Београду, 03.12.2020    
 
1. Ауторство - Дозвољавате умножавање, дистрибуцију и јавно саопштавање дела, и прераде, 
ако се наведе име аутора на начин одређен од стране аутора или даваоца лиценце, чак и у 
комерцијалне сврхе. Ово је најслободнија од свих лиценци. 
2. Ауторство – некомерцијално. Дозвољавате умножавање, дистрибуцију и јавно 
саопштавање дела, и прераде, ако се наведе име аутора на начин одређен од стране аутора 
или даваоца лиценце. Ова лиценца не дозвољава комерцијалну употребу дела. 
3. Ауторство - некомерцијално – без прераде. Дозвољавате умножавање, дистрибуцију и 
јавно саопштавање дела, без промена, преобликовања или употребе дела у свом делу, ако се 
наведе име аутора на начин одређен од стране аутора или даваоца лиценце. Ова лиценца не 
дозвољава комерцијалну употребу дела. У односу на све остале лиценце, овом лиценцом се 
ограничава највећи обим права коришћења дела.  
 4. Ауторство - некомерцијално – делити под истим условима. Дозвољавате умножавање, 
дистрибуцију и јавно саопштавање дела, и прераде, ако се наведе име аутора на начин 
одређен од стране аутора или даваоца лиценце и ако се прерада дистрибуира под истом или 
сличном лиценцом. Ова лиценца не дозвољава комерцијалну употребу дела и прерада. 
5. Ауторство – без прераде. Дозвољавате умножавање, дистрибуцију и јавно саопштавање 
дела, без промена, преобликовања или употребе дела у свом делу, ако се наведе име аутора 
на начин одређен од стране аутора или даваоца лиценце. Ова лиценца дозвољава 
комерцијалну употребу дела. 
6. Ауторство - делити под истим условима. Дозвољавате умножавање, дистрибуцију и јавно 
саопштавање дела, и прераде, ако се наведе име аутора на начин одређен од стране аутора 
или даваоца лиценце и ако се прерада дистрибуира под истом или сличном лиценцом. Ова 
лиценца дозвољава комерцијалну употребу дела и прерада. Слична је софтверским 
лиценцама, односно лиценцама отвореног кода. 
 
 
 
